PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07C 235/00	A2	(11) International Publication Number: WO 99/09000
		(43) International Publication Date: 25 February 1999 (25.02.99)

(21) International Application Number: PCT/US98/17048

(22) International Filing Date: 18 August 1998 (18.08.98)

(30) Priority Data:

60/055,944	18 August 1997 (18.08.97)	US
60/068,335	19 December 1997 (19.12.97)	US

(71) Applicant: DU PONT PHARMACEUTICALS COMPANY [US/US]; WR-1ST18, 974 Centre Road, Wilmington, DE 19807 (US).

(72) Inventors: YAO, Wenqing; 748 Meadowbank Road, Kennett Square, PA 19348 (US). DECICCO, Carl, P.; 17 Ridgewood Turn Street, Newark, DE 19711 (US).

(74) Agent: KONRAD, Karen, H.; Du Pont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS

(57) Abstract

This invention relates to molecules which inhibit metalloproteinases, including aggrecanase, and the production of tumor necrosis factor (TNF). In particular, the compounds are inhibitors of metalloproteinases involved in tissue degradation and inhibitors of the release of tumor necrosis factor. The present invention also relates to pharmaceutical compositions comprising such compounds and to methods of using these compounds for the treatment of inflammatory diseases.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

TITLE

NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS

FIELD OF THE INVENTION

The present invention relates to novel molecules which inhibit metalloproteinases, including aggrecanase, and the production of tumor necrosis factor (TNF), pharmaceutical preparations containing them and to their use as pharmaceutical agents. In particular the compounds are inhibitors of metalloproteinases involved in tissue degradation and inhibitors of the release of tumor necrosis factor.

BACKGROUND OF THE INVENTION

There is now a body of evidence that metalloproteinases (MP) are important in the uncontrolled breakdown of connective tissue, including proteoglycan and collagen, leading to resorption of the extracellular matrix. This is a feature of many pathological conditions, such as rheumatoid and osteoarthritis, corneal, epidermal or gastric ulceration; tumor metastasis or invasion; periodontal disease and bone disease. Normally these catabolic enzymes are tightly regulated at the level of their synthesis as well as at their level of extracellular activity through the action of specific inhibitors, such as alpha-2-macroglobulins and TIMP (tissue inhibitor of metalloproteinase), which form inactive complexes with the MP's.

Osteo- and Rheumatoid Arthritis (OA and RA respectively) are destructive diseases of articular cartilage characterized by localized erosion of the cartilage surface. Findings have shown that articular cartilage from the femoral heads of patients with OA, for example, had a reduced incorporation of radiolabeled sulfate over controls, suggesting that there must be an enhanced rate of cartilage degradation in OA (Mankin et al. J. Bone Joint Surg. 52A, 1970, 424-434). There are four classes of protein degradative enzymes in mammalian cells: serine, cysteine, aspartic and metalloproteinases. The available evidence supports that it is the metalloproteinases which are responsible for the degradation of the extracellular matrix of articullar cartilage in OA and RA. Increased activities of collagenases and stromelysin have been found in OA cartilage and the activity correlates with severity of the lesion (Mankin et al. Arthritis Rheum. 21, 1978, 761-766, Woessner et al. Arthritis Rheum. 26, 1983, 63-68 and Ibid. 27, 1984, 305-312). In addition, aggrecanase (a newly identified metalloproteinase enzymatic activity) has been identified that provides the specific cleavage product of proteoglycan, found in RA and OA patients (Lohmander L.S. et al. Arthritis Rheum. 36, 1993, 1214-22).

Therefore metalloproteinases (MP) have been implicated as the key enzymes in the destruction of mammalian cartilage and bone. It can be expected that the pathogenesis of such diseases can be modified in a beneficial manner by the administration of MP inhibitors, and many compounds have been suggested for this purpose (see Wahl et al. Ann. Rep. Med. Chem. 25, 175-184, AP, San Diego, 1990).

This invention describes novel molecules that inhibit aggrecanase and other metalloproteinases. These novel molecules are provided as cartilage protecting

therapeutics. The inhibition of aggrecanase and other metalloproteinases by these novel molecules prevent the degradation of cartilage by these enzymes, thereby alleviating the pathological conditions of osteo- and rheumatoid arthritis.

Tumor necrosis factor (TNF) is a cell associated cytokine that is processed from a 26kD precursor form to a 17kD active form. TNF has been shown to be a primary mediator in humans and in animals, of inflammation, fever, and acute phase responses, similar to those observed during acute infection and shock. Excess TNF has been shown to be lethal. There is now considerable evidence that blocking the effects of TNF with specific antibodies can be beneficial in a variety of circumstances including autoimmune diseases such as rheumatoid arthritis (Feldman et al, Lancet, 1994, 344, 1105) and non-insulin dependent diabetes melitus. (Lohmander L.S. et al. Arthritis Rheum. 36, 1993, 1214-22) and Crohn's disease (Macdonald T. et al. Clin. Exp. Immunol. 81, 1990, 301) .

Compounds which inhibit the production of TNF are therefore of therapeutic importance for the treatment of inflammatory disorders. Recently it has been shown that a matrix metalloproteinase or family of metalloproteinases, hereafter known as TNF-convertases (TNF-C), as well as other MP's are capable of cleaving TNF from its inactive to active form (Gearing et al Nature, 1994, 370, 555). This invention describes novel molecules that inhibit this conversion and hence the secretion of active TNF-α from cells. These novel molecules provide a means of mechanism based therapeutic intervention for diseases including but not restricted to septic shock, haemodynamic shock, sepsis syndrome, post ischaemic reperfusion injury, malaria, Crohn's disease, inflammatory bowel diseases, mycobacterial infection, meningitis, psoriasis,

congestive heart failure, fibrotic diseases, cachexia, graft rejection, cancer, diseases involving angiogenesis, autoimmune diseases, skin inflammatory diseases, rheumatoid arthritis, multiple sclerosis, radiation damage, hyperoxic alveolar injury, HIV and non-insulin dependent diabetes melitus.

Since excessive TNF production has been noted in several disease conditions also characterized by MMP-mediated tissue degradation, compounds which inhibit both MMPs and TNF production may also have a particular advantage in diseases where both mechanisms are involved.

There are several patents which disclose hydroxamate and carboxylate based MMP inhibitors.

PCT International Publication No. WO 92/213260 describes N-carboxyalkylpeptidyl compounds of general formula:



wherein AA is an amino acid, as inhibitors of matrix metallproteinase mediated diseases.

PCT International Publication No. WO 90/05716 discloses hydroxamic acid based collagenase inhibitors having the general formula:



PCT International Publication No. WO 92/13831 describes related hydroxamic acids having collagenase inhibiting activity with the general formula:



PCT International Publication No. WO 94/02446 discloses metalloproteinase inhibitors which are natural amino acid derivatives of general formula:



WO95/09841 describes compounds that are hydroxamic acid derivatives and are inhibitors of cytokine production.

European Patent Application Publication No. 574,758 A1, discloses hydroxamic acid derivatives as collagenase inhibitors having the general formula:



GB 2 268 934 A and WO 94/24140 claim hydroxamate inhibitors of MMPs as inhibitors of TNF production.

The compounds of the current invention act as inhibitors of MPs, in particular aggrecanase and TNF-C, thereby preventing cartilage loss and destruction and inflammatory disorders involving TNF. The hydroxamic and carboxylic acids and derivatives contain a cyclic peptide mimic attached to a succinate peptide mimic, and thus the inhibitors are non-peptide in nature. A selection of these molecules are water soluble and are orally bioavailable.

SUMMARY OF THE INVENTION

This invention provides novel hydroxamic acids and carboxylic acids and derivatives thereof of formula (I) (described below) which are useful as inhibitors of metalloproteinases, such as aggrecanase and TNF-C. The present invention also includes pharmaceutical compositions comprising such compounds of formula (I) and methods of using such compounds for the treatment of arthritis and other inflammatory disorders as described previously, in a patient.

Also included in the present invention are pharmaceutical kits comprising one or more containers containing pharmaceutical dosage units comprising a compound of formula (I), for the treatment of arthritis

NOT TO BE TAKEN INTO ACCOUNT FOR THE PURPOSE OF INTERNATIONAL PROCESSING

NO TENER EN CUENTA A LOS EFECTOS DE LA TRAMITACIÓN INTERNACIONAL

NE PAS PRENDRE EN COMPTE AUX FINS DU TRAITEMENT INTERNATIONAL

and/or therapeutic agents for the treatment of arthritis and inflammation.

DEFINITIONS

The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.

The term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =O), then 2 hydrogens on the atom are replaced.

When any variable (e.g., R^b) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R^6, then said group may optionally be substituted with up to two R^6 groups and R^6 at each occurrence is selected independently from the definition of R^6.

Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As used herein, "H" is intended to include substitutions with deuterium or tritium. Where "H" is not indicated but is part of a bond then substitutions with deuterium or tritium are also intentded.

As used herein, "C_{1-10} alkyl" or "C_{1-10} alkylene" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, examples of which include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl;

"Alkenyl" or "alkenylene" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like.

"Alkynyl" or "alkynylene" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more carbon-carbon triple bonds which may occur in any stable point along the chain, such as ethynyl, propynyl, and the like.

As used herein, "aryl" or "aromatic residue" is intended to include phenyl or naphthyl as well as

commonly referred to "heterocycle" or "heteroaryl" or "heterocyclic" compounds.

As used herein the term "alkylaryl" represents an aryl group attached through an alkyl bridge.

"Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like.

As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7- to 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin).

As used herein, the term "heterocycle" or "heterocyclic system" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 14-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a

nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1.

As used herein, the term "aromatic heterocyclic system" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 14-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heterotams independently selected from the group consisting of N, O and S. It is preferred that the total number of S and O atoms in the aromatic heterocycle is not more than 1.

Examples of heterocycles include, but are not limited to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4a*H*-carbazolyl, b-carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2*H*,6*H*-1,5,2-dithiazinyl, dihydrofuro[2,3-*b*]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1*H*-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl,

oxazolidinylperimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, 4*H*-quinolizinyl, quinoxalinyl, quinuclidinyl, carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6*H*-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl. Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl, benzimidazolyl, 1*H*-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, or isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

The term "amino acid" as used herein means an organic compound containing both a basic amino group and an acidic carboxyl group. Included within this term are natural amino acids (e.g., L-amino acids), modified and unusual amino acids (e.g., D-amino acids), as well as amino acids which are known to occur biologically in free or combined form but usually do not occur in proteins. Included within this term are modified and unusual amino acids,such as those disclosed in, for example, Roberts and Vellaccio (1983)

The Peptides, 5: 342-429, the teaching of which is hereby incorporated by reference. Natural protein occurring amino acids include, but are not limited to, alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tyrosine, tyrosine, tryptophan, proline, and valine. Natural non-protein amino acids include, but are not limited to arginosuccinic acid, citrulline, cysteine sulfinic acid, 3,4-dihydroxyphenylalanine, homocysteine, homoserine, ornithine, 3-monoiodotyrosine, 3,5-diiodotryosine, 3,5,5'-triiodothyronine, and 3,3',5,5'-tetraiodothyronine. Modified or unusual amino acids which can be used to practice the invention include, but are not limited to, D-amino acids, hydroxylysine, 4-hydroxyproline, an N-Cbz-protected amino acid, 2,4-diaminobutyric acid, homoarginine, norleucine, N-methylaminobutyric acid, naphthylalanine, phenylglycine, ß-phenylproline, tert-leucine, 4-aminocyclohexylalanine, N-methyl-norleucine, 3,4-dehydroproline, N,N-dimethylaminoglycine, N-methylaminoglycine, 4-aminopiperidine-4-carboxylic acid, 6-aminocaproic acid, trans-4-(aminomethyl)-cyclohexanecarboxylic acid, 2-, 3-, and 4-(aminomethyl)-benzoic acid, 1-aminocyclopentanecarboxylic acid, 1-aminocyclopropanecarboxylic acid, and 2-benzyl-5-aminopentanoic acid.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic

response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in *Remington's Pharmaceutical Sciences*, 17th ed., Mack Publishing Company, Easton,

PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.

"Prodrugs" and "prodrug derivatives" are intended to include any covalently bonded carriers which release the active parent drug according to formula (I) *in vivo* when such prodrug is administered to a mammalian subject. Prodrugs of a compound of formula (I) are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or *in vivo*, to the parent compound. Prodrugs include compounds of formula (I) wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug or compound of formula (I) is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I), and the like.

"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

[1] There is provided by this invention a compound of the formula (I):



Formula I

or a pharmaceutically acceptable salt form or a steroisomer thereof, wherein:

R^1 is selected from:
$-CO_2H$, $-C(O)NHOH$, $-C(O)NHOR^7$, $-SH$, $-CH_2CO_2R^7$, $-COR^7$, $-N(OH)COR^7$, $-SN_2H_2R^7$, $-SONHR^7$, $-CH_2CO_2H$, $-PO(OH)_2$, $-PO(OH)NHR^7$, $-CH_2SH$, $-C(O)NHOR^7$, $-CO_2R^7$, and common prodrug derivatives;

R^2 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$,

$NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14

membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^3 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and $C(O)$;

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^4 is selected from:
hydrogen, (C_1-C_5)alkyl, (C_1-C_5)alkyl-aryl,

R^5 and R^6 are independently selected from:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^7 is selected from: C_1-C_{10} alkyl, alkylaryl, and common prodrug derivatives

A is selected from:
SO_2, SO, CHOH;

E is $(CR^8R^9)_m$-W-$(CR^8R^9)_n$,

wherein W can be absent or selected from:

CH_2, CO, O, $S(O)_m$ and NR^{10},

m is 0-2,

n is 0-2;

with the proviso that when W is O, S or NR^{10} then m must not be 0;

R^8 and R^9 is independently selected from:

H,

C1-C8 alkyl substituted with 0-5 R^b,

C1-C8 alkenyl,

C1-C8 alkylaryl substituted with 0-5 R^b,

C_{3-13} carbocyclic residue substituted with 0-5 R^b,

5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

amino,

C1-C8 alkyl-NR^{10}

hydroxyl,

R^8 and R^9 can also form a ring interrupted by NR^{10}, O, $S(O)_m$.

R^{10} is selected from:

hydrogen,

C1-C8 alkyl

C1-C8 alkylaryl

J^1, J^2, J^3, J^4 are independently selected from:

CH, or N.

with no more than two N in the cycle.

[2] The present invention includes compounds of formula (I) wherein:

R^1 is selected from:
$-CO_2H$, $-C(O)NHOH$, $-C(O)NHOR^7$, $-SH$, $-CH_2CO_2R^7$, $-COR^7$, $-N(OH)COR^7$, $-SN_2H_2R^7$, $-SONHR^7$, $-CH_2CO_2H$, $-PO(OH)_2$, $-PO(OH)NHR^7$, $-CH_2SH$, $-C(O)NHOR^7$, $-CO_2R^7$, and common prodrug derivatives;

R^2 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and $C(O)$;

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4

heteroatoms selected from the group consisting of N, O, and S;

R^3 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O'R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^4 is selected from:
hydrogen,

R^5 and R^6 are independently selected from:

$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4

heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^7 is selected from: C_1-C_{10} alkyl, alkylaryl, and common prodrug derivatives

A is selected from:
SO_2, SO, CHOH;

E is $(CR^8R^9)_m$-W-$(CR^8R^9)_n$,
wherein W can be absent or selected from:
CH_2, CO, O, $S(O)_m$ and NR^{10},

m is 0-2,
n is 0-2;

with the proviso that when W is O, S or NR^{10} then m must not be 0;

R^8 and R^9 is independently selected from:
H,
C1-C8 alkyl substituted with 0-5 R^b,
C1-C8 alkenyl,
C1-C8 alkylaryl substituted with 0-5 R^b,
C_{3-13} carbocyclic residue substituted with 0-5 R^b,
5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;
amino,
C1-C8 alkyl-NR^{10}
hydroxyl,

R^8 and R^9 can also form a ring interrupted by NR^{10}, O, S(O)m.

R^{10} is selected from:
hydrogen,
C1-C8 alkyl
C1-C8 alkylaryl

J^1, J^2, J^3, J^4 are independently selected from:
CH,or N.
with no more than two N in the cycle.

[3] The present invention includes preferred compounds of formula (I) wherein:

R^1 is selected from:
$-CO_2H$, -C(O)NHOH, $-C(O)NHOR^7$, -SH, $-CH_2CO_2R^7$,

and common prodrug derivatives;

R^2 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^3 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^4 is selected from:
hydrogen,

R^5 and R^6 are independently selected from:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$,

$NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^7 is selected from: C_1-C_{10} alkyl, alkylaryl, and common prodrug derivatives

A is selected from:
SO_2, SO, CHOH;

E is $(CR^8R^9)_m$-W-$(CR^8R^9)_n$,
wherein W can be absent or selected from:
CH_2, CO, O, $S(O)_m$ and NR^{10},
m is 0-2,
n is 0-2;

with the proviso that when W is O, S or NR^{10} then m must not be 0;

R^8 and R^9 is independently selected from:

H,

C1-C8 alkyl substituted with 0-5 R^b,

C1-C8 alkenyl,

C1-C8 alkylaryl substituted with 0-5 R^b,

C_{3-13} carbocyclic residue substituted with 0-5 R^b,

5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

amino,

C1-C8 alkyl-NR^{10}

hydroxyl,

R^8 and R^9 can also form a ring interrupted by NR^{10}, O, S(O)m.

R^{10} is selected from:

hydrogen,

C1-C8 alkyl

C1-C8 alkylaryl

J^1, J^2, J^3, J^4 are independently selected from:

. CH,or N.

with no more than two N in the cycle.

[4] There is provided by this invention preferred compounds of the formula (II):



Formula II

or a pharmaceutically acceptable salt form or a steroisomer thereof, wherein:

R^1 is selected from:
$-CO_2H$, $-C(O)NHOH$, $-C(O)NHOR^7$, $-SH$, $-CH_2CO_2R^7$, and common prodrug derivatives;

R^2 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and $C(O)$;

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^3 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^5 is selected from:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^7 is selected from: C_1-C_{10} alkyl, alkylaryl, and common prodrug derivatives

E is $(CR^8R^9)_m$-W-$(CR^8R^9)_n$,

wherein W can be absent or selected from:

CH_2, CO, O, $S(O)_m$ and NR^{10},

m is 0-2,

n is 0-2;

with the proviso that when W is O, S or NR^{10} then m must not be 0;

R^8 and R^9 is independently selected from:

H,

C1-C8 alkyl substituted with 0-5 R^b,
C1-C8 alkenyl,
C1-C8 alkylaryl substituted with 0-5 R^b,
C_{3-13} carbocyclic residue substituted with 0-5 R^b,
5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;
amino,
C1-C8 alkyl-NR^{10}
hydroxyl,

R^8 and R^9 can also form a ring interrupted by NR^{10}, O, S(O)m.

R^{10} is selected from:
hydrogen,
C1-C8 alkyl
C1-C8 alkylaryl

J^1, J^2, J^3, J^4 are independently selected from:
CH, or N.
with no more than two N in the cycle.

[5] Preferred compounds of the present invention include compounds of formula (II) wherein:

R^1 is selected from:
-C(O)NHOH,
and common prodrug derivatives;

R^2 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^3 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional

heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^5 is selected from:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4

heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^7 is selected from: C_1-C_{10} alkyl, alkylaryl, and common prodrug derivatives

E is $(CR^8R^9)_m$-W-$(CR^8R^9)_n$,

wherein W can be absent or selected from:

CH_2, CO, O, $S(O)_m$ and NR^{10},

m is 0-2,

n is 0-2;

with the proviso that when W is O, S or NR^{10} then m must not be 0;

R^8 and R^9 is independently selected from:

H,

C1-C8 alkyl substituted with 0-5 R^b,

C1-C8 alkenyl,

C1-C8 alkylaryl substituted with 0-5 R^b,

C_{3-13} carbocyclic residue substituted with 0-5 R^b,

5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

amino,

C1-C8 alkyl-NR^{10}

hydroxyl,

R^8 and R^9 can also form a ring interrupted by NR^{10}, O, S(O)m.

R^{10} is selected from:
hydrogen,
C1-C8 alkyl
C1-C8 alkylaryl

J^1, J^2, J^3, J^4 are independently selected from:
CH,or N.
with no more than two N in the cycle.

[6] More preferred compounds of the present invention are compounds of the formula (III):



Formula III

or a pharmaceutically acceptable salt form or a steroisomer thereof, wherein:

R^1 is selected from:
-C(O)NHOH
and common prodrug derivatives;

R^2 is selected from the formula:

U-X-Y-Z-U^a-X^a-Y^a-Z^a

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^3 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional

heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^5 is selected from:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14

membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2,

$NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^8 and R^9 is independently selected from:

H,

C1-C8 alkyl substituted with 0-5 R^b,

C1-C8 alkenyl,

C1-C8 alkylaryl substituted with 0-5 R^b,

C_{3-13} carbocyclic residue substituted with 0-5 R^b,

5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

amino, C1-C8 alkyl-NR^{10}

hydroxyl,

R^8 and R^9 can also form a ring interrupted by NR^{10}, O, S(O)m.

R^{10} is selected from:

hydrogen,

C1-C8 alkyl

C1-C8 alkylaryl

J^1, J^2, J^3, J^4 are independently selected from:

CH, or N.

with no more than two N in the cycle.

[7] The more preferred compounds provided by this invention are compounds of the formula (IV):



Formula IV

or a pharmaceutically acceptable salt form or a steroisomer therof, wherein:

R^2 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4

heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^3 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and $C(O)$;

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4

heteroatoms selected from the group consisting of N, O, and S;

R^5 is selected from:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and $C(O)$;

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^8 and R^9 is independently selected from:

H,

C1-C8 alkyl substituted with 0-5 R^b,

C1-C8 alkenyl,
C1-C8 alkylaryl substituted with 0-5 R^b,
C_{3-13} carbocyclic residue substituted with 0-5 R^b,
5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;
amino, C1-C8 alkyl-NR^{10}
hydroxyl,

R^8 and R^9 can also form a ring interrupted by NR^{10}, O, S(O)m.

R^{10} is selected from:
hydrogen,
C1-C8 alkyl
C1-C8 alkylaryl

[8] Most preferred compounds of the present invention include compounds selected from the group consisting of:

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-butanediamide;

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-3(S)-(5-hydroxycarbonyl)-pentanamide;

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-3(S)-methyl-butanediamide;

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-3(S)-propyl-butanediamide;

N1-(2(R)-hydroxy-1(S)-indanyl)-N4-hydroxy-2(R)-hexyl-3(S)-propyl-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-hydroxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-methoxy-phenyl)methyl]butanediamide;

N1-[1(S)-indanyl]-N4-hydroxy-2(R)-[4-(hydroxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-phenyl-propyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(benzyloxy)-phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-(benzyloxy)-phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(fluoro-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3,4-(methylenedioxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(methoxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-trifluoromethyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-tert-butylaminosulfonyl-phenyl)phenyl]methyl]-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-methoxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[(3-hydroxy-4-methoxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-(3-thiophene)isoxazoline]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-chloro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-benzofuran)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-methyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3,4-(methylenedioxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-tetrazole-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-methyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(amino-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(benzyloxy-carbonyl)amino]phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-hydroxymethlene)phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,4,5-trimethoxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2,4-di-methoxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,5-di-chloro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-trifluoromethyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-isopropyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2,4-dichloro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-chloro-4-fluoro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(p-toluenesulfonyl-amino)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-phenylmethyl-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,4-methylenedioxyphenyl)phenyl]methyl]-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-methoxyphenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-fluorophenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(fluoro-phenyl)methyl]-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-nitrophenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-(methylsulfonyl-amino)-phenyl)phenyl]methyl]-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(3-trimethylsilyl-propyl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2,2-dimethyl-propionamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(ethyloxy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(iso-butyloxy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(propionamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-methyl-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2,2-dimethylpropyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(methylsulfonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-amino-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(methylsulfonylamino)-phenyl)methyl]-butanediamide;

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-butanediamide;

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-3(S)-(5-hydroxycarbonyl)-pentanamide;

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-3(S)-methyl-butanediamide;

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-3(S)-propyl-butanediamide;

N1-(2(R)-hydroxy-1(S)-indanyl)-N4-hydroxy-2(R)-hexyl-3(S)-propyl-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-hydroxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-methoxy-phenyl)methyl]butanediamide;

N1-[1(S)-indanyl]-N4-hydroxy-2(R)-[4-(hydroxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-phenyl-propyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(benzyloxy)-phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-(benzyloxy)-phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(hydroxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(fluoro-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3,4-(methylenedioxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(methoxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-trifluoromethyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-tert-butylaminosulfonyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-methoxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[(3-hydroxy-4-methoxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-(3-thiophene)isoxazoline]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-chloro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-benzofuran)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-methyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3,4-(methylenedioxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-tetrazole-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-methyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(amino-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(benzyloxy-carbonyl)amino]phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-hydroxymethlene)phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,4,5-trimethoxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2,4-di-methoxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,5-di-chloro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-trifluoromethyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-isopropyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2,4-dichloro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-chloro-4-fluoro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(p-toluenesulfonyl-amino)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-phenylmethyl-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,4-methylenedioxyphenyl)phenyl]methyl]-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-methoxyphenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-fluorophenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(fluoro-phenyl)methyl]-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-nitrophenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-(methylsulfonyl-amino)-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(3-trimethylsilyl-propyl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2,2-dimethyl-propionamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(ethyloxy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(iso-butyloxy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(propionamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-methyl-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2,2-dimethylpropyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(methylsulfonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-amino-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(cyclobutane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-hydroxymethyl-isobutanamide)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-hydroxyl-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-phenyl-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(bezene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-cyano-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-phenyl-cyclopentane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-methyl-cyclohexane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-indole carboxamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-furan carboxamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-quinoline carboxamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(3,4,5-trimethoxy benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-methyl-3-amino-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-methyl-6-amino-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(3-pyridine carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-(2,4-dichloro-phenyl)-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-(4-chloro-phenyl)-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(3-methylsulfonyl)-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-methylsulfonyl-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(3-cyano-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(6-quinoline carboxamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-ethyl,3-methyl-pyrazole 5-carboxamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3-(4-morpholino-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-chloro-4-methylsulfonyl-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(4-(imidazol-1-yl)benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-thiophene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-tert-butyl,3-methyl-pyrazole 5- carboxamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(4-aminomethyl benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-hydroxyl-isobutanamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(cyclopentane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-cyclopentyl acetamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(cyclohexane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(4-(4-N-Boc-piperazinyl-1-yl)benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(4-(piperazinyl-1-yl)benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-Fluoro-6-chloro-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-amino-cyclohexane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-methylthio-acetamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-methoxy-acetamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-allyl-cyclopentane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-n-propyl-cyclopentane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-allyl-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(8-quinoline-sulfonamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(4-nitro-benzene sulfonamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1,4-di-methyl-2-chloro-pyrazole-3- sulfonamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1,5-dimethyl-isooxazole 3- sulfonamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-methyl-imidazole 3-sulfonamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(benzene sulfonamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1,4-dimethyl pyrazole 3-sulfonamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-methylsulfonyl benzene sulfonamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(cyclohexylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(iso-propylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4(2-trifluoromethylphenyl)-phenylmethyl]-3(S)-(2,2-dimethylpropyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(cyclopentylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(cyclopropylmethyl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(benzylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-furanmethylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-4-methylphenyl)methyl]-3(S)-(3-cyanophenylmethylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2,2-dimethylpropyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-pentylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(bis-cyclopropylmethyamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-thiophenemethylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-methyl-propylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-methyl-cyclopropane carboxamido-1-yl)-butanediamide;

The present invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I) as described herein.

The present invention also provides for treating an inflammatory disease in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) as described herein.

The present invention also provides a method for treating a condition or disease mediated by MMPs and/or TNF and/or aggrecanase in a mammal comprising

administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) as described herein.

The present invention also provides a method for treating a condition or disease wherein the disease or condition is referred to as rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, solid tumor growth and tumor invasion by secondary metastases, neovascular glaucoma, multiple sclerosis, or psoriasis in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) as described herein.

The present invention also provides a method for treating a condition or disease wherein the disease or condition is referred to as fever, cardiovascular effects, hemorrhage, coagulation, cachexia, anorexia, alcoholism, acute phase response, acute infection, shock, graft versus host reaction, autoimmune disease or HIV infection in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) as described herein.

In the following description a (-) symbolizes the point of attachment.

SYNTHESIS

The novel compounds of the present invention may be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic

chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by reference.

The novel compounds of this invention may be prepared using the reactions and techniques in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and suitable for the transformation being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvents, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used.

A series of compounds of formula **5** are prepared by the methods outlined in scheme 1. Coupling of carboxylic acid **1** with cis-(1S,2R-(-)-1-amino-2-indanol provided amide **2** The hydroxyl group of **2** was protected as the acetonide **3**, followed by alkylation with tert-butyl 2-bromo-acetate to afford the desired diastereomer **4**. Removal of the tert-butyl group of **4** with TFA in methylene chloride, followed by coupling with O-benzyl hydroxy amine, and hydrogenation afforded the target molecule **5**.

Scheme 1



Compounds of formula **5** can also be prepared by the methods outlined in scheme 2. The 2-substituted succinic acid **10** can be prepared using standard Evans chemistry. An acid **6** (X = Cl) is converted to its oxazolidinone derivative **8** using the standard chemistry. Asymmetric alkylation, followed by hydrolysis using H_2O_2/LiOH afforded the desired acid **10**. The mono-protected succinic acid was coupled to (1S, 2R)-(-) cis -1-amino-2-indanol using standard BOP, or other peptide coupling reagents such as DCC, EDAC, TBTU. The intermediate **11** can then be readily converted into the target compounds **5** using the similar

procedures to that used for the synthesis of target **5** as described in scheme 1.

Scheme 2



Compounds of formula **12** are prepared by the methods outlined in scheme 3. Dianion reaction of the intermidate **10** with an organic halides or triflates produces the 2,3-disubstituted succinate **13**. The acid **13** was coupled with cis -(1S, 2R)-(-)-1-amino-2-indanol. Following similar procedures to that used for the synthesis of target **5** as described in scheme 1, compounds of formula **12** can be readily prepared.

Scheme 3



Compounds of formula **19** are prepared as shown in scheme 4. The intermediate **15** prepared using the method described in scheme 3, was hydrogenated to produce **16**. Compound **16** was then converted to the triflate **17**. The Pd catalyzed Suzuki or stille cross coupling of triflate **17** with either a boronic acid or organostanane afford the coupling product **18**. Using the standard chemistry as described in scheme 3, **18** can be easily converted to the compounds of formula **19**.

Scheme 4



Compounds of formula **20** are prepared as shown in scheme 5. Compound **21** prepared as described in scheme 2 can be hydrogenated to give the free amine **22**. The free amino group can then be protected as sulfonamides, carbamates, and amides **23**. Following similar chemistry to that described in scheme 1, compound **23** can be readily converted to the target of formula **20**.

Scheme 5



Compounds of formula **24** are prepared as shown in scheme 6. Starting from **22** prepared in scheme 5, the free amino group can be further functionalized to afford compound **28** by either palladium catalyzed aryl amination (Wolfe, J. P.; Rennels, R. A.; Buchwald, S. L. *Tetrahedron*, **1996**, *52*, 7525-7546, Hartwig, J. F. *Synlett*, **1996**, 329), or displacement with a substituted aryl fluoride. As described in the previous scheme 5, **28** can be easily converted to the final compound **24**.

Scheme 6



Compounds of formula **29** are prepared as shown in schemes 7-9.

The synthesis of substituted cis-1-amino-2-indanol (**36**) was followed by the route developed by Ghosh et al (Ghosh, A. K.; Kincaid, J. F.; Haske, M. G. *Synthesis*, **1997**, 541-544) The substituted indene (**30**) is converted to the epoxide **31** with MCPBA, or to the optically pure epoxide of **31** with Jacobsen's highly enantioselective epoxidation catalysts (Jacobsen, E. N.; Zhang, W.; Muci, A. R.; Ecker, J. R.; Deng, L. *J. Am. Chem. Soc.* **1991**, *113*, 7063-7064.). The epoxide **31** is converted to the alcohol **32** by treating it with NaN_3. The racemic alcohol of **32** is resolved by Lipase

PS as described by Ghosh et al (Ghosh, A. K.; Kincaid, J. F.; Haske, M. G. *Synthesis*, **1997**, 541-544). The azide of **33** was hydrogenated in the presence of $O(CO_2Et)_2$ to give **34**. The compound **34** was then converted to final substituted cis-1-amino-2-indanol **36** first by mixing with $SOCl_2$, followed by hydrolysis.

Scheme 7



Alternatively, the substituted cis-1-amino-2-indanol **36** is directly prepared from substituted indene (**30**) following a method recently developed by Sharpless, K. B. et al as shown in scheme 8 (Li, G.; Angert, H. H.; Sharpless, K. B. *Angew. Chem. Int. Ed. Engl.* **1996**, *35*, 2813). The cbz group of **38** was removed by hydrogenation to give the free amine **36**.

Scheme 8



Following a similar sequence, the compound **36** can then be readily converted to the final compound **29** as shown in scheme 9.

Scheme 9



Compounds of formula **39** can be synthesized as shown in scheme 10. Following the method developed by Sudo and Saigo (Sudo, A.; Saigo, K. Tetrahedron Asymetry, 1996, 7, 2939-2956), the racemic cis-2-amino-1-indanol can be readily synthesized from substituted indanone **40** as outlined in scheme 9. The indanone can be readily converted into oxime **41** with butyl nitrile under acidic conditions. Reduction of **41** with $NaBH_4$ in methanol could provide the hydroxy oxime, which was

then treated with acetic anhydride and pyridine to give diacetate **42**. Borane reduction of **42** then give the racemic **43**, which can then be directly used or resolved by co-crystalization with tartaric acid or others to provide the desired enantiomerically pure amine **43**. Using similar chemistry to that used for the synthesis of target **5** as described in scheme 1, compound **44** can be readily converted to the target **39**.

5

Scheme 10


n-BuONO, Conc. HCl
2-ethoxyethanol, 0° C
40
41
1), NaBH4, MeOH, -20° C
2), Ac2O, Pyridine, rt
42
BH3-THF
THF, reflux
43
BOP
44
1, TFA, CH2Cl2
2, BOP, H2NOH
39

Compounds of formula **45** are synthesized as shown in scheme 11. The carboxylic group of commercially available aspartic acid was protected as methyl ester **47**. Compound 47 was then treated with LiHMDS in THF at -78 °C to form the enolate, which was reacted with benzyl bromide to afford **48**. The benzyl group of **48** was removed by hydrogenation. The resulting acid was then coupled with cis-2-amino indanol to give **49**. Hydrolysis of compound 49, followed by coupling with hydroxy amine to furnish the desired target **45**.

Scheme 11



Examples

Abbreviations used in the Examples are defined as follows: "1 x" for once, "2 x" for twice, "3 x" for thrice, "°C" for degrees Celsius, "eq" for equivalent or equivalents, "g" for gram or grams, "mg" for milligram or milligrams, "mL" for milliliter or milliliters, "^{1}H" for proton, "h" for hour or hours, "M" for molar, "min" for minute or minutes, "MHz" for megahertz, "MS" for mass spectroscopy, "NMR" for nuclear magnetic resonance spectroscopy, "rt" for room temperature, "tlc" for thin layer chromatography, "v/v" for volume to volume ratio. "R" and "S" are stereochemical designations familiar to those skilled in the art.

Example 1: **N1-(2(R)-hydroxy-1(S)-indanyl)-N4-hydroxy-2(R)-isobutyl-butanediamide:**

(a) **N1-(2R-hydroxy-1S-indanyl)-2R-isobutyl-3-(tert-butoxycarbonyl)propanamide:**

To a stirred, cooled (0° C) solution of 500 mg (2.17 mmol) 2R-isobutyl 3-(tert-butoxycarbonyl)propinoic acid and 323.9 mg (2.17 mmol) (1S, 2R)-(-) cis -1-amino-2-indanol in 4.0 mL of anhydrous DMF was added 731.4 mg of TBTU, followed by addition of 1.19 mL of diisopropylethyl amine. The reaction was allowed to warmed to room temperature. After 1 h, the reaction mixture was diluted with 15 mL 10% citric acid and 50 mL ethyl acetate, the aqueous solution was further extracted with ethyl acetate (2 X 25 mL). The combined organic solution was washed with water, sat. $NaHCO_3$, and brine, dried over $MgSO_4$. The

solution was filtered and concentrated under reduced pressure to afford 0.685 g (87% yield) as a white solid. ESI-MS $(M+H)^+$: calcd 362, found 362.

(b) **N-(2R-hydroxy-1S-indanyl)-2R-isobutyl-3-(hydroxycarbonyl)propanamide:**

To a solution of 0.635 g of N-(2R-hydroxy-1S-indanyl)-2R-isobutyl-3-(tert-butoxycarbonyl) propanamide in 4.5 mL methylene chloride and 0.5 mL water was dropwise added 5.0 mL of TFA. The reaction was stirred at room temperature for 50 min. The solution mixture was concentrated, and dried by co-evaporation with toluene (3 X 15 mL). The resulting material was directly used in the next step. ESI-MS $(M+H)^+$: calcd 306, found 306.

(c) **N1-(2(R)-hydroxy-1(S)-indanyl)-N4-hydroxy-2(R)-isobutyl-butanediamide:**

To a cooled (0° C) solution of 501.0 mg of N-(2R-hydroxy-1S-indanyl)-2R-isobutyl-3-(hydroxycarbonyl) propanamide in 6.4 mL DMF was added 786.5 mg of O-benzyl hydroxyamine-HCl, and 684.6 mg of TBTU, followed by addition of 1.71 mL of ethyldiisopropyl amine. The reaction was stirred at 0° C for 15 min. and warmed to room temperature. After 4 h, the reaction mixture was poured into ethyl acetate / 5% citric acid, the aqueous solution was extracted with ethyl acetate (3 X 25 mL). The combined organic solution was washed with 5% citric acid, water, sat. $NaHCO_3$, brine, and dried over $MgSO_4$. The solution was filtered and concentrated to afford 647 mg of desired product as a white solid.

To 323.5 mg of the above in 20 mL methanol was added 500 mg of 5% $Pd/BaSO_4$. The mixture was shaken under 50 psi H_2 for 16 hour. The reaction mixture was filtered and concentrated and purified by reverse HPLC to afford 110 mg of the desired hydroxamic acid as a white solid. ESI-MS $(M+H)^+$: calcd 321, found 321.

Example 2: **N1-(2(R)-hydroxy-1(S)-indanyl)-N4-hydroxy-2(R)-isobutyl-3(S)-(3-propionic acid)-butanediamide:**

Following a procedure analogous to that used in example 1, 2R-isobutyl 3S-(tert-butoxycarbonyl) 5-benzoxycarbonyl pentanoic acid was coupled with (1S, 2R)-(-) cis -1-amino-2-indanol using TBTU as the coupling reagent. Removal of tert-butyl protecting group was achieved by treating with TFA as described in example 1, followed by coupling with O-benzyl hydroxyamine-HCl mediated by TBTU. The resulting material was hydrogenated to afford the desired product. ESI-MS $(M+H)^+$: calcd 393, found 393.

Example 3: **N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-3(S)-methyl-butanediamide**:

Following a procedure analogous to that used in example 1, 2R-hexyl 3S-(tert-butoxycarbonyl) butanoic acid was coupled with (1S, 2R)-(-) cis -1-amino-2-indanol using TBTU as the coupling reagent. Removal of tert-butyl protecting group was achieved by treating with TFA as described in example 1, followed by coupling with O-benzyl hydroxyamine-HCl mediated by TBTU or BOP. The resulting material was hydrogenated to afford the desired product as a white solid. ESI-MS (M+H)+: calcd 335, found 335.

Example 4: N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-3(S)-propyl-butanediamide:

Following a procedure analogous to that used in example 1, 2R-isobutyl 3S-(tert-butoxycarbonyl) hexanoic acid was coupled with (1S, 2R)-(-) cis -1-amino-2-indanol using TBTU as the coupling reagent. Removal of tert-butyl protecting group was achieved by treating with TFA as described in example 1, followed by coupling with O-benzyl hydroxyamine-HCl mediated by TBTU or BOP. The resulting material was hydrogenated to afford the desired product as a white solid. ESI-MS $(M+H)^+$: calcd 363, found 363.

Example 5: N1-(2(R)-hydroxy-1(S)-indanyl)-N4-hydroxy-2(R)-hexyl-3(S)-propyl-butanediamide;

Following a procedure analogous to that used in example 1, 2R-hexyl 3S-(tert-butoxycarbonyl) hexanoic acid was coupled with (1S, 2R)-(-) cis -1-amino-2-indanol using TBTU as the coupling reagent. Removal of tert-butyl protecting group was achieved by treating with TFA as described in example 1, followed by coupling with O-benzyl hydroxyamine-HCl mediated by TBTU or BOP. The resulting material was hydrogenated to afford the desired product as a white solid. ESI-MS (M+H)+: calcd 391, found 391.

Example 6: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-hydroxy-phenyl)methyl]-butanediamide;

(a) Preparation of N-(2R-hydroxy-1S-indanyl)-3-(4-benzyloxy-phenyl)- propanamide;

To a stirred, cooled (0° C) solution of 10g (39.1 mmol) 3-(4-benzyloxy-phenyl)-propinoic acid and 7 g (46.92 mmol) (1S, 2R)-(-) cis -1-amino-2-indanol in 200 mL of anhydrous DMF was added 17.3g BOP as a solid, followed by addition of 20 mL of diethylisopropyl amine. The reaction was allowed to warmed to room temperature. After 5 h, the reaction mixture was diluted with 100 mL 10% citric acid and 100 mL ethyl acetate, the aqueous solution was further extracted with ethyl acetate (2 X 50 mL). The combined organic solution was washed with water, sat. $NaHCO_3$, and brine, dried over $MgSO_4$. The solution was filtered and concentrated under reduced pressure to afford 15.1 g desired product as a white solid. ESI-MS $(M+H)^+$: calcd 388, found 388.

(b) **N-(1S, 2R-N,O-dimethyl acetonide-indanyl)-3-(4-benzyloxy-phenyl)-propanamide:**

To a stirred, cooled (0° C) solution of 15.1 g N-(2R-hydroxy-1S-indanyl)-3-(4-benzyloxy-phenyl)-propanamide and 1.14 g of PPTS in 300 mL of methylene chloride was slowly added 30 ml of 2-methoxy propene. The solution was slowly warmed to room temperature and stirred overnight. The reaction was quenched by addition of 50 mL of sat. $NaHCO_3$, and extracted with ethyl acetate (3 X 50 mL). The combined solution was washed with sat $NaHCO_3$, water, brine, and dried over $MgSO_4$. The solution was filtered and concentrated. The crude material was purified by flash column (Ethyl acetate/ Hexane: 40:60) to give 15.3 g desired product as a white solid. ESI-MS $(M+H)^+$: calcd 428, found 428.

(c) **N-(1S, 2R-N,O-dimethyl acetonide-indanyl)-2R-(4-Benzyloxy-phenylmethyl)-3-(tert-butoxycarbonyl-propanamide:**

To a stirred and cooled (-78° C) solution of 3.0 g (7.0 mmol) of N-(2R-hydroxy-1S-indanyl)-3-(4-benzyloxy-phenyl)- propanamide in 20 mL THF was dropwise added a freshly prepared, cooled (-78° C) LDA (7.0 mmol) in THF. After 1.0 hour, a solution of 1.14 mL (7.7 mmol) tert-butyl 2-bromoacetate in 3.0 ml THF was added dropwise. The resulting solution was incubated at -78° C for 4.0 h. The reaction was quenched by addition of 10% citric acid, and extracted with ethyl acetate (3 X 100 mL). The combined organic solution was washed with water, brine, and dried over $MgSO_4$. The solution was filtered and concentrated. The crude material was purified by flash column with (Ethyl acetate/ Hexane: 15-25:85-75) to afford the desired product (2.8 g, 71% yield) as a white solid, and 0.1g of other diastereomer. ESI-MS $(M+H)^+$: calcd 542, found 542.

(d) **N-(2R-hydroxy-1S-indanyl)-2R-(4-Benzyloxy-phenylmethyl)-3-(hydroxy-carbonyl) propanamide:**

To a solution of 1.13 g of N-(2R-hydroxy-1S-indanyl)-2R-(4-Benzyloxy-phenylmethyl)-3-(tert-butoxycarbonyl) propanamide in 7.6 mL methylene chloride and 0.4 mL water was dropwise added 8.0 mL of TFA. The reaction was stirred at room temperature for 50 min. The solution mixture was concentrated to half of its original volume. The residue was then dried by co-evaporation with toluene (3 X 15 mL) and directly used in the next step. ESI-MS $(M+H)^+$: calcd 446, found 446.

(e) N-(2R-hydroxy-1S-indanyl)-2R-(4-Benzyloxy-phenylmethyl)-3-(N-hydroxyaminocarbonyl)propan-amide:

To a cooled (0° C) solution of 104 mg of N-(2R-hydroxy-1S-indanyl)-2R-(4-Benzyloxy-phenylmethyl)-3-(hydroxy-carbonyl) propanamide in 1.2 mL DMF was added 112 mg of O-benzyl hydroxylamine-HCl, and 78.8 mg of TBTU, followed by addition of 0.24 mL of ethyldiisopropyl amine. The reaction was stirred at 0° C for 15 min. and warmed to room temperature. After 2h, the reaction mixture was poured into ethyl acetate / 5% citric acid, the aqueous solution was extracted with ethyl acetate (3 X 25 mL). The combined organic solution was washed with 5% citric acid, water, sat. $NaHCO_3$, brine, and dried over $MgSO_4$. The solution was filtered and concentrated to afford 105 mg of desired product.

To 105 mg of the above in 6 mL methanol was added 60 mg of 5% $Pd/BaSO_4$. The mixture was shaken under 50 psi H_2 for 4 hour. The reaction mixture was filtered and concentrated and purified by reverse HPLC to afford 47 mg of the desired hydroxamic acid as a white solid. ESI-MS $(M+H)^+$: calcd 371, found 371.

Example 7: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-methoxy-phenyl)methyl]-butanediamide:

Prepared by the method described in example 6 to give the desired material. ESI-MS $(M+H)^+$: calcd 385, found 385.

Example 8: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(hydroxy-phenyl)methyl]-butanediamide:

Prepared by the method described in example 6 to give the desired material. ESI-MS $(M+H)^+$: calcd 355, found 355.

Example 9: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-phenyl-propyl]butanediamide:

Prepared by the method described in example 6 to give the desired material. ESI-MS $(M+H)^+$: calcd 383, found 383.

Example 10: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(benzyloxy)-phenyl]methyl]-butanediamide:**

Prepared by the method described in example 6 to give the desired material. ESI-MS $(M+H)^+$: calcd 461, found 461.

Example 11: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-(benzyloxy)-phenyl]methyl]-butanediamide:**

Prepared by the method described in example 6 to give the desired material. ESI-MS $(M+H)^+$: calcd 461, found 461.

Example 12: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-butanediamide:**

Prepared by the method described in example 6 to give the desired material. ESI-MS $(M+H)^+$: calcd 371, found 371.

Example 13: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(fluoro-phenyl)methyl]-butanediamide:**

Prepared by the method described in example 6 to give the desired material. ESI-MS $(M+H)^+$: calcd 373, found 373.

Example 14: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3,4-(methylenedioxy-phenyl)methyl]-butanediamide;**

Prepared by the method described in example 6 to give the desired material. ESI-MS $(M+H)^+$: calcd 379, found 379.

Example 15: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(methoxy-phenyl)methyl]-butanediamide;**

Prepared by the method described in example 6 to give the desired material. ESI-MS $(M+H)^+$: calcd 385, found 385.

Example 16: : **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(phenyl)phenyl]methyl]-butanediamide;**

(a) **N-(1S,2R-N,O-dimethyl acetonide-indanyl)-2R-(4-phenyl)phenylmethyl-3-(tert-butoxycarbonyl) propanamide;**

To 2.6 g N-(1S ,2R-N,O-dimethyl acetonide-indanyl)-2R-(4-Benzyloxy-phenylmethyl)-3-(tert-butoxycarbonyl) propanamide in 20 mL methanol was added 300 mg of 5% Pd/C. The mixture was shaken under 50 psi H_2 for 17 hour. The reaction mixture was filtered and concentrated to afford 2.0 g of the desired product.

To a cooled (0° C) solution of 1.2 g of N-(2R-hydroxy-1S-indanyl)-2R-(4-hydroxy-phenylmethyl)-3-(tert-butoxycarbonyl) propanamide and 0.95 g of $PhN(tf)_2$ in 9.0 mL of methylene chloride was dropwise

added 0.77 mL Et_3N. After 45 min at 0° C, the reaction mixture was diluted in ethyl ether (60 mL), washed with sat $NaHCO_3$, brine, and dried over $MgSO_4$. The crude mater was purified by flash column with 20% ethyl acetate in hexane to afford the desired product as a colorless oil.

To a solution of 192.0 mg of above material and 22 mg of PPh_3 in 1.4 mL toluene and 1.4 mL 0.35M Na_2CO_3 aq. solution was added catalytical amount (6.0 mg) of $Pd(Ac)_2$. The resulting mixture was stirred at 60° C for 10 min, followed by addition of 44 mg of benzene bornic acid as solid. The reaction was heated at 70° C. After four hour, the reaction mixture was then diluted with ethyl acetate, washed with water, brine, and dried over MgSO4. The crude material was purified by 15% ethyl acetate in hexane to afford 127.1 mg of desired product as a colorless oil. ESI-MS $(M+H)^+$: calcd 431, found 431.

(b) **N-(2R-hydroxy-1S-indanyl)-2R-(4-phenyl)phenyl-methyl-3-(N-hydroxyaminocarbonyl)propanamide:**

Following the method used in the synthesis of example 1, the above N-(1S ,2R-N,O-dimethyl acetonide-indanyl)-2R-(4-phenyl)phenylmethyl-3-(tert-butoxycarbonyl) propanamide was treated with TFA, followed by coupling with hydroxylamine to yield the desired N-(2R-hydroxy-1S-indanyl)-2R-(4-phenyl)-phenylmethyl-3-(N-hydroxyaminocarbonyl)-propanamide as a white solid. ESI-MS $(M+H)^+$: calcd 431.2, found 431.2

Example 17: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-tert-butylaminosulfonyl-phenyl)phenyl]methyl]butanediamide:**

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 566, found 566.

Example 18: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-methoxy-phenyl)phenyl]methyl-]butanediamide:**

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 461, found 461.

Example 19: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-trifluoromethyl-phenyl)-phenyl]methyl]butanediamide:**

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 499, found 499.

Example 20: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[(3-hydroxy-4-methoxyphenyl)-methyl]butanediamide:**

Prepared by the method described in example 6 to give the desired material. ESI-MS $(M+H)^+$: calcd 401, found 401.

Example 21: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-(3-thiophene)-isoxazoline]-methyl]butanediamide:**

Prepared by the method described in example 6 to give the desired material. ESI-MS $(M+H)^+$: calcd 429, found 429.

Example 22: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-chloro-phenyl)-phenyl]-methyl]butanediamide:

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 465.5, found 465.5.

Example 23: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-benzofuran)-phenyl]-methyl]butanediamide:

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 471, found 471.

Example 24: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-methyl-phenyl)-phenyl]-methyl]butanediamide:

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 445, found 445.

Example 25: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3,4-(methylenedioxy-phenyl)-phenyl]methyl]butanediamide:

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 475, found 475.

Example 26: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-tetrazole-phenyl)-phenyl]-methyl]butane-diamide:

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 499, found 499.

Example 27: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-phenyl)phenyl]methyl]-butanediamide;

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 431, found 431.

Example 28: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-methyl-phenyl)phenyl]methyl]-butanediamide;

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 445, found 445.

Example 29: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(amino-phenyl)methyl]-butanediamide;

Prepared by the method described in example 6 to give the desired material. ESI-MS $(M+H)^+$: calcd 370, found 370.

Example 30: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(benzyloxy-carbonyl)-amino]phenyl)methyl]-butanediamide;

Prepared by the method described in example 6 to give the desired material. ESI-MS $(M+H)^+$: calcd 504, found 504.

Example 31: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-hydroxymethlene)phenyl)-phenyl]methyl]-butanediamide;

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 461, found 461.

Example 32: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,4,5-trimethoxy-phenyl)phenyl]methyl]-butanediamide:

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 521, found 521.

Example 33: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2,4-di-methoxy-phenyl)-phenyl]methyl]-butanediamide:

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 491, found 491.

Example 34: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,5-di-chloro-phenyl)-phenyl]methyl]butane-diamide:

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 499, found 499.

Example 35: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-trifluoromethyl-phenyl)-phenyl]methyl]-butanediamide:

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 499, found 499.

Example 36: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-isopropyl-phenyl)-phenyl]methyl]butane-diamide:**

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 473, found 473.

Example 37: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2,4-dichloro-phenyl)-phenyl]methyl]butane-diamide:**

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 499, found 499.

Example 38: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-chloro-4-fluoro-phenyl)-phenyl]methyl]-butanediamide:**

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 483, found 483.

Example 39: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(p-toluenesulfonylamino)-phenyl]methyl]-butanediamide:**

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 524, found 524.

Example 40: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)- phenylmethyl-3(S)-(tert-butyloxy-carbonyl-amino)-butanediamide:**

To a solution of 20g of Boc-Asp(OBn)-OH and 8.9 g of K_2CO_3 in 200 mL DMF was added 4.04 mL of CH_3I. The reaction mixture was stirred at room temperature for 12 h. The mixture was diluted in water, extracted with diethyl ether. The combined organic layer was washed with sat. $NaHCO_3$, water and brine. The crude material was recrystalized from diethyl ether and hexane to afford 19.2g of the desired product Boc-Asp(OBn)-OCH_3.

To a cooled (-78 °C) solution of 2.5 g of compound Boc-Asp(OBn)-OCH_3 in 49 mL toluene was added dropwise 15.2 mL of (1.o M in THF) LiHMDS over 15 min. The resulting solution was stirred at -78 °C for 1.0 h, followed by addition of 1.4 mL benzyl bromide. The solution was stirred at -50 °C overnight. The reaction was quenched with 10% citric acid, and extracted with diethyl ether. The organic layer was washed with sat. brine, dried over Na_2SO_4. The crude material was purified by 15% ethyl acetate to afford 2.1 g (64% yield) of desired product.

1.0 g (2.34 mmmol) above product and 500 mg of 10% Pd/C was hydrogenated at 32 Psi for two hour. The reaction mixture was filtered, and concentracted to afford a residue.

678 mg (2.01 mmol) above acid was coupled with 314 mg cis-2-amino indanol using 933 mg of BOP as the coupling reagent in DMF to afford 867 mg of coupling product N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-phenylmethyl-3(S)-(tert-butylxoy-carbonyl-amino)-4-(tert-butoxycarbonyl)butan-amide.

To a cooled solution of 268 mg of N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-phenylmethyl-3(S)-(tert-butylxoy-carbonyl-amino)-4-(tert-butoxycarbonyl)butan-amide.in 4.3 mL THF was added 0.43 mL (2.5 M in H_2O) LiOH solution. The reaction mixture was stirred at 0 °C for 30 min. The reaction was quenched with 10% citric acid, extracted with EtOAc,

the organic layer was washed with sat. brine, and dried over Na_2SO_4. The solvent was removed to afford 252.1 mg of the product as white solid.

The above acid (252 mg, 0.555 mmol) was treated with 257 mg of BOP and 116 mg of hydroxylamine in DMF. The crude material was purified by RP-HPLC (column: 41.5 X 250 mm C18 dynamax, gradient: 15 to 65% acetonitrile with 0.1% TFA over 25 min. The sample was detected at 220 nM.) to give the desired material N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-phenylmethyl-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide, ESI-MS $(M+H)^+$: calcd 470, found 470.

Example 41: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,4-methylenedioxyphenyl)-phenyl]methyl]-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide:**

Prepared by the method described in example 40 to give the desired material. ESI-MS $(M+H)^+$: calcd 588, found 588.

Example 42: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-methoxyphenyl)-phenyl]methyl]butanediamide:**

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 461, found 461.

Example 43: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-fluorophenyl)-phenyl]-methyl]butanediamide:**

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 449, found 449.

Example 44: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(fluoro-phenyl)methyl]-3(S)-(tert-butyloxy-carbonyl-amino)-butanediamide:

Prepared by the method described in example 40 to give the desired material. ESI-MS $(M+H)^+$: calcd 488, found 488.

Example 45: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(tert-butyloxy-carbonyl-amino)-butanediamide:

Prepared by the method described in example 40 to give the desired material. ESI-MS $(M+H)^+$: calcd 486, found 486.

Example 46: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-nitrophenyl)phenyl]-methyl]butanediamide:

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 476, found 476.

Example 47: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-(methylsulfonyl-amino)-phenyl)phenyl]-methyl]butanediamide:

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 524, found 524.

Example 48: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2,2-dimethyl-propionamido)-butanediamide:

Prepared by the method described in example 40 to give the desired material. ESI-MS $(M+H)^+$: calcd 470, found 470.

Example 49: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(ethyloxy-carbonyl-amino)-butanediamide;

Prepared by the method described in example 40 to give the desired material. ESI-MS $(M+H)^+$: calcd 458, found 458.

Example 50: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(iso-butyloxy-carbonyl-amino)-butanediamide;

Prepared by the method described in example 40 to give the desired material. ESI-MS $(M+H)^+$: calcd 486, found 486.

Example 51: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(propionamido)-butanediamide;

Prepared by the method described in example 40 to give the desired material. ESI-MS $(M+H)^+$: calcd 458, found 458.

Example 52: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-methyl-cyclo-propane carboxamido-1-yl)-butanediamide;

Prepared by the method described in example 40 to give the desired material. ESI-MS $(M+H)^+$: calcd 452, found 452.

Example 53: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2,2-dimethyl-propyl-amino)-butanediamide;**

Prepared by the method described in example 40 to give the desired material. ESI-MS $(M+H)^+$: calcd 455, found 455.

Example 54: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(methylsulfonyl-amino)-butanediamide;**

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 464, found 464.

Example 55: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-amino-butane-diamide;**

Prepared by the method described in example 40 to give the desired material. ESI-MS $(M+H)^+$: calcd 386, found 386.

Example 56: **N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(methylsulfonylamino)-phenyl)methyl]butane-diamide;**

Prepared by the method described in example 16 to give the desired material. ESI-MS $(M+H)^+$: calcd 448, found 448.

Table 1



Ex#	R_2	R_3	M+H
1	H	iso-butyl	321
2	$CH_2CH_2CO_2H$	iso-butyl	393
3	methyl	iso-butyl	335
4	n-propyl	iso-butyl	363
5	n-propyl	n-C_6H_{13}	391
6	H	4-hydroxyphenylmethyl	371
7	H	4-methoxyphenylmethyl	385
8	H	4-hydroxyphenylmethyl	355
9	H	3-phenylpropyl	383
10	H	4-benzyloxyphenylmethyl	461
11	H	3-benzyloxyphenylmethyl	461
12	H	3-hydroxyphenylmethyl	371
13	H	4-fluorophenylmethyl	373
14	H	3,4-methylenedioxy phenylmethyl	379
15	H	3-methoxyphenylmethyl	385
16	H	4-phenyl-phenylmethyl	431
17	H	4-(2-(tert-butylaminosulfonyl)-phenylphenylmethyl	566
18	H	4-(2-methoxyphenyl)-phenylmethyl	461
19	H	4-(3-trifluoromethyl-phenyl)-phenylmethyl	499
20	H	(3-hydroxy-4-methoxy)phenylmethyl	401
21	H	3-(3-thiophene)-isoxazoline-methyl	429

22	H	4-(2-chlorophenyl)-phenylmethyl	465
23	H	4-(2-benzofuran)-phenylmethyl	471
24	H	4-(2-methylphenyl)-phenyl-methyl	445
25	H	(3,4-methylene-dioxyphenyl)phenyl-methyl	475
26	H	4-(2-tetrazolephenyl)-phenyl-methyl	499
27	H	3-phenylphenylmethyl	431
28	H	(3-methyl-phenyl)-phenylmethyl	445
29	H	4-amino-phenylmethyl	370
30		4-benzyloxy-carbonyl-amino-phenylmethyl	504
31	H	4-(2-hydroxymethylene-phenyl)phenylmethyl	461
32	H	4-(3,4,5-trimethoxy-phenyl)phenylmethyl	521
33	H	4-(2,4-dimethoxy-phenyl)phenylmethyl	491
34	H	4-(3,5-dichloro-phenyl)-phenylmethyl	499
35	H	4-(2-trifluoromethyl-phenyl)phenylmethyl	499
36	H	4-(3-isopropyl-phenyl)phenyl-methyl	473
37	H	4-(2,4-dichloro-phenyl)phenyl-methyl	499
38	H	4-(3-chloro,4-fluoro-phenyl)phenylmethyl	483
39	H	4-(p-toluenesulfonyl-amino)-phenylmethyl	524
40	BocNH	phenylmethyl	470
41	BocNH	4-(3,4-methylenedioxy-phenyl)phenylmethyl	588

42	H	4-(3-methoxy-phenyl)phenylmethyl	461
43	H	4-(3-fluoro-phenyl)phenylmethyl	449
44	BocNH	3-fluorophenylmethyl	488
45	BocNH	3-hydroxyphenylmethyl	486
46	H	4-(3-nitro-phenyl)phenylmethyl	476
47	H	4-(3-methylsulfonylamino-phenyl)phenylmethyl	524
48	2,2-dimethylpropionamido	3-hydroxyphenylmethyl	470
49	ethoxycarbonylamino	3-hydroxyphenylmethyl	458
50	iso-butoxy-carbonyl-amino	3-hydroxyphenylmethyl	486
51	propionamido	3-hydroxyphenylmethyl	458
52	1-methylcyclopropane carboxamido-1-yl	3-hydroxyphenylmethyl	452
53	2,2-dimethylpropylamino	3-hydroxyphenylmethyl	455
54	methylsulfonylamino	3-hydroxyphenylmethyl	464
55	amino	3-hydroxyphenylmethyl	386
56	H	4-(methylsulfonyl-amino)phenylmethyl	448

The following tables contain representative examples of the present invention. Each entry in each table is intended to be paired with the formula at the start of the table.

Table 2



I



II



III



IV



V



VI



n= 0, 1,2

VII



VIII



IX



X



XI



XII



XIII



XIV



XV



XVI



n = 1,2

XVII



XVIII



XIX



n=1, 2, 3

XX



XXI



n=1, 2, 3

XXII



n=1, 2, 3

XXIII



n=1, 2, 3

XXIV



XXV



XXVI



XXVII



XXVIII



XXIX



XXX

X= CH_2, O, S, $S(O)_2$, S(O)



XXXI



XXXII

Ex #	R2	R3	Ms
200	H	H	
201	H	methyl	
202	H	ethyl	
203	H	n-propyl	
204	H	n-butyl	
205	H	n-pentyl	
206	H	n-hexanyl	
207	H	n-heptanyl	
208	H	isopropyl	
209	H	tert-butyl	
210	H	cyclopropyl	
211	H	cyclobutanyl	
212	H	cyclopentanyl	
213	H	cyclohexanyl	
214	H	cycloheptanyl	
215	H	phenyl	
216	H	phenylmethyl	
217	H	3-hydroxyphenyl	
218	H	3-hydroxy-4-methoxyphenyl	
219	H	3-fluorophenyl	
220	H	3-chlorophenyl	
221	H	3-nitrophenyl	
222	H	3-aminophenyl	
223	H	3-methylsulfonamidephenyl	
224	H	3-trifluoro-methylsulfonamidephenyl	
225	H	3-Ac-NHphenyl	
226	H	3-Boc-NHphenyl	
227	H	3-Cbz-NHphenyl	
228	H	3-aminomethylenephenyl	
229	H	3-aminoethylenephenyl	
230	H	3-cyanophenyl	
231	H	3-cyanomethylphenyl	
232	H	3-hydroxymethylenephenyl	
233	H	3-carboxylphenyl	
234	H	3-mercaptophenyl	
235	H	3-methoxyphenyl	
236	H	3,4-methylenedioxophenyl	
237	H	3-tetrazolephenyl	
238	H	3-aminosulfonylphenyl	
239	H	3-methylamino-sulfonylphenyl	
240	H	3-ethylamino-sulfonylphenyl	
241	H	3-tert-butylamino-sulfonylphenyl	
242	H	3-methylsulfonylphenyl	
243	H	4-methoxyphenyl	
244	H	4-phenylphenyl	
245	H	(2-hydroxy-methylenephenyl)-phenyl	
246	H	(2-tert-butylamino-sufonylphenyl)-phenyl	
247	H	(2-methylamino-sufonylphenyl)-phenyl	
248	H	(2-ethylamino-sufonylphenyl)-phenyl	
249	H	(2-amino-sufonylphenyl)-phenyl	
250	H	(2-chlorophenyl)-phenyl	
251	H	(2-fluorophenyl)-phenyl	
252	H	(2,4-dichlorophenyl)-phenyl	

253	H	(2,6-dichlorophenyl)-phenyl	
254	H	(3,5-dichlorophenyl)-phenyl	
256	H	(2,3-dichlorophenyl)-phenyl	
257	H	(2-methylphenyl)-phenyl	
258	H	(2-tetrazole-phenyl)-phenyl	
259	H	(2-methoxy-phenyl)-phenyl	
260	H	(2-tmethyl-phenyl)-phenyl	
261	H	(2-formyl-phenyl)-phenyl	
262	H	(2-amino-phenyl)-phenyl	
263	H	(2-methylamino-phenyl)-phenyl	
264	H	(2-ethylamino-phenyl)-phenyl	
265	H	(2-propylamino-phenyl)-phenyl	
266	H	(2-methylsulfonylamino-phenyl)-phenyl	
267	H	(2-trifluoromethyl-sulfonyl-amino-phenyl)-phenyl	
268	H	(3-methylphenyl)-phenyl	
269	H	(3-isopropylphenyl)-phenyl	
270	H	(3-trifluoromethyl-sulfonyl-amino-phenyl)-phenyl	
271	H	(3-methylsulfonylamino-phenyl)-phenyl	
272	H	(3-amino-phenyl)-phenyl	
273	H	(3-nitro-phenyl)-phenyl	
274	H	2-pyridyl	
275	H	3-pyridyl	
276	H	4-pyridyl	
277	H	3-amino-4-pyridyl	
278	H	3-hydroxy-4-pyridyl	
279	H	3-imidazole	
280	H	2-nitro-3-imidazole	
281	H	5-thiazole	
282	H	5-oxazole	
283	H	4-pyazole	
284	H	phenylethyl	
285	H	2-aminophenylethyl	
286	H	2-methylsulfonylamino-phenylethyl	
287	H	2-trifluoromethylsulfonylamino-phenylethyl	
288	H	2-hydroxymethylene-phenylethyl	
289	H	2-aminomethylene-phenylethyl	
290	H	2-tetrazolephenylethyl	
291	H	2-tert-butylamino-sulfonylphenylethyl	
292	H	2-aminosulfonyl-phenylethyl	
293	H	2-methoxyphenylethyl	
294	H	3-aminophenylethyl	
295	H	3-methylsulfonylamino-phenylethyl	
296	H	3-trifluoromethylsulfonylamino-phenylethyl	
297	H	3-hydroxymethylene-phenylethyl	
298	H	3-aminomethylene-phenylethyl	

299	H	3-tetrazolephenylethyl	
300	H	3-tert-butylamino-sulfonylphenylethyl	
301	H	3-aminosulfonyl-phenylethyl	
302	H	3-methoxyphenylethyl	
303	methyl	H	
304	methyl	methyl	
305	methyl	ethyl	
306	methyl	n-propyl	
307	methyl	n-butyl	
308	methyl	n-pentyl	
309	methyl	n-hexanyl	
310	methyl	n-heptanyl	
311	methyl	isopropyl	
312	methyl	tert-butyl	
313	methyl	cyclopropyl	
314	methyl	cyclobutanyl	
315	methyl	cyclpentanyl	
316	methyl	cyclohexanyl	
317	methyl	cycloheptanyl	
318	methyl	phenyl	
319	methyl	phenylmethyl	
320	methyl	3-hydroxyphenyl	
321	methyl	3-hydroxy-4-methoxyphenyl	
322	methyl	3-fluorophenyl	
323	methyl	3-chlorophenyl	
324	methyl	3-nitrophenyl	
325	methyl	3-aminophenyl	
326	methyl	3-methylsulfonamidephenyl	
327	methyl	3-trifluoro-methylsulfonamidephenyl	
327	methyl	3-Ac-NHphenyl	
329	methyl	3-Boc-NHphenyl	
330	methyl	3-Cbz-NHphenyl	
331	Methyl	3-aminomethylenephenyl	
332	methyl	3-aminoethylenephenyl	
333	methyl	3-cyanophenyl	
334	methyl	3-cyanomethylphenyl	
335	methyl	3-hydroxymethylenephenyl	
336	methyl	3-carboxylphenyl	
337	methyl	3-mercaptophenyl	
338	methyl	3-methoxyphenyl	
339	methyl	3,4-methylenedioxophenyl	
340	methyl	3-tetrazolephenyl	
341	methyl	3-aminosulfonylphenyl	
342	methyl	3-methylamino-sulfonylphenyl	
343	methyl	3-ethylamino-sulfonylphenyl	
344	methyl	3-tert-butylamino-sulfonylphenyl	
345	methyl	3-methylsulfonylphenyl	
346	methyl	4-methoxyphenyl	
347	methyl	4-phenylphenyl	
348	methyl	2-hydroxymethylene-phenyl)-phenyl	
349	methyl	(2-tert-butylamino-sufonylphenyl)-phenyl	
350	methyl	(2-methylamino-sufonylphenyl)-phenyl	
351	methyl	(2-ethylamino-sufonylphenyl)-phenyl	
352	methyl	(2-aminosufonyl-phenyl)-phenyl	
353	methyl	(2-chlorophenyl)-phenyl	

354	methyl	(2-fluorophenyl)-phenyl	
355	methyl	(2,4-dichlorophenyl)-phenyl	
356	methyl	(2,6-dichlorophenyl)-phenyl	
357	methyl	(3,5-dichlorophenyl)-phenyl	
358	methyl	(2,3-dichlorophenyl)-phenyl	
359	methyl	(2-methylphenyl)-phenyl	
360	methyl	(2-tetrazole-phenyl)-phenyl	
361	methyl	(2-methoxy-phenyl)-phenyl	
362	methyl	(2-tmethyl-phenyl)-phenyl	
363	methyl	(2-formyl-phenyl)-phenyl	
364	methyl	(2-amino-phenyl)-phenyl	
365	methyl	(2-methylamino-phenyl)-phenyl	
366	methyl	(2-ethylamino-phenyl)-phenyl	
367	methyl	(2-propylamino-phenyl)-phenyl	
368	methyl	(2-methylsulfonylamino-phenyl)-phenyl	
369	methyl	(2-trifluoromethyl-sulfonyl-amino-phenyl)-phenyl	
370	methyl	(3-methylphenyl)-phenyl	
371	methyl	(3-isopropylphenyl)-phenyl	
372	methyl	(3-trifluoromethyl-sulfonyl-amino-phenyl)-phenyl	
373	methyl	(3-methylsulfonylamino-phenyl)-phenyl	
374	methyl	(3-amino-phenyl)-phenyl	
375	methyl	(3-nitro-phenyl)-phenyl	
376	methyl	2-pyridyl	
377	methyl	3-pyridyl	
378	methyl	4-pyridyl	
379	methyl	3-amino-4-pyridyl	
380	methyl	3-hydroxy-4-pyridyl	
381	methyl	3-imidazole	
382	methyl	2-nitro-3-imidazole	
383	methyl	5-thiazole	
384	methyl	5-oxazole	
385	methyl	4-pyazole	
386	methyl	phenylethyl	
387	methyl	2-aminophenylethyl	
388	methyl	2-methylsulfonylamino-phenylethyl	
389	methyl	2-trifluoromethyl-sulfonylamino-phenylethyl	
390	methyl	2-hydroxymethylene-phenylethyl	
391	methyl	2-aminomethylene-phenylethyl	
392	methyl	2-tetrazolephenylethyl	
393	methyl	2-tert-butylamino-sulfonylphenylethyl	
394	methyl	2-aminosulfonyl-phenylethyl	
395	methyl	2-methoxyphenylethyl	
396	methyl	3-aminophenylethyl	
397	methyl	3-methylsulfonylamino-phenylethyl	
398	methyl	3-trifluoromethylsulfonylamino-phenylethyl	
399	methyl	3-hydroxymethylene-phenylethyl	

400	methyl	3-aminomethylene-phenylethyl	
401	methyl	3-tetrazolephenylethyl	
402	methyl	3-tert-butylamino-sulfonylphenylethyl	
403	methyl	3-aminosulfonyl-phenylethyl	
404	methyl	3-methoxyphenylethyl	
405	OH	H	
406	OH	methyl	
407	OH	ethyl	
408	OH	n-propyl	
409	OH	n-butyl	
410	OH	n-pentyl	
411	OH	n-hexanyl	
412	OH	n-heptanyl	
413	OH	isopropyl	
414	OH	tert-butyl	
415	OH	cyclopropyl	
416	OH	cyclobutanyl	
417	OH	cyclpentanyl	
418	OH	cyclohexanyl	
419	OH	cycloheptanyl	
420	OH	phenyl	
421	OH	phenylmethyl	
422	OH	3-hydroxyphenyl	
423	OH	3-hydroxy-4-methoxyphenyl	
424	OH	3-fluorophenyl	
425	OH	3-chlorophenyl	
426	OH	3-nitrophenyl	
427	OH	3-aminophenyl	
428	OH	3-methylsulfonamidephenyl	
429	OH	3-trifluoro-methylsulfonamidephenyl	
430	OH	3-Ac-NHphenyl	
431	OH	3-Boc-NHphenyl	
432	OH	3-Cbz-NHphenyl	
433	OH	3-aminomethylenephenyl	
434	OH	3-aminoethylenephenyl	
435	OH	3-cyanophenyl	
436	OH	3-cyanomethylphenyl	
437	OH	3-hydroxymethylenephenyl	
438	OH	3-carboxylphenyl	
439	OH	3-mercaptophenyl	
440	OH	3-methoxyphenyl	
441	OH	3,4-methylenedioxophenyl	
442	OH	3-tetrazolephenyl	
443	OH	3-aminosulfonylphenyl	
444	OH	3-methylamino-sulfonylphenyl	
445	OH	3-ethylamino-sulfonylphenyl	
446	OH	3-tert-butylamino-sulfonylphenyl	
447	OH	3-methylsulfonylphenyl	
448	OH	4-methoxyphenyl	
449	OH	4-phenylphenyl	
450	OH	(2-hydroxymethylene-phenyl)-phenyl	
451	OH	(2-tert-butylamino-sufonylphenyl)-phenyl	
452	OH	(2-methylamino-sufonylphenyl)-phenyl	
453	OH	(2-ethylamino-sufonylphenyl)-phenyl	

454	OH	(2-aminosufonyl-phenyl)-phenyl	
455	OH	(2-chlorophenyl)-phenyl	
456	OH	(2-fluorophenyl)-phenyl	
457	OH	(2,4-dichlorophenyl)-phenyl	
458	OH	(2,6-dichlorophenyl)-phenyl	
459	OH	(3,5-dichlorophenyl)-phenyl	
460	OH	(2,3-dichlorophenyl)-phenyl	
461	OH	(2-methylphenyl)-phenyl	
462	OH	(2-tetrazole-phenyl)-phenyl	
463	OH	(2-methoxy-phenyl)-phenyl	
464	OH	(2-tmethyl-phenyl)-phenyl	
465	OH	(2-formyl-phenyl)-phenyl	
466	OH	(2-amino-phenyl)-phenyl	
467	OH	(2-methylamino-phenyl)-phenyl	
468	OH	(2-ethylamino-phenyl)-phenyl	
469	OH	(2-propylamino-phenyl)-phenyl	
470	OH	(2-methylsulfonylamino-phenyl)-phenyl	
471	OH	(2-trifluoromethyl-sulfonyl-amino-phenyl)-phenyl	
472	OH	(3-methylphenyl)-phenyl	
473	OH	(3-isopropylphenyl)-phenyl	
474	OH	(3-trifluoromethyl-sulfonyl-amino-phenyl)-phenyl	
475	OH	(3-methylsulfonylamino-phenyl)-phenyl	
476	OH	(3-amino-phenyl)-phenyl	
477	OH	(3-nitro-phenyl)-phenyl	
478	OH	2-pyridyl	
479	OH	3-pyridyl	
480	OH	4-pyridyl	
481	OH	3-amino-4-pyridyl	
482	OH	3-hydroxy-4-pyridyl	
483	OH	3-imidazole	
484	OH	2-nitro-3-imidazole	
485	OH	5-thiazole	
486	OH	5-oxazole	
487	OH	4-pyazole	
488	OH	phenylethyl	
489	OH	2-aminophenylethyl	
490	OH	2-methylsulfonylamino-phenylethyl	
491	OH	2-trifluoromethyl-sulfonylamino-phenylethyl	
492	OH	2-hydroxymethylene-phenylethyl	
493	OH	2-aminomethylene-phenylethyl	
494	OH	2-tetrazolephenylethyl	
495	OH	2-tert-butylamino-sulfonylphenylethyl	
496	OH	2-aminosulfonyl-phenylethyl	
497	OH	2-methoxyphenylethyl	
498	OH	3-aminophenylethyl	
499	OH	3-methylsulfonylamino-phenylethyl	
500	OH	3-trifluoromethylsulfonylamino-phenylethyl	

501	OH	3-hydroxymethylene-phenylethyl	
502	OH	3-aminomethylene-phenylethyl	
503	OH	3-tetrazolephenylethyl	
504	OH	3-tert-butylamino-sulfonylphenylethyl	
505	OH	3-aminosulfonyl-phenylethyl	
506	OH	3-methoxyphenylethyl	
507	$NH(CO)CH_3$	H	
508	$NH(CO)CH_3$	methyl	
509	$NH(CO)CH_3$	ethyl	
510	$NH(CO)CH_3$	n-propyl	
511	$NH(CO)CH_3$	n-butyl	
512	$NH(CO)CH_3$	n-pentyl	
513	$NH(CO)CH_3$	n-hexanyl	
514	$NH(CO)CH_3$	n-heptanyl	
515	$NH(CO)CH_3$	isopropyl	
516	$NH(CO)CH_3$	tert-butyl	
517	$NH(CO)CH_3$	cyclopropyl	
518	$NH(CO)CH_3$	cyclobutanyl	
519	$NH(CO)CH_3$	cyclpentanyl	
520	$NH(CO)CH_3$	cyclohexanyl	
521	$NH(CO)CH_3$	cycloheptanyl	
522	$NH(CO)CH_3$	phenyl	
523	$NH(CO)CH_3$	phenylmethyl	
524	$NH(CO)CH_3$	3-hydroxyphenyl	
525	$NH(CO)CH_3$	3-hydroxy-4-methoxyphenyl	
526	$NH(CO)CH_3$	3-fluorophenyl	
527	$NH(CO)CH_3$	3-chlorophenyl	
528	$NH(CO)CH_3$	3-nitrophenyl	
529	$NH(CO)CH_3$	3-aminophenyl	
530	$NH(CO)CH_3$	3-methyl-sulfonamidephenyl	
531	$NH(CO)CH_3$	3-trifluoro-methylsulfonamidephenyl	
532	$NH(CO)CH_3$	3-Ac-NHphenyl	
533	$NH(CO)CH_3$	3-Boc-NHphenyl	
534	$NH(CO)CH_3$	3-Cbz-NHphenyl	
535	$NH(CO)CH_3$	3-aminomethylenephenyl	
536	$NH(CO)CH_3$	3-aminoethylenephenyl	
537	$NH(CO)CH_3$	3-cyanophenyl	
538	$NH(CO)CH_3$	3-cyanomethylphenyl	
539	$NH(CO)CH_3$	3-hydroxy-methylenephenyl	
540	$NH(CO)CH_3$	3-carboxylphenyl	
541	$NH(CO)CH_3$	3-mercaptophenyl	
542	$NH(CO)CH_3$	3-methoxyphenyl	
543	$NH(CO)CH_3$	3,4-methylenedioxophenyl	
544	$NH(CO)CH_3$	3-tetrazolephenyl	
545	$NH(CO)CH_3$	3-aminosulfonylphenyl	
546	$NH(CO)CH_3$	3-methylamino-sulfonylphenyl	
547	$NH(CO)CH_3$	3-ethylamino-sulfonylphenyl	
548	$NH(CO)CH_3$	3-tert-butylamino-sulfonylphenyl	
549	$NH(CO)CH_3$	3-methylsulfonylphenyl	
550	$NH(CO)CH_3$	4-methoxyphenyl	
551	$NH(CO)CH_3$	4-phenylphenyl	

552	$NH(CO)CH_3$	(2-hydroxymethylene-phenyl)-phenyl	
553	$NH(CO)CH_3$	(2-tert-butylamino-sufonylphenyl)-phenyl	
554	$NH(CO)CH_3$	(2-methylamino-sufonylphenyl)-phenyl	
555	$NH(CO)CH_3$	(2-ethylamino-sufonylphenyl)-phenyl	
556	$NH(CO)CH_3$	(2-aminosufonyl-phenyl)-phenyl	
557	$NH(CO)CH_3$	(2-chlorophenyl)-phenyl	
558	$NH(CO)CH_3$	(2-fluorophenyl)-phenyl	
559	$NH(CO)CH_3$	(2,4-dichlorophenyl)-phenyl	
560	$NH(CO)CH_3$	(2,6-dichlorophenyl)-phenyl	
561	$NH(CO)CH_3$	(3,5-dichlorophenyl)-phenyl	
562	$NH(CO)CH_3$	(2,3-dichlorophenyl)-phenyl	
563	$NH(CO)CH_3$	(2-methylphenyl)-phenyl	
564	$NH(CO)CH_3$	(2-tetrazole-phenyl)-phenyl	
565	$NH(CO)CH_3$	(2-methoxy-phenyl)-phenyl	
566	$NH(CO)CH_3$	(2-tmethyl-phenyl)-phenyl	
567	$NH(CO)CH_3$	(2-formyl-phenyl)-phenyl	
568	$NH(CO)CH_3$	(2-amino-phenyl)-phenyl	
569	$NH(CO)CH_3$	(2-methylamino-phenyl)-phenyl	
570	$NH(CO)CH_3$	(2-ethylamino-phenyl)-phenyl	
571	$NH(CO)CH_3$	(2-propylamino-phenyl)-phenyl	
572	$NH(CO)CH_3$	(2-methylsulfonylamino-phenyl)-phenyl	
573	$NH(CO)CH_3$	(2-trifluoromethyl-sulfonyl-amino-phenyl)-phenyl	
574	$NH(CO)CH_3$	(3-methylphenyl)-phenyl	
575	$NH(CO)CH_3$	(3-isopropylphenyl)-phenyl	
576	$NH(CO)CH_3$	(3-trifluoromethyl-sulfonyl-amino-phenyl)-phenyl	
577	$NH(CO)CH_3$	(3-methylsulfonylamino-phenyl)-phenyl	
578	$NH(CO)CH_3$	(3-amino-phenyl)-phenyl	
579	$NH(CO)CH_3$	(3-nitro-phenyl)-phenyl	
580	$NH(CO)CH_3$	2-pyridyl	
581	$NH(CO)CH_3$	3-pyridyl	
582	$NH(CO)CH_3$	4-pyridyl	
583	$NH(CO)CH_3$	3-amino-4-pyridyl	
584	$NH(CO)CH_3$	3-hydroxy-4-pyridyl	
585	$NH(CO)CH_3$	3-imidazole	
586	$NH(CO)CH_3$	2-nitro-3-imidazole	
587	$NH(CO)CH_3$	5-thiazole	
588	$NH(CO)CH_3$	5-oxazole	
589	$NH(CO)CH_3$	4-pyazole	
590	$NH(CO)CH_3$	phenylethyl	
591	$NH(CO)CH_3$	2-aminophenylethyl	
592	$NH(CO)CH_3$	2-methylsulfonylamino-phenylethyl	
593	$NH(CO)CH_3$	2-trifluoromethylsulfonylamino-phenylethyl	
594	$NH(CO)CH_3$	2-hydroxymethylene-phenylethyl	

595	$NH(CO)CH_3$	2-aminomethylene-phenylethyl	
596	$NH(CO)CH_3$	2-tetrazolephenylethyl	
597	$NH(CO)CH_3$	2-tert-butylamino-sulfonylphenylethyl	
598	$NH(CO)CH_3$	2-aminosulfonyl-phenylethyl	
599	$NH(CO)CH_3$	2-methoxyphenylethyl	
600	$NH(CO)CH_3$	3-aminophenylethyl	
601	$NH(CO)CH_3$	3-methylsulfonylamino-phenylethyl	
602	$NH(CO)CH_3$	3-trifluoromethyl-sulfonylamino-phenylethyl	
603	$NH(CO)CH_3$	3-hydroxymethylene-phenylethyl	
604	$NH(CO)CH_3$	3-aminomethylene-phenylethyl	
605	$NH(CO)CH_3$	3-tetrazolephenylethyl	
606	$NH(CO)CH_3$	3-tert-butylamino-sulfonylphenylethyl	
607	$NH(CO)CH_3$	3-aminosulfonyl-phenylethyl	
608	$NH(CO)CH_3$	3-methoxyphenylethyl	
609			
610	$NH(CO)C_2H_5$	H	
611	$NH(CO)C_2H_5$	methyl	
612	$NH(CO)C_2H_5$	ethyl	
613	$NH(CO)C_2H_5$	n-propyl	
614	$NH(CO)C_2H_5$	n-butyl	
615	$NH(CO)C_2H_5$	n-pentyl	
616	$NH(CO)C_2H_5$	n-hexanyl	
617	$NH(CO)C_2H_5$	n-heptanyl	
618	$NH(CO)C_2H_5$	isopropyl	
619	$NH(CO)C_2H_5$	tert-butyl	
620	$NH(CO)C_2H_5$	cyclopropyl	
621	$NH(CO)C_2H_5$	cyclobutanyl	
622	$NH(CO)C_2H_5$	cyclpentanyl	
623	$NH(CO)C_2H_5$	cyclohexanyl	
624	$NH(CO)C_2H_5$	cycloheptanyl	
625	$NH(CO)C_2H_5$	phenyl	
626	$NH(CO)C_2H_5$	phenylmethyl	
627	$NH(CO)C_2H_5$	3-hydroxyphenyl	
628	$NH(CO)C_2H_5$	3-hydroxy-4-methoxyphenyl	
629	$NH(CO)C_2H_5$	3-fluorophenyl	
630	$NH(CO)C_2H_5$	3-chlorophenyl	
631	$NH(CO)C_2H_5$	3-nitrophenyl	
632	$NH(CO)C_2H_5$	3-aminophenyl	
633	$NH(CO)C_2H_5$	3-methylsulfonamidephenyl	
634	$NH(CO)C_2H_5$	3-trifluoro-methylsulfonamidephenyl	
635	$NH(CO)C_2H_5$	3-Ac-NHphenyl	
636	$NH(CO)C_2H_5$	3-Boc-NHphenyl	
637	$NH(CO)C_2H_5$	3-Cbz-NHphenyl	
638	$NH(CO)C_2H_5$	3-aminomethylenephenyl	
639	$NH(CO)C_2H_5$	3-aminoethylenephenyl	
640	$NH(CO)C_2H_5$	3-cyanophenyl	
641	$NH(CO)C_2H_5$	3-cyanomethylphenyl	
642	$NH(CO)C_2H_5$	3-hydroxymethylenephenyl	
643	$NH(CO)C_2H_5$	3-carboxylphenyl	
644	$NH(CO)C_2H_5$	3-mercaptophenyl	
645	$NH(CO)C_2H_5$	3-methoxyphenyl	

646	$NH(CO)C_2H_5$	3,4-methylenedioxophenyl	
647	$NH(CO)C_2H_5$	3-tetrazolephenyl	
648	$NH(CO)C_2H_5$	3-aminosulfonylphenyl	
649	$NH(CO)C_2H_5$	3-methylamino-sulfonylphenyl	
650	$NH(CO)C_2H_5$	3-ethylamino-sulfonylphenyl	
651	$NH(CO)C_2H_5$	3-tert-butylamino-sulfonylphenyl	
652	$NH(CO)C_2H_5$	3-methylsulfonylphenyl	
653	$NH(CO)C_2H_5$	4-methoxyphenyl	
654	$NH(CO)C_2H_5$	4-phenylphenyl	
655	$NH(CO)C_2H_5$	4-(2-hydroxymethylene-phenyl)-phenyl	
656	$NH(CO)C_2H_5$	4-(2-tert-butylamino-sufonylphenyl)-phenyl	
657	$NH(CO)C_2H_5$	4-(2-methylamino-sufonylphenyl)-phenyl	
658	$NH(CO)C_2H_5$	4-(2-ethylamino-sufonylphenyl)-phenyl	
659	$NH(CO)C_2H_5$	4-(2-aminosufonyl-phenyl)-phenyl	
660	$NH(CO)C_2H_5$	4-(2-chlorophenyl)-phenyl	
661	$NH(CO)C_2H_5$	4-(2-fluorophenyl)-phenyl	
662	$NH(CO)C_2H_5$	4-(2,4-dichlorophenyl)-phenyl	
663	$NH(CO)C_2H_5$	4-(2,6-dichlorophenyl)-phenyl	
664	$NH(CO)C_2H_5$	4-(3,5-dichlorophenyl)-phenyl	
665	$NH(CO)C_2H_5$	4-(2,3-dichlorophenyl)-phenyl	
666	$NH(CO)C_2H_5$	4-(2-methylphenyl)-phenyl	
667	$NH(CO)C_2H_5$	4-(2-tetrazole-phenyl)-phenyl	
668	$NH(CO)C_2H_5$	4-(2-methoxy-phenyl)-phenyl	
669	$NH(CO)C_2H_5$	4-(2-tmethyl-phenyl)-phenyl	
670	$NH(CO)C_2H_5$	4-(2-formyl-phenyl)-phenyl	
671	$NH(CO)C_2H_5$	4-(2-amino-phenyl)-phenyl	
672	$NH(CO)C_2H_5$	4-(2-methylamino-phenyl)-phenyl	
673	$NH(CO)C_2H_5$	4-(2-ethylamino-phenyl)-phenyl	
674	$NH(CO)C_2H_5$	4-(2-propylamino-phenyl)-phenyl	
675	$NH(CO)C_2H_5$	4-(2-methylsulfonylamino-phenyl)-phenyl	
676	$NH(CO)C_2H_5$	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
677	$NH(CO)C_2H_5$	4-(3-methylphenyl)-phenyl	
678	$NH(CO)C_2H_5$	4-(3-isopropylphenyl)-phenyl	
679	$NH(CO)C_2H_5$	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
680	$NH(CO)C_2H_5$	4-(3-methylsulfonylamino-phenyl)-phenyl	
681	$NH(CO)C_2H_5$	4-(3-amino-phenyl)-phenyl	
682	$NH(CO)C_2H_5$	4-(3-nitro-phenyl)-phenyl	
683	$NH(CO)C_2H_5$	2-pyridyl	
684	$NH(CO)C_2H_5$	3-pyridyl	
685	$NH(CO)C_2H_5$	4-pyridyl	

686	$NH(CO)C_2H_5$	3-amino-4-pyridyl	
687	$NH(CO)C_2H_5$	3-hydroxy-4-pyridyl	
688	$NH(CO)C_2H_5$	3-imidazole	
689	$NH(CO)C_2H_5$	2-nitro-3-imidazole	
690	$NH(CO)C_2H_5$	5-thiazole	
691	$NH(CO)C_2H_5$	5-oxazole	
692	$NH(CO)C_2H_5$	4-pyazole	
693	$NH(CO)C_2H_5$	phenylethyl	
694	$NH(CO)C_2H_5$	2-aminophenylethyl	
695	$NH(CO)C_2H_5$	2-methylsulfonylamino-phenylethyl	
696	$NH(CO)C_2H_5$	2-trifluoromethylsulfonylamino-phenylethyl	
697	$NH(CO)C_2H_5$	2-hydroxymethylene-phenylethyl	
698	$NH(CO)C_2H_5$	2-aminomethylene-phenylethyl	
699	$NH(CO)C_2H_5$	2-tetrazolephenylethyl	
700	$NH(CO)C_2H_5$	2-tert-butylamino-sulfonylphenylethyl	
701	$NH(CO)C_2H_5$	2-aminosulfonyl-phenylethyl	
702	$NH(CO)C_2H_5$	2-methoxyphenylethyl	
703	$NH(CO)C_2H_5$	3-aminophenylethyl	
704	$NH(CO)C_2H_5$	3-methylsulfonylamino-phenylethyl	
705	$NH(CO)C_2H_5$	3-trifluoromethylsulfonylamino-phenylethyl	
706	$NH(CO)C_2H_5$	3-hydroxymethylene-phenylethyl	
707	$NH(CO)C_2H_5$	3-aminomethylene-phenylethyl	
708	$NH(CO)C_2H_5$	3-tetrazolephenylethyl	
709	$NH(CO)C_2H_5$	3-tert-butylamino-sulfonylphenylethyl	
710	$NH(CO)C_2H_5$	3-aminosulfonyl-phenylethyl	
711	$NH(CO)C_2H_5$	3-methoxyphenylethyl	
712	$NH(CO)OC2H_5$	H	
713	$NH(CO)OC_2H_5$	methyl	
714	$NH(CO)OC_2H_5$	ethyl	
715	$NH(CO)OC_2H_5$	n-propyl	
716	$NH(CO)OC_2H_5$	n-butyl	
717	$NH(CO)OC_2H_5$	n-pentyl	
718	$NH(CO)OC_2H_5$	n-hexanyl	
719	$NH(CO)OC_2H_5$	n-heptanyl	
720	$NH(CO)OC_2H_5$	isopropyl	
721	$NH(CO)OC_2H_5$	tert-butyl	
722	$NH(CO)OC_2H_5$	cyclopropyl	
723	$NH(CO)OC_2H_5$	cyclobutanyl	
724	$NH(CO)OC_2H_5$	cyclpentanyl	
725	$NH(CO)OC_2H_5$	cyclohexanyl	
726	$NH(CO)OC_2H_5$	cycloheptanyl	
727	$NH(CO)OC_2H_5$	phenyl	
728	$NH(CO)OC_2H_5$	phenylmethyl	
729	$NH(CO)OC_2H_5$	3-hydroxyphenyl	
730	$NH(CO)OC_2H_5$	3-hydroxy-4-methoxyphenyl	
731	$NH(CO)OC_2H_5$	3-fluorophenyl	
732	$NH(CO)OC_2H_5$	3-chlorophenyl	

733	$NH(CO)OC_2H_5$	3-nitrophenyl	
734	$NH(CO)OC_2H_5$	3-aminophenyl	
735	$NH(CO)OC_2H_5$	3-methyl-sulfonamidephenyl	
736	$NH(CO)OC_2H_5$	3-trifluoro-methylsulfonamidephenyl	
737	$NH(CO)OC_2H_5$	3-Ac-NHphenyl	
738	$NH(CO)OC_2H_5$	3-Boc-NHphenyl	
739	$NH(CO)OC_2H_5$	3-Cbz-NHphenyl	
740	$NH(CO)OC_2H_5$	3-aminomethylenephenyl	
741	$NH(CO)OC_2H_5$	3-aminoethylenephenyl	
742	$NH(CO)OC_2H_5$	3-cyanophenyl	
743	$NH(CO)OC_2H_5$	3-cyanomethylphenyl	
744	$NH(CO)OC_2H_5$	3-hydroxy-methylenephenyl	
745	$NH(CO)OC_2H_5$	3-carboxylphenyl	
746	$NH(CO)OC_2H_5$	3-mercaptophenyl	
747	$NH(CO)OC_2H_5$	3-methoxyphenyl	
748	$NH(CO)OC_2H_5$	3,4-methylenedioxophenyl	
749	$NH(CO)OC_2H_5$	3-tetrazolephenyl	
750	$NH(CO)OC_2H_5$	3-aminosulfonylphenyl	
751	$NH(CO)OC_2H_5$	3-methylamino-sulfonylphenyl	
752	$NH(CO)OC_2H_5$	3-ethylamino-sulfonylphenyl	
753	$NH(CO)OC_2H_5$	3-tert-butylamino-sulfonylphenyl	
754	$NH(CO)OC_2H_5$	3-methylsulfonylphenyl	
755	$NH(CO)OC_2H_5$	4-methoxyphenyl	
756	$NH(CO)OC_2H_5$	4-phenylphenyl	
757	$NH(CO)OC_2H_5$	4-(2-hydroxymethylene-phenyl)-phenyl	
758	$NH(CO)OC_2H_5$	4-(2-tert-butylamino-sufonylphenyl)-phenyl	
759	$NH(CO)OC_2H_5$	4-(2-methylamino-sufonylphenyl)-phenyl	
760	$NH(CO)OC_2H_5$	4-(2-ethylamino-sufonylphenyl)-phenyl	
761	$NH(CO)OC_2H_5$	4-(2-aminosufonyl-phenyl)-phenyl	
762	$NH(CO)OC_2H_5$	4-(2-chlorophenyl)-phenyl	
763	$NH(CO)OC_2H_5$	4-(2-fluorophenyl)-phenyl	
764	$NH(CO)OC_2H_5$	4-(2,4-dichlorophenyl)-phenyl	
765	$NH(CO)OC_2H_5$	4-(2,6-dichlorophenyl)-phenyl	
766	$NH(CO)OC_2H_5$	4-(3,5-dichlorophenyl)-phenyl	
767	$NH(CO)OC_2H_5$	4-(2,3-dichlorophenyl)-phenyl	
768	$NH(CO)OC_2H_5$	4-(2-methylphenyl)-phenyl	
769	$NH(CO)OC_2H_5$	4-(2-tetrazole-phenyl)-phenyl	
770	$NH(CO)OC_2H_5$	4-(2-methoxy-phenyl)-phenyl	
771	$NH(CO)OC_2H_5$	4-(2-tmethyl-phenyl)-phenyl	
772	$NH(CO)OC_2H_5$	4-(2-formyl-phenyl)-phenyl	
773	$NH(CO)OC_2H_5$	4-(2-amino-phenyl)-phenyl	
774	$NH(CO)OC_2H_5$	4-(2-methylamino-phenyl)-phenyl	
775	$NH(CO)OC_2H_5$	4-(2-ethylamino-phenyl)-phenyl	
776	$NH(CO)OC_2H_5$	4-(2-propylamino-phenyl)-phenyl	

777	$NH(CO)OC_2H_5$	4-(2-methylsulfonylamino-phenyl)-phenyl	
778	$NH(CO)OC_2H_5$	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
779	$NH(CO)OC_2H_5$	4-(3-methylphenyl)-phenyl	
780	$NH(CO)OC_2H_5$	4-(3-isopropylphenyl)-phenyl	
781	$NH(CO)OC_2H_5$	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
782	$NH(CO)OC_2H_5$	4-(3-methylsulfonylamino-phenyl)-phenyl	
783	$NH(CO)OC_2H_5$	4-(3-amino-phenyl)-phenyl	
784	$NH(CO)OC_2H_5$	4-(3-nitro-phenyl)-phenyl	
785	$NH(CO)OC_2H_5$	2-pyridyl	
786	$NH(CO)OC_2H_5$	3-pyridyl	
787	$NH(CO)OC_2H_5$	4-pyridyl	
788	$NH(CO)OC_2H_5$	3-amino-4-pyridyl	
789	$NH(CO)OC_2H_5$	3-hydroxy-4-pyridyl	
790	$NH(CO)OC_2H_5$	3-imidazole	
791	$NH(CO)OC_2H_5$	2-nitro-3-imidazole	
792	$NH(CO)OC_2H_5$	5-thiazole	
793	$NH(CO)OC_2H_5$	5-oxazole	
794	$NH(CO)OC_2H_5$	4-pyazole	
795	$NH(CO)OC_2H_5$	phenylethyl	
796	$NH(CO)OC_2H_5$	2-aminophenylethyl	
797	$NH(CO)OC_2H_5$	2-methylsulfonylamino-phenylethyl	
798	$NH(CO)OC_2H_5$	2-trifluoromethylsulfonylamino-phenylethyl	
799	$NH(CO)OC_2H_5$	2-hydroxymethylene-phenylethyl	
800	$NH(CO)OC_2H_5$	2-aminomethylene-phenylethyl	
801	$NH(CO)OC_2H_5$	2-tetrazolephenylethyl	
802	$NH(CO)OC_2H_5$	2-tert-butylamino-sulfonylphenylethyl	
803	$NH(CO)OC_2H_5$	2-aminosulfonyl-phenylethyl	
804	$NH(CO)OC_2H_5$	2-methoxyphenylethyl	
805	$NH(CO)OC_2H_5$	3-aminophenylethyl	
806	$NH(CO)OC_2H_5$	3-methylsulfonylamino-phenylethyl	
807	$NH(CO)OC_2H_5$	3-trifluoro-methylsulfonylamino-phenylethyl	
808	$NH(CO)OC_2H_5$	3-hydroxymethylene-phenylethyl	
809	$NH(CO)OC_2H_5$	3-aminomethylene-phenylethyl	
810	$NH(CO)OC_2H_5$	3-tetrazolephenylethyl	
811	$NH(CO)OC_2H_5$	3-tert-butylamino-sulfonylphenylethyl	
812	$NH(CO)OC_2H_5$	3-aminosulfonyl-phenylethyl	
813	$NH(CO)OC_2H_5$	3-methoxyphenylethyl	
814	$NH(CO)OCH_3$	H	
815	$NH(CO)OCH_3$	methyl	
816	$NH(CO)OCH_3$	ethyl	
817	$NH(CO)OCH_3$	n-propyl	
818	$NH(CO)OCH_3$	n-butyl	

819	$NH(CO)OCH_3$	n-pentyl	
820	$NH(CO)OCH_3$	n-hexanyl	
821	$NH(CO)OCH_3$	n-heptanyl	
822	$NH(CO)OCH_3$	isopropyl	
823	$NH(CO)OCH_3$	tert-butyl	
824	$NH(CO)OCH_3$	cyclopropyl	
825	$NH(CO)OCH_3$	cyclobutanyl	
826	$NH(CO)OCH_3$	cyclpentanyl	
827	$NH(CO)OCH_3$	cyclohexanyl	
828	$NH(CO)OCH_3$	cycloheptanyl	
829	$NH(CO)OCH_3$	phenyl	
830	$NH(CO)OCH_3$	phenylmethyl	
831	$NH(CO)OCH_3$	3-hydroxyphenyl	
832	$NH(CO)OCH_3$	3-hydroxy-4-methoxyphenyl	
833	$NH(CO)OCH_3$	3-fluorophenyl	
834	$NH(CO)OCH_3$	3-chlorophenyl	
835	$NH(CO)OCH_3$	3-nitrophenyl	
836	$NH(CO)OCH_3$	3-aminophenyl	
837	$NH(CO)OCH_3$	3-methy-lsulfonamidephenyl	
838	$NH(CO)OCH_3$	3-trifluoro-methylsulfonamidephenyl	
839	$NH(CO)OCH_3$	3-Ac-NHphenyl	
840	$NH(CO)OCH_3$	3-Boc-NHphenyl	
841	$NH(CO)OCH_3$	3-Cbz-NHphenyl	
842	$NH(CO)OCH_3$	3-aminomethylenephenyl	
843	$NH(CO)OCH_3$	3-aminoethylenephenyl	
844	$NH(CO)OCH_3$	3-cyanophenyl	
845	$NH(CO)OCH_3$	3-cyanomethylphenyl	
846	$NH(CO)OCH_3$	3-hydroxy-methylenephenyl	
847	$NH(CO)OCH_3$	3-carboxylphenyl	
848	$NH(CO)OCH_3$	3-mercaptophenyl	
849	$NH(CO)OCH_3$	3-methoxyphenyl	
850	$NH(CO)OCH_3$	3,4-methylenedioxophenyl	
851	$NH(CO)OCH_3$	3-tetrazolephenyl	
852	$NH(CO)OCH_3$	3-aminosulfonylphenyl	
853	$NH(CO)OCH_3$	3-methylamino-sulfonylphenyl	
854	$NH(CO)OCH_3$	3-ethylamino-sulfonylphenyl	
855	$NH(CO)OCH_3$	3-tert-butylamino-sulfonylphenyl	
856	$NH(CO)OCH_3$	3-methylsulfonylphenyl	
857	$NH(CO)OCH_3$	4-methoxyphenyl	
858	$NH(CO)OCH_3$	4-phenylphenyl	
859	$NH(CO)OCH_3$	4-(2-hydroxymethylene-phenyl)-phenyl	
860	$NH(CO)OCH_3$	4-(2-tert-butylamino-sufonylphenyl)-phenyl	
861	$NH(CO)OCH_3$	4-(2-methylamino-sufonylphenyl)-phenyl	
862	$NH(CO)OCH_3$	4-(2-ethylamino-sufonylphenyl)-phenyl	
863	$NH(CO)OCH_3$	4-(2-aminosufonyl-phenyl)-phenyl	
864	$NH(CO)OCH_3$	4-(2-chlorophenyl)-phenyl	
865	$NH(CO)OCH_3$	4-(2-fluorophenyl)-phenyl	
866	$NH(CO)OCH_3$	4-(2,4-dichlorophenyl)-phenyl	
867	$NH(CO)OCH_3$	4-(2,6-dichlorophenyl)-phenyl	

868	$NH(CO)OCH_3$	4-(3,5-dichlorophenyl)-phenyl	
869	$NH(CO)OCH_3$	4-(2,3-dichlorophenyl)-phenyl	
870	$NH(CO)OCH_3$	4-(2-methylphenyl)-phenyl	
871	$NH(CO)OCH_3$	4-(2-tetrazole-phenyl)-phenyl	
872	$NH(CO)OCH_3$	4-(2-methoxy-phenyl)-phenyl	
873	$NH(CO)OCH_3$	4-(2-tmethyl-phenyl)-phenyl	
874	$NH(CO)OCH_3$	4-(2-formyl-phenyl)-phenyl	
875	$NH(CO)OCH_3$	4-(2-amino-phenyl)-phenyl	
876	$NH(CO)OCH_3$	4-(2-methylamino-phenyl)-phenyl	
877	$NH(CO)OCH_3$	4-(2-ethylamino-phenyl)-phenyl	
878	$NH(CO)OCH_3$	4-(2-propylamino-phenyl)-phenyl	
879	$NH(CO)OCH_3$	4-(2-methylsulfonylamino-phenyl)-phenyl	
880	$NH(CO)OCH_3$	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
881	$NH(CO)OCH_3$	4-(3-methylphenyl)-phenyl	
882	$NH(CO)OCH_3$	4-(3-isopropylphenyl)-phenyl	
883	$NH(CO)OCH_3$	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
884	$NH(CO)OCH_3$	4-(3-methylsulfonylamino-phenyl)-phenyl	
885	$NH(CO)OCH_3$	4-(3-amino-phenyl)-phenyl	
886	$NH(CO)OCH_3$	4-(3-nitro-phenyl)-phenyl	
887	$NH(CO)OCH_3$	2-pyridyl	
888	$NH(CO)OCH_3$	3-pyridyl	
889	$NH(CO)OCH_3$	4-pyridyl	
890	$NH(CO)OCH_3$	3-amino-4-pyridyl	
891	$NH(CO)OCH_3$	3-hydroxy-4-pyridyl	
892	$NH(CO)OCH_3$	3-imidazole	
893	$NH(CO)OCH_3$	2-nitro-3-imidazole	
894	$NH(CO)OCH_3$	5-thiazole	
895	$NH(CO)OCH_3$	5-oxazole	
896	$NH(CO)OCH_3$	4-pyazole	
897	$NH(CO)OCH_3$	phenylethyl	
898	$NH(CO)OCH_3$	2-aminophenylethyl	
899	$NH(CO)OCH_3$	2-methylsulfonylamino-phenylethyl	
900	$NH(CO)OCH_3$	2-trifluoromethylsulfonylaminophenylethyl	
901	$NH(CO)OCH_3$	2-hydroxymethylene-phenylethyl	
902	$NH(CO)OCH_3$	2-aminomethylene-phenylethyl	
903	$NH(CO)OCH_3$	2-tetrazolephenylethyl	
904	$NH(CO)OCH_3$	2-tert-butylamino-sulfonylphenylethyl	
905	$NH(CO)OCH_3$	2-aminosulfonyl-phenylethyl	
906	$NH(CO)OCH_3$	2-methoxyphenylethyl	
907	$NH(CO)OCH_3$	3-aminophenylethyl	
908	$NH(CO)OCH_3$	3-methylsulfonylamino-phenylethyl	

909	$NH(CO)OCH_3$	3-trifluoromethyl-sulfonylamino-phenylethyl	
910	$NH(CO)OCH_3$	3-hydroxymethylene-phenylethyl	
911	$NH(CO)OCH_3$	3-aminomethylene-phenylethyl	
912	$NH(CO)OCH_3$	3-tetrazolephenylethyl	
913	$NH(CO)OCH_3$	3-tert-butylamino-sulfonylphenylethyl	
914	$NH(CO)OCH_3$	3-aminosulfonyl-phenylethyl	
915	$NH(CO)OCH_3$	3-methoxyphenylethyl	
916	NHBoc	H	
917	NHBoc	methyl	
918	NHBoc	ethyl	
919	NHBoc	n-propyl	
920	NHBoc	n-butyl	
921	NHBoc	n-pentyl	
922	NHBoc	n-hexanyl	
923	NHBoc	n-heptanyl	
924	NHBoc	isopropyl	
925	NHBoc	tert-butyl	
926	NHBoc	cyclopropyl	
927	NHBoc	cyclobutanyl	
928	NHBoc	cyclpentanyl	
929	NHBoc	cyclohexanyl	
930	NHBoc	cycloheptanyl	
931	NHBoc	phenyl	
932	NHBoc	phenylmethyl	
933	NHBoc	3-hydroxyphenyl	
934	NHBoc	3-hydroxy-4-methoxyphenyl	
935	NHBoc	3-fluorophenyl	
936	NHBoc	3-chlorophenyl	
937	NHBoc	3-nitrophenyl	
938	NHBoc	3-aminophenyl	
939	NHBoc	3-methyl-sulfonamidephenyl	
940	NHBoc	3-trifluoro-methylsulfonamidephenyl	
941	NHBoc	3-Ac-NHphenyl	
942	NHBoc	3-Boc-NHphenyl	
943	NHBoc	3-Cbz-NHphenyl	
944	NHBoc	3-aminomethylenephenyl	
945	NHBoc	3-aminoethylenephenyl	
946	NHBoc	3-cyanophenyl	
947	NHBoc	3-cyanomethylphenyl	
948	NHBoc	3-hydroxymethylenephenyl	
949	NHBoc	3-carboxylphenyl	
950	NHBoc	3-mercaptophenyl	
951	NHBoc	3-methoxyphenyl	
952	NHBoc	3,4-methylenedioxophenyl	
953	NHBoc	3-tetrazolephenyl	
954	NHBoc	3-aminosulfonylphenyl	
955	NHBoc	3-methylamino-sulfonylphenyl	
956	NHBoc	3-ethylamino-sulfonylphenyl	
957	NHBoc	3-tert-butylamino-sulfonylphenyl	
958	NHBoc	3-methylsulfonylphenyl	
959	NHBoc	4-methoxyphenyl	
960	NHBoc	4-phenylphenyl	
961	NHBoc	4-(2-hydroxymethylene-phenyl)-phenyl	
962	NHBoc	4-(2-tert-butylamino-sufonylphenyl)-phenyl	

963	NHBoc	4-(2-methylamino-sufonylphenyl)-phenyl	
964	NHBoc	4-(2-ethylamino-sufonylphenyl)-phenyl	
965	NHBoc	4-(2-aminosufonyl-phenyl)-phenyl	
966	NHBoc	4-(2-chlorophenyl)-phenyl	
967	NHBoc	4-(2-fluorophenyl)-phenyl	
968	NHBoc	4-(2,4-dichlorophenyl)-phenyl	
969	NHBoc	4-(2,6-dichlorophenyl)-phenyl	
970	NHBoc	4-(3,5-dichlorophenyl)-phenyl	
971	NHBoc	4-(2,3-dichlorophenyl)-phenyl	
972	NHBoc	4-(2-methylphenyl)-phenyl	
973	NHBoc	4-(2-tetrazole-phenyl)-phenyl	
974	NHBoc	4-(2-methoxy-phenyl)-phenyl	
975	NHBoc	4-(2-tmethyl-phenyl)-phenyl	
976	NHBoc	4-(2-formyl-phenyl)-phenyl	
977	NHBoc	4-(2-amino-phenyl)-phenyl	
978	NHBoc	4-(2-methylamino-phenyl)-phenyl	
979	NHBoc	4-(2-ethylamino-phenyl)-phenyl	
980	NHBoc	4-(2-propylamino-phenyl)-phenyl	
981	NHBoc	4-(2-methylsulfonylamino-phenyl)-phenyl	
982	NHBoc	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
983	NHBoc	4-(3-methylphenyl)-phenyl	
984	NHBoc	4-(3-isopropylphenyl)-phenyl	
985	NHBoc	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
986	NHBoc	4-(3-methylsulfonylamino-phenyl)-phenyl	
987	NHBoc	4-(3-amino-phenyl)-phenyl	
988	NHBoc	4-(3-nitro-phenyl)-phenyl	
989	NHBoc	2-pyridyl	
990	NHBoc	3-pyridyl	
991	NHBoc	4-pyridyl	
992	NHBoc	3-amino-4-pyridyl	
993	NHBoc	3-hydroxy-4-pyridyl	
994	NHBoc	3-imidazole	
995	NHBoc	2-nitro-3-imidazole	
996	NHBoc	5-thiazole	
997	NHBoc	5-oxazole	
998	NHBoc	4-pyazole	
999	NHBoc	phenylethyl	
1000	NHBoc	2-aminophenylethyl	
1001	NHBoc	2-methylsulfonylamino-phenylethyl	
1002	NHBoc	2-trifluoromethylsulfonylamino-phenylethyl	
1003	NHBoc	2-hydroxymethylene-phenylethyl	
1004	NHBoc	2-aminomethylene-phenylethyl	

1005	NHBoc	2-tetrazolephenylethyl	
1006	NHBoc	2-tert-butylamino-sulfonylphenylethyl	
1007	NHBoc	2-aminosulfonyl-phenylethyl	
1008	NHBoc	2-methoxyphenylethyl	
1009	NHBoc	3-aminophenylethyl	
1010	NHBoc	3-methylsulfonylamino-phenylethyl	
1011	NHBoc	3-trifluoromethylsulfonylamino-phenylethyl	
1012	NHBoc	3-hydroxymethylene-phenylethyl	
1013	NHBoc	3-aminomethylene-phenylethyl	
1014	NHBoc	3-tetrazolephenylethyl	
1015	NHBoc	3-tert-butylamino-sulfonylphenylethyl	
1016	NHBoc	3-aminosulfonyl-phenylethyl	
1017	NHBoc	3-methoxyphenylethyl	
1018	NH(CO)OCH_2-4-pyridyl	H	
1019	NH(CO)OCH_2-4-pyridyl	methyl	
1020	NH(CO)OCH_2-4-pyridyl	ethyl	
1021	NH(CO)OCH_2-4-pyridyl	n-propyl	
1022	NH(CO)OCH_2-4-pyridyl	n-butyl	
1023	NH(CO)OCH_2-4-pyridyl	n-pentyl	
1024	NH(CO)OCH_2-4-pyridyl	n-hexanyl	
1025	NH(CO)OCH_2-4-pyridyl	n-heptanyl	
1026	NH(CO)OCH_2-4-pyridyl	isopropyl	
1027	NH(CO)OCH_2-4-pyridyl	tert-butyl	
1028	NH(CO)OCH_2-4-pyridyl	cyclopropyl	
1029	NH(CO)OCH_2-4-pyridyl	cyclobutanyl	
1030	NH(CO)OCH_2-4-pyridyl	cyclpentanyl	
1031	NH(CO)OCH_2-4-pyridyl	cyclohexanyl	
1032	NH(CO)OCH_2-4-pyridyl	cycloheptanyl	
1033	NH(CO)OCH_2-4-pyridyl	phenyl	
1034	NH(CO)OCH_2-4-pyridyl	phenylmethyl	
1035	NH(CO)OCH_2-4-pyridyl	3-hydroxyphenyl	
1036	NH(CO)OCH_2-4-pyridyl	3-hydroxy-4-methoxyphenyl	
1037	NH(CO)OCH_2-4-pyridyl	3-fluorophenyl	
1038	NH(CO)OCH_2-4-pyridyl	3-chlorophenyl	
1039	NH(CO)OCH_2-4-pyridyl	3-nitrophenyl	
1040	NH(CO)OCH_2-4-pyridyl	3-aminophenyl	
1041	NH(CO)OCH_2-4-pyridyl	3-methyl-sulfonamidephenyl	
1042	NH(CO)OCH_2-4-pyridyl	3-trifluoro-methylsulfonamidephenyl	
1043	NH(CO)OCH_2-4-pyridyl	3-Ac-NHphenyl	
1044	NH(CO)OCH_2-4-pyridyl	3-Boc-NHphenyl	
1045	NH(CO)OCH_2-4-pyridyl	3-Cbz-NHphenyl	
1046	NH(CO)OCH_2-4-pyridyl	3-aminomethylenephenyl	
1047	NH(CO)OCH_2-4-pyridyl	3-aminoethylenephenyl	
1048	NH(CO)OCH_2-4-pyridyl	3-cyanophenyl	
1049	NH(CO)OCH_2-4-pyridyl	3-cyanomethylphenyl	
1050	NH(CO)OCH_2-4-pyridyl	3-hydroxymethylenephenyl	
1051	NH(CO)OCH_2-4-pyridyl	3-carboxylphenyl	
1052	NH(CO)OCH_2-4-pyridyl	3-mercaptophenyl	
1053	NH(CO)OCH_2-4-pyridyl	3-methoxyphenyl	
1054	NH(CO)OCH_2-4-pyridyl	3,4-methylenedioxophenyl	
1055	NH(CO)OCH_2-4-pyridyl	3-tetrazolephenyl	

1056	$NH(CO)OCH_2$-4-pyridyl	3-aminosulfonylphenyl	
1057	$NH(CO)OCH_2$-4-pyridyl	3-methylamino-sulfonylphenyl	
1058	$NH(CO)OCH_2$-4-pyridyl	3-ethylamino-sulfonylphenyl	
1059	$NH(CO)OCH_2$-4-pyridyl	3-tert-butylamino-sulfonylphenyl	
1060	$NH(CO)OCH_2$-4-pyridyl	3-methylsulfonylphenyl	
1061	$NH(CO)OCH_2$-4-pyridyl	4-methoxyphenyl	
1062	$NH(CO)OCH_2$-4-pyridyl	4-phenylphenyl	
1063	$NH(CO)OCH_2$-4-pyridyl	4-(2-hydroxymethylene-phenyl)-phenyl	
1064	$NH(CO)OCH_2$-4-pyridyl	4-(2-tertbutylamino-sufonylphenyl)-phenyl	
1065	$NH(CO)OCH_2$-4-pyridyl	4-(2-methylamino-sufonylphenyl)-phenyl	
1066	$NH(CO)OCH_2$-4-pyridyl	4-(2-ethylamino-sufonylphenyl)-phenyl	
1067	$NH(CO)OCH_2$-4-pyridyl	4-(2-aminosufonyl-phenyl)-phenyl	
1068	$NH(CO)OCH_2$-4-pyridyl	4-(2-chlorophenyl)-phenyl	
1069	$NH(CO)OCH_2$-4-pyridyl	4-(2-fluorophenyl)-phenyl	
1070	$NH(CO)OCH_2$-4-pyridyl	4-(2,4-dichlorophenyl)-phenyl	
1071	$NH(CO)OCH_2$-4-pyridyl	4-(2,6-dichlorophenyl)-phenyl	
1072	$NH(CO)OCH_2$-4-pyridyl	4-(3,5-dichlorophenyl)-phenyl	
1073	$NH(CO)OCH_2$-4-pyridyl	4-(2,3-dichlorophenyl)-phenyl	
1074	$NH(CO)OCH_2$-4-pyridyl	4-(2-methylphenyl)-phenyl	
1075	$NH(CO)OCH_2$-4-pyridyl	4-(2-tetrazole-phenyl)-phenyl	
1076	$NH(CO)OCH_2$-4-pyridyl	4-(2-methoxy-phenyl)-phenyl	
1077	$NH(CO)OCH_2$-4-pyridyl	4-(2-tmethyl-phenyl)-phenyl	
1078	$NH(CO)OCH_2$-4-pyridyl	4-(2-formyl-phenyl)-phenyl	
1079	$NH(CO)OCH_2$-4-pyridyl	4-(2-amino-phenyl)-phenyl	
1080	$NH(CO)OCH_2$-4-pyridyl	4-(2-methylamino-phenyl)-phenyl	
1081	$NH(CO)OCH_2$-4-pyridyl	4-(2-ethylamino-phenyl)-phenyl	
1082	$NH(CO)OCH_2$-4-pyridyl	4-(2-propylamino-phenyl)-phenyl	
1083	$NH(CO)OCH_2$-4-pyridyl	4-(2-methylsulfonylamino-phenyl)-phenyl	
1084	$NH(CO)OCH_2$-4-pyridyl	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1085	$NH(CO)OCH_2$-4-pyridyl	4-(3-methylphenyl)-phenyl	
1086	$NH(CO)OCH_2$-4-pyridyl	4-(3-isopropylphenyl)-phenyl	
1087	$NH(CO)OCH_2$-4-pyridyl	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1088	$NH(CO)OCH_2$-4-pyridyl	4-(3-methylsulfonylamino-phenyl)-phenyl	
1089	$NH(CO)OCH_2$-4-pyridyl	4-(3-amino-phenyl)-phenyl	
1090	$NH(CO)OCH_2$-4-pyridyl	4-(3-nitro-phenyl)-phenyl	
1091	$NH(CO)OCH_2$-4-pyridyl	2-pyridyl	
1092	$NH(CO)OCH_2$-4-pyridyl	3-pyridyl	
1093	$NH(CO)OCH_2$-4-pyridyl	4-pyridyl	
1094	$NH(CO)OCH_2$-4-pyridyl	3-amino-4-pyridyl	
1095	$NH(CO)OCH_2$-4-pyridyl	3-hydroxy-4-pyridyl	

1096	NH(CO)OCH_2-4-pyridyl	3-imidazole	
1097	NH(CO)OCH_2-4-pyridyl	2-nitro-3-imidazole	
1098	NH(CO)OCH_2-4-pyridyl	5-thiazole	
1099	NH(CO)OCH_2-4-pyridyl	5-oxazole	
1100	NH(CO)OCH_2-4-pyridyl	4-pyazole	
1101	NH(CO)OCH_2-4-pyridyl	phenylethyl	
1102	NH(CO)OCH_2-4-pyridyl	2-aminophenylethyl	
1103	NH(CO)OCH_2-4-pyridyl	2-methylsulfonylamino-phenylethyl	
1104	NH(CO)OCH_2-4-pyridyl	2-trifluoromethylsulfonylamino-phenylethyl	
1105	NH(CO)OCH_2-4-pyridyl	2-hydroxymethylene-phenylethyl	
1106	NH(CO)OCH_2-4-pyridyl	2-aminomethylene-phenylethyl	
1107	NH(CO)OCH_2-4-pyridyl	2-tetrazolephenylethyl	
1108	NH(CO)OCH_2-4-pyridyl	2-tertbutylamino-sulfonylphenylethyl	
1109	NH(CO)OCH_2-4-pyridyl	2-aminosulfonyl-phenylethyl	
1110	NH(CO)OCH_2-4-pyridyl	2-methoxyphenylethyl	
1111	NH(CO)OCH_2-4-pyridyl	3-aminophenylethyl	
1112	NH(CO)OCH_2-4-pyridyl	3-methylsulfonylamino-phenylethyl	
1113	NH(CO)OCH_2-4-pyridyl	3-trifluoromethylsulfonylamino-phenylethyl	
1114	NH(CO)OCH_2-4-pyridyl	3-hydroxymethylene-phenylethyl	
1115	NH(CO)OCH_2-4-pyridyl	3-aminomethylene-phenylethyl	
1116	NH(CO)OCH_2-4-pyridyl	3-tetrazolephenylethyl	
1117	NH(CO)OCH_2-4-pyridyl	3-tert-butylamino-sulfonylphenylethyl	
1118	NH(CO)OCH_2-4-pyridyl	3-aminosulfonyl-phenylethyl	
1119	NH(CO)OCH_2-4-pyridyl	3-methoxyphenylethyl	
1120	$NHS(O_2)CH_3$	H	
1121	$NHS(O_2)CH_3$	methyl	
1122	$NHS(O_2)CH_3$	ethyl	
1123	$NHS(O_2)CH_3$	n-propyl	
1124	$NHS(O_2)CH_3$	n-butyl	
1125	$NHS(O_2)CH_3$	n-pentyl	
1126	$NHS(O_2)CH_3$	n-hexanyl	
1127	$NHS(O_2)CH_3$	n-heptanyl	
1128	$NHS(O_2)CH_3$	isopropyl	
1129	$NHS(O_2)CH_3$	tert-butyl	
1130	$NHS(O_2)CH_3$	cyclopropyl	
1131	$NHS(O_2)CH_3$	cyclobutanyl	
1132	$NHS(O_2)CH_3$	cyclpentanyl	
1133	$NHS(O_2)CH_3$	cyclohexanyl	
1134	$NHS(O_2)CH_3$	cycloheptanyl	
1135	$NHS(O_2)CH_3$	phenyl	
1136	$NHS(O_2)CH_3$	phenylmethyl	
1137	$NHS(O_2)CH_3$	3-hydroxyphenyl	
1138	$NHS(O_2)CH_3$	3-hydroxy-4-methoxyphenyl	
1139	$NHS(O_2)CH_3$	3-fluorophenyl	
1140	$NHS(O_2)CH_3$	3-chlorophenyl	
1141	$NHS(O_2)CH_3$	3-nitrophenyl	
1142	$NHS(O_2)CH_3$	3-aminophenyl	

1143	$NHS(O_2)CH_3$	3-methyl-sulfonamidephenyl	
1144	$NHS(O_2)CH_3$	3-trifluoro-methylsulfonamidephenyl	
1145	$NHS(O_2)CH_3$	3-Ac-NHphenyl	
1146	$NHS(O_2)CH_3$	3-Boc-NHphenyl	
1147	$NHS(O_2)CH_3$	3-Cbz-NHphenyl	
1148	$NHS(O_2)CH_3$	3-aminomethylenephenyl	
1149	$NHS(O_2)CH_3$	3-aminoethylenephenyl	
1150	$NHS(O_2)CH_3$	3-cyanophenyl	
1151	$NHS(O_2)CH_3$	3-cyanomethylphenyl	
1152	$NHS(O_2)CH_3$	3-hydroxymethylenephenyl	
1153	$NHS(O_2)CH_3$	3-carboxylphenyl	
1154	$NHS(O_2)CH_3$	3-mercaptophenyl	
1155	$NHS(O_2)CH_3$	3-methoxyphenyl	
1156	$NHS(O_2)CH_3$	3,4-methylenedioxophenyl	
1157	$NHS(O_2)CH_3$	3-tetrazolephenyl	
1158	$NHS(O_2)CH_3$	3-aminosulfonylphenyl	
1159	$NHS(O_2)CH_3$	3-methylamino-sulfonylphenyl	
1160	$NHS(O_2)CH_3$	3-ethylamino-sulfonylphenyl	
1161	$NHS(O_2)CH_3$	3-tertbutylamino-sulfonylphenyl	
1162	$NHS(O_2)CH_3$	3-methylsulfonylphenyl	
1163	$NHS(O_2)CH_3$	4-methoxyphenyl	
1164	$NHS(O_2)CH_3$	4-phenylphenyl	
1165	$NHS(O_2)CH_3$	4-(2-hydroxymethylene-phenyl)-phenyl	
1166	$NHS(O_2)CH_3$	4-(2-tert-butylamino-sufonylphenyl)-phenyl	
1167	$NHS(O_2)CH_3$	4-(2-methylamino-sufonylphenyl)-phenyl	
1168	$NHS(O_2)CH_3$	4-(2-ethylamino-sufonylphenyl)-phenyl	
1169	$NHS(O_2)CH_3$	4-(2-aminosufonyl-phenyl)-phenyl	
1170	$NHS(O_2)CH_3$	4-(2-chlorophenyl)-phenyl	
1171	$NHS(O_2)CH_3$	4-(2-fluorophenyl)-phenyl	
1172	$NHS(O_2)CH_3$	4-(2,4-dichlorophenyl)-phenyl	
1173	$NHS(O_2)CH_3$	4-(2,6-dichlorophenyl)-phenyl	
1174	$NHS(O_2)CH_3$	4-(3,5-dichlorophenyl)-phenyl	
1175	$NHS(O_2)CH_3$	4-(2,3-dichlorophenyl)-phenyl	
1176	$NHS(O_2)CH_3$	4-(2-methylphenyl)-phenyl	
1177	$NHS(O_2)CH_3$	4-(2-tetrazole-phenyl)-phenyl	
1178	$NHS(O_2)CH_3$	4-(2-methoxy-phenyl)-phenyl	
1179	$NHS(O_2)CH_3$	4-(2-tmethyl-phenyl)-phenyl	
1180	$NHS(O_2)CH_3$	4-(2-formyl-phenyl)-phenyl	
1181	$NHS(O_2)CH_3$	4-(2-amino-phenyl)-phenyl	
1182	$NHS(O_2)CH_3$	4-(2-methylamino-phenyl)-phenyl	
1183	$NHS(O_2)CH_3$	4-(2-ethylamino-phenyl)-phenyl	
1184	$NHS(O_2)CH_3$	4-(2-propylamino-phenyl)-phenyl	
1185	$NHS(O_2)CH_3$	4-(2-methylsulfonyl-aminophenyl)-phenyl	

1186	$NHS(O_2)CH_3$	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1187	$NHS(O_2)CH_3$	4-(3-methylphenyl)-phenyl	
1188	$NHS(O_2)CH_3$	4-(3-isopropylphenyl)-phenyl	
1189	$NHS(O_2)CH_3$	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1190	$NHS(O_2)CH_3$	4-(3-methylsulfonylamino-phenyl)-phenyl	
1191	$NHS(O_2)CH_3$	4-(3-amino-phenyl)-phenyl	
1192	$NHS(O_2)CH_3$	4-(3-nitro-phenyl)-phenyl	
1193	$NHS(O_2)CH_3$	2-pyridyl	
1194	$NHS(O_2)CH_3$	3-pyridyl	
1195	$NHS(O_2)CH_3$	4-pyridyl	
1196	$NHS(O_2)CH_3$	3-amino-4-pyridyl	
1197	$NHS(O_2)CH_3$	3-hydroxy-4-pyridyl	
1198	$NHS(O_2)CH_3$	3-imidazole	
1199	$NHS(O_2)CH_3$	2-nitro-3-imidazole	
1200	$NHS(O_2)CH_3$	5-thiazole	
1201	$NHS(O_2)CH_3$	5-oxazole	
1202	$NHS(O_2)CH_3$	4-pyazole	
1203	$NHS(O_2)CH_3$	phenylethyl	
1204	$NHS(O_2)CH_3$	2-aminophenylethyl	
1205	$NHS(O_2)CH_3$	2-methylsulfonylamino-phenylethyl	
1206	$NHS(O_2)CH_3$	2-trifluoromethylsulfonylamino-phenylethyl	
1207	$NHS(O_2)CH_3$	2-hydroxymethylene-phenylethyl	
1208	$NHS(O_2)CH_3$	2-aminomethylene-phenylethyl	
1209	$NHS(O_2)CH_3$	2-tetrazolephenylethyl	
1210	$NHS(O_2)CH_3$	2-tert-butylamino-sulfonylphenylethyl	
1211	$NHS(O_2)CH_3$	2-aminosulfonyl-phenylethyl	
1212	$NHS(O_2)CH_3$	2-methoxyphenylethyl	
1213	$NHS(O_2)CH_3$	3-aminophenylethyl	
1214	$NHS(O_2)CH_3$	3-methylsulfonylamino-phenylethyl	
1215	$NHS(O_2)CH_3$	3-trifluoromethylsulfonylamino-phenylethyl	
1216	$NHS(O_2)CH_3$	3-hydroxymethylene-phenylethyl	
1217	$NHS(O_2)CH_3$	3-aminomethylene-phenylethyl	
1218	$NHS(O_2)CH_3$	3-tetrazolephenylethyl	
1219	$NHS(O_2)CH_3$	3-tert-butylamino-sulfonylphenylethyl	
1220	$NHS(O_2)CH_3$	3-aminosulfonyl-phenylethyl	
1221	$NHS(O_2)CH_3$	3-methoxyphenylethyl	
1222	$NHS(O_2)CF_3$	H	
1223	$NHS(O_2)CF_3$	methyl	
1224	$NHS(O_2)CF_3$	ethyl	
1225	$NHS(O_2)CF_3$	n-propyl	
1226	$NHS(O_2)CF_3$	n-butyl	
1227	$NHS(O_2)CF_3$	n-pentyl	
1228	$NHS(O_2)CF_3$	n-hexanyl	

1229	$NHS(O_2)CF_3$	n-heptanyl	
1230	$NHS(O_2)CF_3$	isopropyl	
1231	$NHS(O_2)CF_3$	tert-butyl	
1232	$NHS(O_2)CF_3$	cyclopropyl	
1233	$NHS(O_2)CF_3$	cyclobutanyl	
1234	$NHS(O_2)CF_3$	cyclpentanyl	
1235	$NHS(O_2)CF_3$	cyclohexamyl	
1236	$NHS(O_2)CF_3$	cycloheptanyl	
1237	$NHS(O_2)CF_3$	phenyl	
1238	$NHS(O_2)CF_3$	phenylmethyl	
1239	$NHS(O_2)CF_3$	3-hydroxyphenyl	
1240	$NHS(O_2)CF_3$	3-hydroxy-4-methoxyphenyl	
1241	$NHS(O_2)CF_3$	3-fluorophenyl	
1242	$NHS(O_2)CF_3$	3-chlorophenyl	
1243	$NHS(O_2)CF_3$	3-nitrophenyl	
1244	$NHS(O_2)CF_3$	3-aminophenyl	
1245	$NHS(O_2)CF_3$	3-methyl-sulfonamidephenyl	
1246	$NHS(O_2)CF_3$	3-trifluoro-methylsulfonamidephenyl	
1247	$NHS(O_2)CF_3$	3-Ac-NHphenyl	
1248	$NHS(O_2)CF_3$	3-Boc-NHphenyl	
1249	$NHS(O_2)CF_3$	3-Cbz-NHphenyl	
1250	$NHS(O_2)CF_3$	3-aminomethylenephenyl	
1251	$NHS(O_2)CF_3$	3-aminoethylenephenyl	
1252	$NHS(O_2)CF_3$	3-cyanophenyl	
1253	$NHS(O_2)CF_3$	3-cyanomethylphenyl	
1254	$NHS(O_2)CF_3$	3-hydroxymethylenephenyl	
1255	$NHS(O_2)CF_3$	3-carboxylphenyl	
1256	$NHS(O_2)CF_3$	3-mercaptophenyl	
1257	$NHS(O_2)CF_3$	3-methoxyphenyl	
1258	$NHS(O_2)CF_3$	3,4-methylenedioxophenyl	
1259	$NHS(O_2)CF_3$	3-tetrazolephenyl	
1260	$NHS(O_2)CF_3$	3-aminosulfonylphenyl	
1261	$NHS(O_2)CF_3$	3-methylamino-sulfonylphenyl	
1262	$NHS(O_2)CF_3$	3-ethylamino-sulfonylphenyl	
1263	$NHS(O_2)CF_3$	3-tert-butylamino-sulfonylphenyl	
1264	$NHS(O_2)CF_3$	3-methylsulfonylphenyl	
1265	$NHS(O_2)CF_3$	4-methoxyphenyl	
1266	$NHS(O_2)CF_3$	4-phenylphenyl	
1267	$NHS(O_2)CF_3$	4-(2-hydroxymethylene-phenyl)-phenyl	
1268	$NHS(O_2)CF_3$	4-(2-tertbutylamino-sufonylphenyl)-phenyl	
1269	$NHS(O_2)CF_3$	4-(2-methylamino-sufonylphenyl)-phenyl	
1270	$NHS(O_2)CF_3$	4-(2-ethylamino-sufonylphenyl)-phenyl	
1271	$NHS(O_2)CF_3$	4-(2-aminosufonyl-phenyl)-phenyl	
1272	$NHS(O_2)CF_3$	4-(2-chlorophenyl)-phenyl	
1273	$NHS(O_2)CF_3$	4-(2-fluorophenyl)-phenyl	
1274	$NHS(O_2)CF_3$	4-(2,4-dichlorophenyl)-phenyl	
1275	$NHS(O_2)CF_3$	4-(2,6-dichlorophenyl)-phenyl	
1276	$NHS(O_2)CF_3$	4-(3,5-dichlorophenyl)-phenyl	

1277	$NHS(O_2)CF_3$	4-(2,3-dichlorophenyl)-phenyl	
1278	$NHS(O_2)CF_3$	4-(2-methylphenyl)-phenyl	
1279	$NHS(O_2)CF_3$	4-(2-tetrazole-phenyl)-phenyl	
1280	$NHS(O_2)CF_3$	4-(2-methoxy-phenyl)-phenyl	
1281	$NHS(O_2)CF_3$	4-(2-tmethyl-phenyl)-phenyl	
1282	$NHS(O_2)CF_3$	4-(2-formyl-phenyl)-phenyl	
1283	$NHS(O_2)CF_3$	4-(2-amino-phenyl)-phenyl	
1284	$NHS(O_2)CF_3$	4-(2-methylamino-phenyl)-phenyl	
1285	$NHS(O_2)CF_3$	4-(2-ethylamino-phenyl)-phenyl	
1286	$NHS(O_2)CF_3$	4-(2-propylamino-phenyl)-phenyl	
1287	$NHS(O_2)CF_3$	4-(2-methylsulfonylamino-phenyl)-phenyl	
1288	$NHS(O_2)CF_3$	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1289	$NHS(O_2)CF_3$	4-(3-methylphenyl)-phenyl	
1290	$NHS(O_2)CF_3$	4-(3-isopropylphenyl)-phenyl	
1291	$NHS(O_2)CF_3$	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1292	$NHS(O_2)CF_3$	4-(3-methylsulfonylamino-phenyl)-phenyl	
1293	$NHS(O_2)CF_3$	4-(3-amino-phenyl)-phenyl	
1294	$NHS(O_2)CF_3$	4-(3-nitro-phenyl)-phenyl	
1295	$NHS(O_2)CF_3$	2-pyridyl	
1296	$NHS(O_2)CF_3$	3-pyridyl	
1297	$NHS(O_2)CF_3$	4-pyridyl	
1298	$NHS(O_2)CF_3$	3-amino-4-pyridyl	
1299	$NHS(O_2)CF_3$	3-hydroxy-4-pyridyl	
1300	$NHS(O_2)CF_3$	3-imidazole	
1301	$NHS(O_2)CF_3$	2-nitro-3-imidazole	
1302	$NHS(O_2)CF_3$	5-thiazole	
1303	$NHS(O_2)CF_3$	5-oxazole	
1304	$NHS(O_2)CF_3$	4-pyazole	
1305	$NHS(O_2)CF_3$	phenylethyl	
1306	$NHS(O_2)CF_3$	2-aminophenylethyl	
1307	$NHS(O_2)CF_3$	2-methylsulfonylamino-phenylethyl	
1308	$NHS(O_2)CF_3$	2-trifluoromethylsulfonylamino-phenylethyl	
1309	$NHS(O_2)CF_3$	2-hydroxymethylene-phenylethyl	
1310	$NHS(O_2)CF_3$	2-aminomethylene-phenylethyl	
1311	$NHS(O_2)CF_3$	2-tetrazolephenylethyl	
1312	$NHS(O_2)CF_3$	2-tert-butylamino-sulfonylphenylethyl	
1313	$NHS(O_2)CF_3$	2-aminosulfonyl-phenylethyl	
1314	$NHS(O_2)CF_3$	2-methoxyphenylethyl	
1315	$NHS(O_2)CF_3$	3-aminophenylethyl	
1316	$NHS(O_2)CF_3$	3-methylsulfonylamino-phenylethyl	
1317	$NHS(O_2)CF_3$	3-trifluoromethylsulfonylamino-phenylethyl	

1318	$NHS(O_2)CF_3$	3-hydroxymethylene-phenylethyl	
1319	$NHS(O_2)CF_3$	3-aminomethylene-phenylethyl	
1320	$NHS(O_2)CF_3$	3-tetrazolephenylethyl	
1321	$NHS(O_2)CF_3$	3-tertbutylamino-sulfonylphenylethyl	
1322	$NHS(O_2)CF_3$	3-aminosulfonyl-phenylethyl	
1323	$NHS(O_2)CF_3$	3-methoxyphenylethyl	
1324	4- aminophenylS(O)2NH	H	
1325	4- aminophenylS(O)2NH	methyl	
1326	4- aminophenylS(O)2NH	ethyl	
1327	4- aminophenylS(O)2NH	n-propyl	
1328	4- aminophenylS(O)2NH	n-butyl	
1329	4- aminophenylS(O)2NH	n-pentyl	
1330	4- aminophenylS(O)2NH	n-hexanyl	
1331	4- aminophenylS(O)2NH	n-heptanyl	
1332	4- aminophenylS(O)2NH	isopropyl	
1333	4- aminophenylS(O)2NH	tert-butyl	
1334	4- aminophenylS(O)2NH	cyclopropyl	
1335	4- aminophenylS(O)2NH	cyclobutanyl	
1336	4- aminophenylS(O)2NH	cyclpentanyl	
1337	4- aminophenylS(O)2NH	cyclohexanyl	
1338	4- aminophenylS(O)2NH	cycloheptanyl	
1339	4- aminophenylS(O)2NH	phenyl	
1340	4- aminophenylS(O)2NH	phenylmethyl	
1341	4- aminophenylS(O)2NH	3-hydroxyphenyl	
1342	4- aminophenylS(O)2NH	3-hydroxy-4-methoxyphenyl	
1343	4- aminophenylS(O)2NH	3-fluorophenyl	
1344	4- aminophenylS(O)2NH	3-chlorophenyl	
1345	4- aminophenylS(O)2NH	3-nitrophenyl	
1346	4- aminophenylS(O)2NH	3-aminophenyl	
1347	4- aminophenylS(O)2NH	3-methyl-sulfonamidephenyl	
1348	4- aminophenylS(O)2NH	3-trifluoro-methylsulfonamidephenyl	
1349	4- aminophenylS(O)2NH	3-Ac-NHphenyl	
1350	4- aminophenylS(O)2NH	3-Boc-NHphenyl	
1351	4- aminophenylS(O)2NH	3-Cbz-NHphenyl	
1352	4- aminophenylS(O)2NH	3-aminomethylenephenyl	
1353	4- aminophenylS(O)2NH	3-aminoethylenephenyl	
1354	4- aminophenylS(O)2NH	3-cyanophenyl	
1355	4- aminophenylS(O)2NH	3-cyanomethylphenyl	
1356	4- aminophenylS(O)2NH	3-hydroxymethylenephenyl	
1357	4- aminophenylS(O)2NH	3-carboxylphenyl	
1358	4- aminophenylS(O)2NH	3-mercaptophenyl	
1359	4- aminophenylS(O)2NH	3-methoxyphenyl	
1360	4- aminophenylS(O)2NH	3,4-methylenedioxophenyl	
1361	4- aminophenylS(O)2NH	3-tetrazolephenyl	
1362	4- aminophenylS(O)2NH	3-aminosulfonylphenyl	
1363	4- aminophenylS(O)2NH	3-methylamino-sulfonylphenyl	
1364	4- aminophenylS(O)2NH	3-ethylamino-sulfonylphenyl	
1365	4- aminophenylS(O)2NH	3-tert-butylamino-sulfonylphenyl	
1366	4- aminophenylS(O)2NH	3-methylsulfonylphenyl	
1367	4- aminophenylS(O)2NH	4-methoxyphenyl	
1368	4- aminophenylS(O)2NH	4-phenylphenyl	
1369	4- aminophenylS(O)2NH	4-(2-hydroxymethylene-phenyl)-phenyl	
1370	4- aminophenylS(O)2NH	4-(2-tert-butylamino-sufonylphenyl)-phenyl	
1371	4- aminophenylS(O)2NH	4-(2-methylamino-sufonylphenyl)-phenyl	

1372	4- aminophenylS(O)2NH	4-(2-ethylamino-sufonylphenyl)-phenyl	
1373	4- aminophenylS(O)2NH	4-(2-aminosufonyl-phenyl)-phenyl	
1374	4- aminophenylS(O)2NH	4-(2-chlorophenyl)-phenyl	
1375	4- aminophenylS(O)2NH	4-(2-fluorophenyl)-phenyl	
1376	4- aminophenylS(O)2NH	4-(2,4-dichlorophenyl)-phenyl	
1377	4- aminophenylS(O)2NH	4-(2,6-dichlorophenyl)-phenyl	
1378	4- aminophenylS(O)$_2$NH	4-(3,5-dichlorophenyl)-phenyl	
1379	4- aminophenylS(O)$_2$NH	4-(2,3-dichlorophenyl)-phenyl	
1380	4- aminophenylS(O)$_2$NH	4-(2-methylphenyl)-phenyl	
1381	4- aminophenylS(O)$_2$NH	4-(2-tetrazole-phenyl)-phenyl	
1382	4- aminophenylS(O)$_2$NH	4-(2-methoxy-phenyl)-phenyl	
1383	4- aminophenylS(O)$_2$NH	4-(2-tmethyl-phenyl)-phenyl	
1384	4- aminophenylS(O)$_2$NH	4-(2-formyl-phenyl)-phenyl	
1385	4- aminophenylS(O)$_2$NH	4-(2-amino-phenyl)-phenyl	
1386	4- aminophenylS(O)$_2$NH	4-(2-methylamino-phenyl)-phenyl	
1387	4- aminophenylS(O)$_2$NH	4-(2-ethylamino-phenyl)-phenyl	
1388	4- aminophenylS(O)$_2$NH	4-(2-propylamino-phenyl)-phenyl	
1389	4- aminophenylS(O)$_2$NH	4-(2-methylsulfonylamino-phenyl)-phenyl	
1390	4- aminophenylS(O)$_2$NH	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1391	4- aminophenylS(O)$_2$NH	4-(3-methylphenyl)-phenyl	
1392	4- aminophenylS(O)$_2$NH	4-(3-isopropylphenyl)-phenyl	
1393	4- aminophenylS(O)$_2$NH	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1394	4- aminophenylS(O)$_2$NH	4-(3-methylsulfonylamino-phenyl)-phenyl	
1395	4- aminophenylS(O)$_2$NH	4-(3-amino-phenyl)-phenyl	
1396	4- aminophenylS(O)$_2$NH	4-(3-nitro-phenyl)-phenyl	
1397	4- aminophenylS(O)$_2$NH	2-pyridyl	
1398	4- aminophenylS(O)$_2$NH	3-pyridyl	
1399	4- aminophenylS(O)$_2$NH	4-pyridyl	
1400	4- aminophenylS(O)$_2$NH	3-amino-4-pyridyl	
1401	4- aminophenylS(O)$_2$NH	3-hydroxy-4-pyridyl	
1402	4- aminophenylS(O)$_2$NH	3-imidazole	
1403	4- aminophenylS(O)$_2$NH	2-nitro-3-imidazole	
1404	4- aminophenylS(O)$_2$NH	5-thiazole	
1405	4- aminophenylS(O)$_2$NH	5-oxazole	
1406	4- aminophenylS(O)$_2$NH	4-pyazole	
1407	4- aminophenylS(O)$_2$NH	phenylethyl	
1408	4- aminophenylS(O)$_2$NH	2-aminophenylethyl	
1409	4- aminophenylS(O)$_2$NH	2-methylsulfonylamino-phenylethyl	
1410	4- aminophenylS(O)$_2$NH	2-trifluoromethylsulfonylamino-phenylethyl	
1411	4- aminophenylS(O)$_2$NH	2-hydroxymethylene-phenylethyl	

1412	4- aminophenylS(O)$_2$NH	2-aminomethylene-phenylethyl	
1413	4- aminophenylS(O)$_2$NH	2-tetrazolephenylethyl	
1414	4- aminophenylS(O)$_2$NH	2-tert-butylamino-sulfonylphenylethyl	
1415	4- aminophenylS(O)$_2$NH	2-aminosulfonyl-phenylethyl	
1416	4- aminophenylS(O)$_2$NH	2-methoxyphenylethyl	
1417	4- aminophenylS(O)$_2$NH	3-aminophenylethyl	
1418	4- aminophenylS(O)$_2$NH	3-methylsulfonylamino-phenylethyl	
1419	4- aminophenylS(O)$_2$NH	3-trifluoromethylsulfonylamino-phenylethyl	
1420	4- aminophenylS(O)$_2$NH	3-hydroxymethylene-phenylethyl	
1421	4- aminophenylS(O)$_2$NH	3-aminomethylene-phenylethyl	
1422	4- aminophenylS(O)$_2$NH	3-tetrazolephenylethyl	
1423	4- aminophenylS(O)$_2$NH	3-tert-butylamino-sulfonylphenylethyl	
1424	4- aminophenylS(O)$_2$NH	3-aminosulfonyl-phenylethyl	
1425	4- aminophenylS(O)$_2$NH	3-methoxyphenylethyl	
1426	NH(CO)NMe$_2$	H	
1427	NH(CO)NMe$_2$	methyl	
1428	NH(CO)NMe$_2$	ethyl	
1429	NH(CO)NMe$_2$	n-propyl	
1430	NH(CO)NMe$_2$	n-butyl	
1431	NH(CO)NMe$_2$	n-pentyl	
1432	NH(CO)NMe$_2$	n-hexanyl	
1433	NH(CO)NMe$_2$	n-heptanyl	
1434	NH(CO)NMe$_2$	isopropyl	
1435	NH(CO)NMe$_2$	tert-butyl	
1436	NH(CO)NMe$_2$	cyclopropyl	
1437	NH(CO)NMe$_2$	cyclobutanyl	
1438	NH(CO)NMe$_2$	cyclpentanyl	
1439	NH(CO)NMe$_2$	cyclohexanyl	
1440	NH(CO)NMe$_2$	cycloheptanyl	
1441	NH(CO)NMe$_2$	phenyl	
1442	NH(CO)NMe$_2$	phenylmethyl	
1443	NH(CO)NMe$_2$	3-hydroxyphenyl	
1444	NH(CO)NMe$_2$	3-hydroxy-4-methoxyphenyl	
1445	NH(CO)NMe$_2$	3-fluorophenyl	
1446	NH(CO)NMe$_2$	3-chlorophenyl	
1447	NH(CO)NMe$_2$	3-nitrophenyl	
1448	NH(CO)NMe$_2$	3-aminophenyl	
1449	NH(CO)NMe$_2$	3-methylsulfonamidephenyl	
1450	NH(CO)NMe$_2$	3-trifluoro-methyl-sulfonamidephenyl	
1451	NH(CO)NMe$_2$	3-Ac-NHphenyl	
1452	NH(CO)NMe$_2$	3-Boc-NHphenyl	
1453	NH(CO)NMe$_2$	3-Cbz-NHphenyl	
1454	NH(CO)NMe$_2$	3-aminomethylenephenyl	
1455	NH(CO)NMe$_2$	3-aminoethylenephenyl	
1456	NH(CO)NMe$_2$	3-cyanophenyl	
1457	NH(CO)NMe$_2$	3-cyanomethylphenyl	
1458	NH(CO)NMe$_2$	3-hydroxy-methylenephenyl	
1459	NH(CO)NMe$_2$	3-carboxylphenyl	
1460	NH(CO)NMe$_2$	3-mercaptophenyl	
1461	NH(CO)NMe$_2$	3-methoxyphenyl	

1462	$NH(CO)NMe_2$	3,4-methylenedioxophenyl	
1463	$NH(CO)NMe_2$	3-tetrazolephenyl	
1464	$NH(CO)NMe_2$	3-aminosulfonylphenyl	
1465	$NH(CO)NMe_2$	3-methylamino-sulfonylphenyl	
1466	$NH(CO)NMe_2$	3-ethylamino-sulfonylphenyl	
1467	$NH(CO)NMe_2$	3-tert-butylamino-sulfonylphenyl	
1468	$NH(CO)NMe_2$	3-methylsulfonylphenyl	
1469	$NH(CO)NMe_2$	4-methoxyphenyl	
1470	$NH(CO)NMe_2$	4-phenylphenyl	
1471	$NH(CO)NMe_2$	4-(2-hydroxymethylene-phenyl)-phenyl	
1472	$NH(CO)NMe_2$	4-(2-tertbutylamino-sufonylphenyl)-phenyl	
1473	$NH(CO)NMe_2$	4-(2-methylamino-sufonyl-phenyl)-phenyl	
1474	$NH(CO)NMe_2$	4-(2-ethylamino-sufonylphenyl)-phenyl	
1475	$NH(CO)NMe_2$	4-(2-aminosufonyl-phenyl)-phenyl	
1476	$NH(CO)NMe_2$	4-(2-chlorophenyl)-phenyl	
1477	$NH(CO)NMe_2$	4-(2-fluorophenyl)-phenyl	
1478	$NH(CO)NMe_2$	4-(2,4-dichlorophenyl)-phenyl	
1479	$NH(CO)NMe_2$	4-(2,6-dichlorophenyl)-phenyl	
1480	$NH(CO)NMe_2$	4-(3,5-dichlorophenyl)-phenyl	
1481	$NH(CO)NMe_2$	4-(2,3-dichlorophenyl)-phenyl	
1482	$NH(CO)NMe_2$	4-(2-methylphenyl)-phenyl	
1483	$NH(CO)NMe_2$	4-(2-tetrazole-phenyl)-phenyl	
1484	$NH(CO)NMe_2$	4-(2-methoxy-phenyl)-phenyl	
1485	$NH(CO)NMe_2$	4-(2-tmethyl-phenyl)-phenyl	
1486	$NH(CO)NMe_2$	4-(2-formyl-phenyl)-phenyl	
1487	$NH(CO)NMe_2$	4-(2-amino-phenyl)-phenyl	
1488	$NH(CO)NMe_2$	4-(2-methylamino-phenyl)-phenyl	
1489	$NH(CO)NMe_2$	4-(2-ethylamino-phenyl)-phenyl	
1490	$NH(CO)NMe_2$	4-(2-propylamino-phenyl)-phenyl	
1491	$NH(CO)NMe_2$	4-(2-methylsulfonylamino-phenyl)-phenyl	
1492	$NH(CO)NMe_2$	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1493	$NH(CO)NMe_2$	4-(3-methylphenyl)-phenyl	
1494	$NH(CO)NMe_2$	4-(3-isopropylphenyl)-phenyl	
1495	$NH(CO)NMe_2$	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1496	$NH(CO)NMe_2$	4-(3-methylsulfonylamino-phenyl)-phenyl	
1497	$NH(CO)NMe_2$	4-(3-amino-phenyl)-phenyl	
1498	$NH(CO)NMe_2$	4-(3-nitro-phenyl)-phenyl	
1499	$NH(CO)NMe_2$	2-pyridyl	
1500	$NH(CO)NMe_2$	3-pyridyl	
1501	$NH(CO)NMe_2$	4-pyridyl	

1502	$NH(CO)NMe_2$	3-amino-4-pyridyl	
1503	$NH(CO)NMe_2$	3-hydroxy-4-pyridyl	
1504	$NH(CO)NMe_2$	3-imidazole	
1505	$NH(CO)NMe_2$	2-nitro-3-imidazole	
1506	$NH(CO)NMe_2$	5-thiazole	
1507	$NH(CO)NMe_2$	5-oxazole	
1508	$NH(CO)NMe_2$	4-pyazole	
1509	$NH(CO)NMe_2$	phenylethyl	
1510	$NH(CO)NMe_2$	2-aminophenylethyl	
1511	$NH(CO)NMe_2$	2-methylsulfonylamino-phenylethyl	
1512	$NH(CO)NMe_2$	2-trifluoromethylsulfonylamino-phenylethyl	
1513	$NH(CO)NMe_2$	2-hydroxymethylene-phenylethyl	
1514	$NH(CO)NMe_2$	2-aminomethylene-phenylethyl	
1515	$NH(CO)NMe_2$	2-tetrazolephenylethyl	
1516	$NH(CO)NMe_2$	2-tert-butylamino-sulfonylphenylethyl	
1517	$NH(CO)NMe_2$	2-aminosulfonyl-phenylethyl	
1518	$NH(CO)NMe_2$	2-methoxyphenylethyl	
1519	$NH(CO)NMe_2$	3-aminophenylethyl	
1520	$NH(CO)NMe_2$	3-methylsulfonylamino-phenylethyl	
1521	$NH(CO)NMe_2$	3-trifluoromethylsulfonylamino-phenylethyl	
1522	$NH(CO)NMe_2$	3-hydroxymethylene-phenylethyl	
1523	$NH(CO)NMe_2$	3-aminomethylene-phenylethyl	
1524	$NH(CO)NMe_2$	3-tetrazolephenylethyl	
1525	$NH(CO)NMe_2$	3-tertbutylamino-sulfonylphenylethyl	
1526	$NH(CO)NMe_2$	3-aminosulfonyl-phenylethyl	
1527	$NH(CO)NMe_2$	3-methoxyphenylethyl	
1528	$NH(CO)N(CH_2CH_2)_2O$	H	
1529	$NH(CO)N(CH_2CH_2)_2O$	methyl	
1530	$NH(CO)N(CH_2CH_2)_2O$	ethyl	
1531	$NH(CO)N(CH_2CH_2)_2O$	n-propyl	
1532	$NH(CO)N(CH_2CH_2)_2O$	n-butyl	
1533	$NH(CO)N(CH_2CH_2)_2O$	n-pentyl	
1534	$NH(CO)N(CH_2CH_2)_2O$	n-hexanyl	
1535	$NH(CO)N(CH_2CH_2)_2O$	n-heptanyl	
1536	$NH(CO)N(CH_2CH_2)_2O$	isopropyl	
1537	$NH(CO)N(CH_2CH_2)_2O$	tert-butyl	
1538	$NH(CO)N(CH_2CH_2)_2O$	cyclopropyl	
1539	$NH(CO)N(CH_2CH_2)_2O$	cyclobutanyl	
1540	$NH(CO)N(CH_2CH_2)_2O$	cyclpentanyl	
1541	$NH(CO)N(CH_2CH_2)_2O$	cyclohexanyl	
1542	$NH(CO)N(CH_2CH_2)_2O$	cycloheptanyl	
1543	$NH(CO)N(CH_2CH_2)_2O$	phenyl	
1544	$NH(CO)N(CH_2CH_2)_2O$	phenylmethyl	
1545	$NH(CO)N(CH_2CH_2)_2O$	3-hydroxyphenyl	
1546	$NH(CO)N(CH_2CH_2)_2O$	3-hydroxy-4-methoxyphenyl	
1547	$NH(CO)N(CH_2CH_2)_2O$	3-fluorophenyl	
1548	$NH(CO)N(CH_2CH_2)_2O$	3-chlorophenyl	

1549	$NH(CO)N(CH_2CH_2)_2O$	3-nitrophenyl	
1550	$NH(CO)N(CH_2CH_2)_2O$	3-aminophenyl	
1551	$NH(CO)N(CH_2CH_2)_2O$	3-methyl-sulfonamidephenyl	
1552	$NH(CO)N(CH_2CH_2)_2O$	3-trifluoro-methylsulfonamidephenyl	
1553	$NH(CO)N(CH_2CH_2)_2O$	3-Ac-NHphenyl	
1554	$NH(CO)N(CH_2CH_2)_2O$	3-Boc-NHphenyl	
1555	$NH(CO)N(CH_2CH_2)_2O$	3-Cbz-NHphenyl	
1556	$NH(CO)N(CH_2CH_2)_2O$	3-aminomethylenephenyl	
1557	$NH(CO)N(CH_2CH_2)_2O$	3-aminoethylenephenyl	
1558	$NH(CO)N(CH_2CH_2)_2O$	3-cyanophenyl	
1559	$NH(CO)N(CH_2CH_2)_2O$	3-cyanomethylphenyl	
1560	$NH(CO)N(CH_2CH_2)_2O$	3-hydroxy-methylenephenyl	
1561	$NH(CO)N(CH_2CH_2)_2O$	3-carboxylphenyl	
1562	$NH(CO)N(CH_2CH_2)_2O$	3-mercaptophenyl	
1563	$NH(CO)N(CH_2CH_2)_2O$	3-methoxyphenyl	
1564	$NH(CO)N(CH_2CH_2)_2O$	3,4-methylenedioxophenyl	
1565	$NH(CO)N(CH_2CH_2)_2O$	3-tetrazolephenyl	
1566	$NH(CO)N(CH_2CH_2)_2O$	3-aminosulfonylphenyl	
1567	$NH(CO)N(CH_2CH_2)_2O$	3-methylamino-sulfonylphenyl	
1568	$NH(CO)N(CH_2CH_2)_2O$	3-ethylamino-sulfonylphenyl	
1569	$NH(CO)N(CH_2CH_2)_2O$	3-tertbutylamino-sulfonylphenyl	
1570	$NH(CO)N(CH_2CH_2)_2O$	3-methylsulfonylphenyl	
1571	$NH(CO)N(CH_2CH_2)_2O$	4-methoxyphenyl	
1572	$NH(CO)N(CH_2CH_2)_2O$	4-phenylphenyl	
1573	$NH(CO)N(CH_2CH_2)_2O$	4-(2-hydroxymethylene-phenyl)-phenyl	
1574	$NH(CO)N(CH_2CH_2)_2O$	4-(2-tert-butylamino-sufonylphenyl)-phenyl	
1575	$NH(CO)N(CH_2CH_2)_2O$	4-(2-methylamino-sufonylphenyl)-phenyl	
1576	$NH(CO)N(CH_2CH_2)_2O$	4-(2-ethylamino-sufonylphenyl)-phenyl	
1577	$NH(CO)N(CH_2CH_2)_2O$	4-(2-aminosufonyl-phenyl)-phenyl	
1578	$NH(CO)N(CH_2CH_2)_2O$	4-(2-chlorophenyl)-phenyl	
1579	$NH(CO)N(CH_2CH_2)_2O$	4-(2-fluorophenyl)-phenyl	
1580	$NH(CO)N(CH_2CH_2)_2O$	4-(2,4-dichlorophenyl)-phenyl	
1581	$NH(CO)N(CH_2CH_2)_2O$	4-(2,6-dichlorophenyl)-phenyl	
1582	$NH(CO)N(CH_2CH_2)_2O$	4-(3,5-dichlorophenyl)-phenyl	
1583	$NH(CO)N(CH_2CH_2)_2O$	4-(2,3-dichlorophenyl)-phenyl	
1584	$NH(CO)N(CH_2CH_2)_2O$	4-(2-methylphenyl)-phenyl	
1585	$NH(CO)N(CH_2CH_2)_2O$	4-(2-tetrazole-phenyl)-phenyl	
1586	$NH(CO)N(CH_2CH_2)_2O$	4-(2-methoxy-phenyl)-phenyl	
1587	$NH(CO)N(CH_2CH_2)_2O$	4-(2-tmethyl-phenyl)-phenyl	
1588	$NH(CO)N(CH_2CH_2)_2O$	4-(2-formyl-phenyl)-phenyl	
1589	$NH(CO)N(CH_2CH_2)_2O$	4-(2-amino-phenyl)-phenyl	
1590	$NH(CO)N(CH_2CH_2)_2O$	4-(2-methylamino-phenyl)-phenyl	
1591	$NH(CO)N(CH_2CH_2)_2O$	4-(2-ethylamino-phenyl)-phenyl	
1592	$NH(CO)N(CH_2CH_2)_2O$	4-(2-propylamino-phenyl)-phenyl	

1593	$NH(CO)N(CH_2CH_2)_2O$	4-(2-methylsulfonylamino-phenyl)-phenyl	
1594	$NH(CO)N(CH_2CH_2)_2O$	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1595	$NH(CO)N(CH_2CH_2)_2O$	4-(3-methylphenyl)-phenyl	
1596	$NH(CO)N(CH_2CH_2)_2O$	4-(3-isopropylphenyl)-phenyl	
1597	$NH(CO)N(CH_2CH_2)_2O$	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1598	$NH(CO)N(CH_2CH_2)_2O$	4-(3-methylsulfonylamino-phenyl)-phenyl	
1599	$NH(CO)N(CH_2CH_2)_2O$	4-(3-amino-phenyl)-phenyl	
1600	$NH(CO)N(CH_2CH_2)_2O$	4-(3-nitro-phenyl)-phenyl	
1601	$NH(CO)N(CH_2CH_2)_2O$	2-pyridyl	
1602	$NH(CO)N(CH_2CH_2)_2O$	3-pyridyl	
1603	$NH(CO)N(CH_2CH_2)_2O$	4-pyridyl	
1604	$NH(CO)N(CH_2CH_2)_2O$	3-amino-4-pyridyl	
1605	$NH(CO)N(CH_2CH_2)_2O$	3-hydroxy-4-pyridyl	
1606	$NH(CO)N(CH_2CH_2)_2O$	3-imidazole	
1607	$NH(CO)N(CH_2CH_2)_2O$	2-nitro-3-imidazole	
1608	$NH(CO)N(CH_2CH_2)_2O$	5-thiazole	
1609	$NH(CO)N(CH_2CH_2)_2O$	5-oxazole	
1610	$NH(CO)N(CH_2CH_2)_2O$	4-pyazole	
1611	$NH(CO)N(CH_2CH_2)_2O$	phenylethyl	
1612	$NH(CO)N(CH_2CH_2)_2O$	2-aminophenylethyl	
1613	$NH(CO)N(CH_2CH_2)_2O$	2-methylsulfonylamino-phenylethyl	
1614	$NH(CO)N(CH_2CH_2)_2O$	2-trifluoromethylsulfonylamino-phenylethyl	
1615	$NH(CO)N(CH_2CH_2)_2O$	2-hydroxymethylene-phenylethyl	
1616	$NH(CO)N(CH_2CH_2)_2O$	2-aminomethylene-phenylethyl	
1617	$NH(CO)N(CH_2CH_2)_2O$	2-tetrazolephenylethyl	
1618	$NH(CO)N(CH_2CH_2)_2O$	2-tert-butylamino-sulfonylphenylethyl	
1619	$NH(CO)N(CH_2CH_2)_2O$	2-aminosulfonyl-phenylethyl	
1620	$NH(CO)N(CH_2CH_2)_2O$	2-methoxyphenylethyl	
1621	$NH(CO)N(CH_2CH_2)_2O$	3-aminophenylethyl	
1622	$NH(CO)N(CH_2CH_2)_2O$	3-methylsulfonylamino-phenylethyl	
1623	$NH(CO)N(CH_2CH_2)_2O$	3-trifluoromethylsulfonylamino-phenylethyl	
1624	$NH(CO)N(CH_2CH_2)_2O$	3-hydroxymethylene-phenylethyl	
1625	$NH(CO)N(CH_2CH_2)_2O$	3-aminomethylene-phenylethyl	
1626	$NH(CO)N(CH_2CH_2)_2O$	3-tetrazolephenylethyl	
1627	$NH(CO)N(CH_2CH_2)_2O$	3-tertbutylamino-sulfonylphenylethyl	
1628	$NH(CO)N(CH_2CH_2)_2O$	3-aminosulfonyl-phenylethyl	
1629	$NH(CO)N(CH_2CH_2)_2O$	3-methoxyphenylethyl	
1630	tert-BuCONH	H	
1631	tert-BuCONH	methyl	
1632	tert-BuCONH	ethyl	
1633	tert-BuCONH	n-propyl	
1634	tert-BuCONH	n-butyl	
1635	tert-BuCONH	n-pentyl	

1636	tert-BuCONH	n-hexanyl	
1637	tert-BuCONH	n-heptanyl	
1638	tert-BuCONH	isopropyl	
1639	tert-BuCONH	tert-butyl	
1640	tert-BuCONH	cyclopropyl	
1641	tert-BuCONH	cyclobutanyl	
1642	tert-BuCONH	cyclpentanyl	
1643	tert-BuCONH	cyclohexanyl	
1644	tert-BuCONH	cycloheptanyl	
1645	tert-BuCONH	phenyl	
1646	tert-BuCONH	phenylmethyl	
1647	tert-BuCONH	3-hydroxyphenyl	
1648	tert-BuCONH	3-hydroxy-4-methoxyphenyl	
1649	tert-BuCONH	3-fluorophenyl	
1650	tert-BuCONH	3-chlorophenyl	
1651	tert-BuCONH	3-nitrophenyl	
1652	tert-BuCONH	3-aminophenyl	
1653	tert-BuCONH	3-methyl-sulfonamidephenyl	
1654	tert-BuCONH	3-trifluoro-methylsulfonamidephenyl	
1655	tert-BuCONH	3-Ac-NHphenyl	
1656	tert-BuCONH	3-Boc-NHphenyl	
1657	tert-BuCONH	3-Cbz-NHphenyl	
1658	tert-BuCONH	3-aminomethylenephenyl	
1659	tert-BuCONH	3-aminoethylenephenyl	
1660	tert-BuCONH	3-cyanophenyl	
1661	tert-BuCONH	3-cyanomethylphenyl	
1662	tert-BuCONH	3-hydroxy-methylenephenyl	
1663	tert-BuCONH	3-carboxylphenyl	
1664	tert-BuCONH	3-mercaptophenyl	
1665	tert-BuCONH	3-methoxyphenyl	
1666	tert-BuCONH	3,4-methylenedioxophenyl	
1667	tert-BuCONH	3-tetrazolephenyl	
1668	tert-BuCONH	3-aminosulfonylphenyl	
1669	tert-BuCONH	3-methylamino-sulfonylphenyl	
1670	tert-BuCONH	3-ethylamino-sulfonylphenyl	
1671	tert-BuCONH	3-tert-butylamino-sulfonylphenyl	
1672	tert-BuCONH	3-methylsulfonylphenyl	
1673	tert-BuCONH	4-methoxyphenyl	
1674	tert-BuCONH	4-phenylphenyl	
1675	tert-BuCONH	4-(2-hydroxymethylene-phenyl)-phenyl	
1676	tert-BuCONH	4-(2-tertbutylamino-sufonylphenyl)-phenyl	
1677	tert-BuCONH	4-(2-methylamino-sufonylphenyl)-phenyl	
1678	tert-BuCONH	4-(2-ethylamino-sufonylphenyl)-phenyl	
1679	tert-BuCONH	4-(2-aminosufonyl-phenyl)-phenyl	
1680	tert-BuCONH	4-(2-chlorophenyl)-phenyl	
1681	tert-BuCONH	4-(2-fluorophenyl)-phenyl	
1682	tert-BuCONH	4-(2,4-dichlorophenyl)-phenyl	
1683	tert-BuCONH	4-(2,6-dichlorophenyl)-phenyl	
1684	tert-BuCONH	4-(3,5-dichlorophenyl)-phenyl	
1685	tert-BuCONH	4-(2,3-dichlorophenyl)-phenyl	
1686	tert-BuCONH	4-(2-methylphenyl)-phenyl	

1687	tert-BuCONH	4-(2-tetrazole-phenyl)-phenyl	
1688	tert-BuCONH	4-(2-methoxy-phenyl)-phenyl	
1689	tert-BuCONH	4-(2-tmethyl-phenyl)-phenyl	
1690	tert-BuCONH	4-(2-formyl-phenyl)-phenyl	
1691	tert-BuCONH	4-(2-amino-phenyl)-phenyl	
1692	tert-BuCONH	4-(2-methylamino-phenyl)-phenyl	
1693	tert-BuCONH	4-(2-ethylamino-phenyl)-phenyl	
1694	tert-BuCONH	4-(2-propylamino-phenyl)-phenyl	
1695	tert-BuCONH	4-(2-methylsulfonylamino-phenyl)-phenyl	
1696	tert-BuCONH	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1697	tert-BuCONH	4-(3-methylphenyl)-phenyl	
1698	tert-BuCONH	4-(3-isopropylphenyl)-phenyl	
1699	tert-BuCONH	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1700	tert-BuCONH	4-(3-methylsulfonylamino-phenyl)-phenyl	
1701	tert-BuCONH	4-(3-amino-phenyl)-phenyl	
1702	tert-BuCONH	4-(3-nitro-phenyl)-phenyl	
1703	tert-BuCONH	2-pyridyl	
1704	tert-BuCONH	3-pyridyl	
1705	tert-BuCONH	4-pyridyl	
1706	tert-BuCONH	3-amino-4-pyridyl	
1707	tert-BuCONH	3-hydroxy-4-pyridyl	
1708	tert-BuCONH	3-imidazole	
1709	tert-BuCONH	2-nitro-3-imidazole	
1710	tert-BuCONH	5-thiazole	
1711	tert-BuCONH	5-oxazole	
1712	tert-BuCONH	4-pyazole	
1713	tert-BuCONH	phenylethyl	
1714	tert-BuCONH	2-aminophenylethyl	
1715	tert-BuCONH	2-methylsulfonylamino-phenylethyl	
1716	tert-BuCONH	2-trifluoromethylsulfonylamino-phenylethyl	
1717	tert-BuCONH	2-hydroxymethylene-phenylethyl	
1718	tert-BuCONH	2-aminomethylene-phenylethyl	
1719	tert-BuCONH	2-tetrazolephenylethyl	
1720	tert-BuCONH	2-tert-butylamino-sulfonylphenylethyl	
1721	tert-BuCONH	2-aminosulfonyl-phenylethyl	
1722	tert-BuCONH	2-methoxyphenylethyl	
1723	tert-BuCONH	3-aminophenylethyl	
1724	tert-BuCONH	3-methylsulfonylamino-phenylethyl	
1725	tert-BuCONH	3-trifluoromethylsulfonylamino-phenylethyl	
1726	tert-BuCONH	3-hydroxymethylene-phenylethyl	
1727	tert-BuCONH	3-aminomethylene-phenylethyl	
1728	tert-BuCONH	3-tetrazolephenylethyl	

1729	tert-BuCONH	3-tert-butylamino-sulfonylphenylethyl	
1730	tert-BuCONH	3-aminosulfonyl-phenylethyl	
1731	tert-BuCONH	3-methoxyphenylethyl	
1732	c-C_3H_5CONH	H	
1733	c-C_3H_5CONH	methyl	
1734	c-C_3H_5CONH	ethyl	
1735	c-C_3H_5CONH	n-propyl	
1736	c-C_3H_5CONH	n-butyl	
1737	c-C_3H_5CONH	n-pentyl	
1738	c-C_3H_5CONH	n-hexanyl	
1739	c-C_3H_5CONH	n-heptanyl	
1740	c-C_3H_5CONH	isopropyl	
1741	c-C_3H_5CONH	tert-butyl	
1742	c-C_3H_5CONH	cyclopropyl	
1743	c-C_3H_5CONH	cyclobutanyl	
1744	c-C_3H_5CONH	cyclpentanyl	
1745	c-C_3H_5CONH	cyclohexanyl	
1746	c-C_3H_5CONH	cycloheptanyl	
1747	c-C_3H_5CONH	phenyl	
1748	c-C_3H_5CONH	phenylmethyl	
1749	c-C_3H_5CONH	3-hydroxyphenyl	
1750	c-C_3H_5CONH	3-hydroxy-4-methoxyphenyl	
1751	c-C_3H_5CONH	3-fluorophenyl	
1752	c-C_3H_5CONH	3-chlorophenyl	
1753	c-C_3H_5CONH	3-nitrophenyl	
1754	c-C_3H_5CONH	3-aminophenyl	
1755	c-C_3H_5CONH	3-methyl-sulfonamidephenyl	
1756	c-C_3H_5CONH	3-trifluoro-methylsulfonamidephenyl	
1757	c-C_3H_5CONH	3-Ac-NHphenyl	
1758	c-C_3H_5CONH	3-Boc-NHphenyl	
1759	c-C_3H_5CONH	3-Cbz-NHphenyl	
1760	c-C_3H_5CONH	3-aminomethylenephenyl	
1761	c-C_3H_5CONH	3-aminoethylenephenyl	
1762	c-C_3H_5CONH	3-cyanophenyl	
1763	c-C_3H_5CONH	3-cyanomethylphenyl	
1764	c-C_3H_5CONH	3-hydroxy-methylenephenyl	
1765	c-C_3H_5CONH	3-carboxylphenyl	
1766	c-C_3H_5CONH	3-mercaptophenyl	
1767	c-C_3H_5CONH	3-methoxyphenyl	
1768	c-C_3H_5CONH	3,4-methylenedioxophenyl	
1769	c-C_3H_5CONH	3-tetrazolephenyl	
1770	c-C_3H_5CONH	3-aminosulfonylphenyl	
1771	c-C_3H_5CONH	3-methylamino-sulfonylphenyl	
1772	c-C_3H_5CONH	3-ethylamino-sulfonylphenyl	
1773	c-C_3H_5CONH	3-tertbutylamino-sulfonylphenyl	
1774	c-C_3H_5CONH	3-methylsulfonylphenyl	
1775	c-C_3H_5CONH	4-methoxyphenyl	
1776	c-C_3H_5CONH	4-phenylphenyl	
1777	c-C_3H_5CONH	4-(2-hydroxymethylene-phenyl)-phenyl	
1778	c-C_3H_5CONH	4-(2-tertbutylamino-sufonylphenyl)-phenyl	
1779	c-C_3H_5CONH	4-(2-methylamino-sufonylphenyl)-phenyl	

1780	c-C_3H_5CONH	4-(2-ethylamino-sufonylphenyl)-phenyl	
1781	c-C_3H_5CONH	4-(2-aminosufonyl-phenyl)-phenyl	
1782	c-C_3H_5CONH	4-(2-chlorophenyl)-phenyl	
1783	c-C_3H_5CONH	4-(2-fluorophenyl)-phenyl	
1784	c-C_3H_5CONH	4-(2,4-dichlorophenyl)-phenyl	
1785	c-C_3H_5CONH	4-(2,6-dichlorophenyl)-phenyl	
1786	c-C_3H_5CONH	4-(3,5-dichlorophenyl)-phenyl	
1787	c-C_3H_5CONH	4-(2,3-dichlorophenyl)-phenyl	
1788	c-C_3H_5CONH	4-(2-methylphenyl)-phenyl	
1789	c-C_3H_5CONH	4-(2-tetrazole-phenyl)-phenyl	
1790	c-C_3H_5CONH	4-(2-methoxy-phenyl)-phenyl	
1791	c-C_3H_5CONH	4-(2-tmethyl-phenyl)-phenyl	
1792	c-C_3H_5CONH	4-(2-formyl-phenyl)-phenyl	
1793	c-C_3H_5CONH	4-(2-amino-phenyl)-phenyl	
1794	c-C_3H_5CONH	4-(2-methylamino-phenyl)-phenyl	
1795	c-C_3H_5CONH	4-(2-ethylamino-phenyl)-phenyl	
1796	c-C_3H_5CONH	4-(2-propylamino-phenyl)-phenyl	
1797	c-C_3H_5CONH	4-(2-methylsulfonyl-amino-phenyl)-phenyl	
1798	c-C_3H_5CONH	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1799	c-C_3H_5CONH	4-(3-methylphenyl)-phenyl	
1800	c-C_3H_5CONH	4-(3-isopropylphenyl)-phenyl	
1801	c-C_3H_5CONH	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1802	c-C_3H_5CONH	4-(3-methylsulfonyl-amino-phenyl)-phenyl	
1803	c-C_3H_5CONH	4-(3-amino-phenyl)-phenyl	
1804	c-C_3H_5CONH	4-(3-nitro-phenyl)-phenyl	
1805	c-C_3H_5CONH	2-pyridyl	
1806	c-C_3H_5CONH	3-pyridyl	
1807	c-C_3H_5CONH	4-pyridyl	
1808	c-C_3H_5CONH	3-amino-4-pyridyl	
1809	c-C_3H_5CONH	3-hydroxy-4-pyridyl	
1810	c-C_3H_5CONH	3-imidazole	
1811	c-C_3H_5CONH	2-nitro-3-imidazole	
1812	c-C_3H_5CONH	5-thiazole	
1813	c-C_3H_5CONH	5-oxazole	
1814	c-C_3H_5CONH	4-pyazole	
1815	c-C_3H_5CONH	phenylethyl	
1816	c-C_3H_5CONH	2-aminophenylethyl	
1817	c-C_3H_5CONH	2-methylsulfonylamino-phenylethyl	
1818	c-C_3H_5CONH	2-trifluoromethylsulfonylamino-phenylethyl	
1819	c-C_3H_5CONH	2-hydroxymethylene-phenylethyl	

1820	c-C_3H_5CONH	2-aminomethylene-phenylethyl	
1821	c-C_3H_5CONH	2-tetrazolephenylethyl	
1822	c-C_3H_5CONH	2-tert-butylamino-sulfonylphenylethyl	
1823	c-C_3H_5CONH	2-aminosulfonyl-phenylethyl	
1824	c-C_3H_5CONH	2-methoxyphenylethyl	
1825	c-C_3H_5CONH	3-aminophenylethyl	
1826	c-C_3H_5CONH	3-methylsulfonylamino-phenylethyl	
1827	c-C_3H_5CONH	3-trifluoromethylsulfonylamino-phenylethyl	
1828	c-C_3H_5CONH	3-hydroxymethylene-phenylethyl	
1829	c-C_3H_5CONH	3-aminomethylene-phenylethyl	
1830	c-C_3H_5CONH	3-tetrazolephenylethyl	
1831	c-C_3H_5CONH	3-tert-butylamino-sulfonylphenylethyl	
1832	c-C_3H_5CONH	3-aminosulfonyl-phenylethyl	
1833	c-C_3H_5CONH	3-methoxyphenylethyl	
1834			
1835	[illegible]	H	
1836	"	methyl	
1837	"	ethyl	
1838	"	n-propyl	
1839	"	n-butyl	
1840	"	n-pentyl	
1841	"	n-hexanyl	
1842	"	n-heptanyl	
1843	"	isopropyl	
1844	"	tert-butyl	
1845	"	cyclopropyl	
1846	"	cyclobutanyl	
1847	"	cyclpentanyl	
1848	"	cyclohexanyl	
1849	"	cycloheptanyl	
1850	"	phenyl	
1851	"	phenylmethyl	
1852	"	3-hydroxyphenyl	
1853	"	3-hydroxy-4-methoxyphenyl	
1854	"	3-fluorophenyl	
1855	"	3-chlorophenyl	
1856	"	3-nitrophenyl	
1857	"	3-aminophenyl	
1858	"	3-methyl-sulfonamidephenyl	
1859	"	3-trifluoro-methylsulfonamidephenyl	
1860	"	3-Ac-NHphenyl	
1861	"	3-Boc-NHphenyl	
1862	"	3-Cbz-NHphenyl	
1863	"	3-aminomethylenephenyl	
1864	"	3-aminoethylenephenyl	
1865	"	3-cyanophenyl	
1866	"	3-cyanomethylphenyl	
1867	"	3-hydroxy-methylenephenyl	
1868	"	3-carboxylphenyl	
1869	"	3-mercaptophenyl	
1870	"	3-methoxyphenyl	
1871	"	3,4-methylenedioxophenyl	
1872	"	3-tetrazolephenyl	
1873	"	3-aminosulfonylphenyl	

1874	"	3-methylamino-sulfonylphenyl	
1875	"	3-ethylamino-sulfonylphenyl	
1876	"	3-tert-butylamino-sulfonylphenyl	
1877	"	3-methylsulfonylphenyl	
1878	"	4-methoxyphenyl	
1879	"	4-phenylphenyl	
1880	"	4-(2-hydroxymethylene-phenyl)-phenyl	
1881	"	4-(2-terbutylamino-sufonylphenyl)-phenyl	
1882	"	4-(2-methylamino-sufonylphenyl)-phenyl	
1883	"	4-(2-ethylamino-sufonylphenyl)-phenyl	
1884	"	4-(2-aminosufonyl-phenyl)-phenyl	
1885	"	4-(2-chlorophenyl)-phenyl	
1886	"	4-(2-fluorophenyl)-phenyl	
1887	"	4-(2,4-dichlorophenyl)-phenyl	
1888	"	4-(2,6-dichlorophenyl)-phenyl	
1889	"	4-(3,5-dichlorophenyl)-phenyl	
1890	"	4-(2,3-dichlorophenyl)-phenyl	
1891	"	4-(2-methylphenyl)-phenyl	
1892	"	4-(2-tetrazole-phenyl)-phenyl	
1893	"	4-(2-methoxy-phenyl)-phenyl	
1894	"	4-(2-tmethyl-phenyl)-phenyl	
1895	"	4-(2-formyl-phenyl)-phenyl	
1896	"	4-(2-amino-phenyl)-phenyl	
1897	"	4-(2-methylamino-phenyl)-phenyl	
1898	"	4-(2-ethylamino-phenyl)-phenyl	
1899	"	4-(2-propylamino-phenyl)-phenyl	
1900	"	4-(2-methylsulfonyl-amino-phenyl)-phenyl	
1901	"	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1902	"	4-(3-methylphenyl)-phenyl	
1903	"	4-(3-isopropylphenyl)-phenyl	
1904	"	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
1905	"	4-(3-methylsulfonyl-amino-phenyl)-phenyl	
1906	"	4-(3-amino-phenyl)-phenyl	
1907	"	4-(3-nitro-phenyl)-phenyl	
1908	"	2-pyridyl	
1909	"	3-pyridyl	
1910	"	4-pyridyl	
1911	"	3-amino-4-pyridyl	
1912	"	3-hydroxy-4-pyridyl	
1913	"	3-imidazole	
1914	"	2-nitro-3-imidazole	
1915	"	5-thiazole	
1916	"	5-oxazole	

1917	"	4-pyrazole	
1918	"	phenylethyl	
1919	"	2-aminophenylethyl	
1920	"	2-methylsulfonylamino-phenylethyl	
1921	"	2-trifluoromethylsulfonylamino-phenylethyl	
1922	"	2-hydroxymethylene-phenylethyl	
1923	"	2-aminomethylene-phenylethyl	
1924	"	2-tetrazolephenylethyl	
1925	"	2-tert-butylamino-sulfonylphenylethyl	
1926	"	2-aminosulfonyl-phenylethyl	
1927	"	2-methoxyphenylethyl	
1928	"	3-aminophenylethyl	
1929	"	3-methylsulfonylamino-phenylethyl	
1930	"	3-trifluoromethylsulfonylamino-phenylethyl	
1931	"	3-hydroxymethylene-phenylethyl	
1932	"	3-aminomethylene-phenylethyl	
1933	"	3-tetrazolephenylethyl	
1934	"	3-tertbutylamino-sulfonylphenylethyl	
1935	"	3-aminosulfonyl-phenylethyl	
1936	"	3-methoxyphenylethyl	

Table 3




XVI


XVII


XVIII


XIX


XX


XXI


XXII


XXIII


XXIV


XXV


XXVI


n= 1, 2, 3
XXVII

Ex#	R3	Ms		Ex#	R3	Ms
2000	H			2001	4-(2-aminosufonylphenyl)-phenyl	
2002	methyl			2003	4-(2-chlorophenyl)-phenyl	
2004	ethyl			2005	4-(2-fluorophenyl)-phenyl	
2006	n-propyl			2007	4-(2,4-dichlorophenyl)-phenyl	
2008	n-butyl			2009	4-(2,6-dichlorophenyl)-phenyl	
2010	n-pentyl			2011	4-(3,5-dichlorophenyl)-phenyl	
2012	n-hexanyl			2013	4-(2,3-dichlorophenyl)-phenyl	
2014	n-heptanyl			2015	4-(2-methylphenyl)-phenyl	
2016	isopropyl			2017	4-(2-tetrazole-phenyl)-phenyl	
2018	tert-butyl			2019	4-(2-methoxy-phenyl)-phenyl	
2020	cyclopropyl			2021	4-(2-tmethyl-phenyl)-phenyl	
2022	cyclobutanyl			2023	4-(2-formyl-phenyl)-phenyl	
2024	cyclpentanyl			2025	4-(2-amino-phenyl)-phenyl	
2026	cyclohexanyl			2027	4-(2-methylamino-phenyl)-phenyl	
2028	cycloheptanyl			2029	4-(2-ethylamino-phenyl)-phenyl	
2030	phenyl			2031	4-(2-propylamino-phenyl)-phenyl	
2032	phenylmethyl			2033	4-(2-methylsulfonylamino-phenyl)-phenyl	
2034	3-hydroxyphenyl			2035	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
2036	3-hydroxy-4-methoxyphenyl			2037	4-(3-methylphenyl)-phenyl	
2038	3-fluorophenyl			2039	4-(3-isopropylphenyl)-phenyl	
2040	3-chlorophenyl			2041	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
2042	3-nitrophenyl			2043	4-(3-methylsulfonylamino-phenyl)-phenyl	
2044	3-aminophenyl			2045	4-(3-amino-phenyl)-phenyl	
2046	3-methylsulfonamidepheny l			2047	4-(3-nitro-phenyl)-phenyl	
2048	3-trifluoro-methyl-sulfonamidephenyl			2049	2-pyridyl	
2050	3-Ac-NHphenyl			2051	3-pyridyl	
2052	3-Boc-NHphenyl			2053	4-pyridyl	
2054	3-Cbz-NHphenyl			2055	3-amino-4-pyridyl	

2056	3-aminomethylene-phenyl			2057	3-hydroxy-4-pyridyl		
2058	3-amino-ethylenephenyl			2059	3-imidazole		
2060	3-cyanophenyl			2061	2-nitro-3-imidazole		
2062	3-cyanomethylphenyl			2063	5-thiazole		
2064	3-hydroxy-methylenephenyl			2065	5-oxazole		
2066	3-carboxylphenyl			2067	4-pyazole		
2068	3-mercaptophenyl			2069	phenylethyl		
2070	3-methoxyphenyl			2071	2-aminophenylethyl		
2072	3,4-methylenedioxo-phenyl			2073	2-methylsulfonyl-amino-phenylethyl		
2074	3-tetrazolephenyl			2075	2-trifluoromethylsulfonylamino-phenylethyl		
2076	3-aminosulfonylphenyl			2077	2-hydroxymethylene-phenylethyl		
2078	3-methylamino-sulfonylphenyl			2079	2-aminomethylene-phenylethyl		
2080	3-ethylamino-sulfonylphenyl			2081	2-tetrazole-phenylethyl		
2082	3-tert-butylamino-sulfonylphenyl			2083	2-tertbutylamino-sulfonylphenylethyl		
2084	3-methylsulfonyl-phenyl			2085	2-aminosulfonyl-phenylethyl		
2086	4-methoxyphenyl			2087	2-methoxy-phenylethyl		
2088	4-phenylphenyl			2089	3-aminophenylethyl		
2090	4-(2-hydroxymethylene-phenyl)-phenyl			2091	3-methylsulfonyl-amino-phenylethyl		
2092	4-(2-tert-butylaminosufonylphenyl)-phenyl			2093	3-trifluoromethylsulfonylamino-phenylethyl		
2094	4-(2-methylamino-sufonylphenyl)-phenyl			2095	3-hydroxymethylene-phenylethyl		
2096	4-(2-ethylamino-sufonylphenyl)-phenyl			2097	3-aminomethylene-phenylethyl		
2098				2099	3-tetrazole-phenylethyl		
2100				2101	3-tert-butylamino-sulfonylphenylethyl		
2102				2103	3-aminosulfonyl-phenylethyl		
2104				2105	3-methoxy-phenylethyl		

Table 4



X= NH, CH_2

I



II

X= H, NH_2, CO_2H, CH_2CO_2H, Cl, F,



CN, CH_2NH_2



III



IV

X= H, NH_2, CO_2H, CH_2CO_2H, Cl, F,



CN, CH_2NH_2



V



VI

Ex#	R2	R3	
2500	n-Bu	H	
2501	"	methyl	
2502	"	ethyl	
2503	"	n-propyl	
2504	"	n-butyl	
2505	"	n-pentyl	
2506	"	n-hexanyl	
2507	"	n-heptanyl	
2508	"	isopropyl	
2509	"	tert-butyl	
2510	"	cyclopropyl	
2511	"	cyclobutanyl	
2512	"	cyclpentanyl	

2513	"	cyclohexanyl	
2514	"	cycloheptanyl	
2515	"	phenyl	
2516	"	phenylmethyl	
2517	"	3-hydroxyphenyl	
2518	"	3-hydroxy-4-methoxyphenyl	
2519	"	3-fluorophenyl	
2520	"	3-chlorophenyl	
2521	"	3-nitrophenyl	
2522	"	3-aminophenyl	
2523	"	3-methyl-sulfonamidephenyl	
2524	"	3-trifluoro-methyl-sulfonamidephenyl	
2525	"	3-Ac-NHphenyl	
2526	"	3-Boc-NHphenyl	
2527	"	3-Cbz-NHphenyl	
2528	"	3-aminomethylenephenyl	
2529	"	3-aminoethylenephenyl	
2530	"	3-cyanophenyl	
2531	"	3-cyanomethylphenyl	
2532	"	3-hydroxy-methylenephenyl	
2533	"	3-carboxylphenyl	
2534	"	3-mercaptophenyl	
2535	"	3-methoxyphenyl	
2536	"	3,4-methylene-dioxophenyl	
2537	"	3-tetrazolephenyl	
2538	"	3-aminosulfonylphenyl	
2539	"	3-methylamino-sulfonylphenyl	
2540	"	3-ethylamino-sulfonylphenyl	
2541	"	3-tertbutylamino-sulfonylphenyl	
2542	"	3-methylsulfonylphenyl	
2543	"	4-methoxyphenyl	
2544	"	4-phenylphenyl	
2545	"	4-(2-hydroxymethylene-phenyl)-phenyl	
2546	"	4-(2-tertbutylamino-sufonylphenyl)-phenyl	
2547	"	4-(2-methylamino-sufonylphenyl)-phenyl	
2548	"	4-(2-ethylamino-sufonylphenyl)-phenyl	
2549	"	4-(2-aminosufonyl-phenyl)-phenyl	
2550	"	4-(2-chlorophenyl)-phenyl	
2551	"	4-(2-fluorophenyl)-phenyl	
2552	"	4-(2,4-dichlorophenyl)-phenyl	
2553	"	4-(2,6-dichlorophenyl)-phenyl	
2554	"	4-(3,5-dichlorophenyl)-phenyl	
2555	"	4-(2,3-dichlorophenyl)-phenyl	
2556	"	4-(2-methylphenyl)-phenyl	
2557	"	4-(2-tetrazole-phenyl)-phenyl	
2558	"	4-(2-methoxy-phenyl)-phenyl	
2559	"	4-(2-tmethyl-phenyl)-phenyl	
2560	"	4-(2-formyl-phenyl)-phenyl	
2561	"	4-(2-amino-phenyl)-phenyl	

2562	"	4-(2-methylamino-phenyl)-phenyl	
2563	"	4-(2-ethylamino-phenyl)-phenyl	
2564	"	4-(2-propylamino-phenyl)-phenyl	
2565	"	4-(2-methylsulfonylamino-phenyl)-phenyl	
2566	"	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
2567	"	4-(3-methylphenyl)-phenyl	
2568	"	4-(3-isopropylphenyl)-phenyl	
2569	"	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
2570	"	4-(3-methylsulfonylamino-phenyl)-phenyl	
2571	"	4-(3-amino-phenyl)-phenyl	
2572	"	4-(3-nitro-phenyl)-phenyl	
2573	"	2-pyridyl	
2574	"	3-pyridyl	
2575	"	4-pyridyl	
2576	"	3-amino-4-pyridyl	
2577	"	3-hydroxy-4-pyridyl	
2578	"	3-imidazole	
2579	"	2-nitro-3-imidazole	
2580	"	5-thiazole	
2581	"	5-oxazole	
2582	"	4-pyazole	
2583	"	phenylethyl	
2584	"	2-aminophenylethyl	
2585	"	2-methylsulfonylamino-phenylethyl	
2586	"	2-trifluoromethyl-sulfonylamino-phenylethyl	
2587	"	2-hydroxy-methylenephenylethyl	
2588	"	2-aminomethylene-phenylethyl	
2589	"	2-tetrazolephenylethyl	
2590	"	2-tertbutylamino-sulfonylphenylethyl	
2591	"	2-aminosulfonyl-phenylethyl	
2592	"	2-methoxyphenylethyl	
2593	"	3-aminophenylethyl	
2594	"	3-methylsulfonylamino-phenylethyl	
2595	"	3-trifluoromethyl-sulfonylamino-phenylethyl	
2596	"	3-hydroxymethylene-phenylethyl	
2597	"	3-aminomethylene-phenylethyl	
2598	"	3-tetrazolephenylethyl	
2599	"	3-tertbutylamino-sulfonylphenylethyl	
2600	"	3-aminosulfonyl-phenylethyl	
2601	"	3-methoxyphenylethyl	
2602	"	4-phenylphenylmethyl	

2603	"	4-(2-hydroxymethylenephenyl)-phenylmethyl	
2604	"	4-(2-tert-butyl-aminosufonyl-phenyl)-phenylmethyl	
2605	"	4-(2-methylamino-sufonylphenyl)-phenylmethyl	
2606	"	4-(2-ethylamino-sufonylphenyl)-phenylmethyl	
2607	"	4-(2-aminosufonylphenyl)-phenylmethyl	
2608	"	4-(2-chlorophenyl)-phenylmethyl	
2609	"	4-(2-fluorophenyl)-phenylmethyl	
2610	"	4-(2,4-dichlorophenyl)-phenylmethyl	
2611	"	4-(2,6-dichlorophenyl)-phenylmethyl	
2612	"	4-(3,5-dichlorophenyl)-phenylmethyl	
2613	"	4-(2,3-dichlorophenyl)-phenylmethyl	
2614	"	4-(2-methylphenyl)-phenylmethyl	
2615	"	4-(2-tetrazole-phenyl)-phenylmethyl	
2616	"	4-(2-methoxy-phenyl)-phenylmethyl	
2617	"	4-(2-tmethyl-phenyl)-phenylmethyl	
2618	"	4-(2-formyl-phenyl)-phenylmethyl	
2619	"	4-(2-amino-phenyl)-phenylmethyl	
2620	"	4-(2-methylamino-phenyl)-phenylmethyl	
2621	"	4-(2-ethylamino-phenyl)-phenylmethyl	
2622	"	4-(2-propylamino-phenyl)-phenylmethyl	
2623	"	4-(2-methylsulfonylamino-phenyl)-phenylmethyl	
2624	"	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenylmethyl	
2625	"	4-(3-methylphenyl)-phenylmethyl	
2626	"	4-(3-isopropylphenyl)-phenylmethyl	
2627	"	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenylmethyl	
2628	"	4-(3-methylsulfonylamino-phenyl)-phenylmethyl	
2629	"	4-(3-amino-phenyl)-phenylmethyl	
2630	"	4-(3-nitro-phenyl)-phenylmethyl	
2631			
2632	CH_3	H	
2633	"	methyl	

2634	"	ethyl	
2635	"	n-propyl	
2636	"	n-butyl	
2637	"	n-pentyl	
2638	"	n-hexanyl	
2639	"	n-heptanyl	
2640	"	isopropyl	
2641	"	tert-butyl	
2642	"	cyclopropyl	
2643	"	cyclobutanyl	
2644	"	cyclpentanyl	
2645	"	cyclohexanyl	
2646	"	cycloheptanyl	
2647	"	phenyl	
2648	"	phenylmethyl	
2649	"	3-hydroxyphenyl	
2650	"	3-hydroxy-4-methoxyphenyl	
2651	"	3-fluorophenyl	
2652	"	3-chlorophenyl	
2653	"	3-nitrophenyl	
2654	"	3-aminophenyl	
2655	"	3-methyl-sulfonamidephenyl	
2656	"	3-trifluoro-methylsulfonamidephenyl	
2657	"	3-Ac-NHphenyl	
2658	"	3-Boc-NHphenyl	
2659	"	3-Cbz-NHphenyl	
2660	"	3-aminomethylenephenyl	
2661	"	3-aminoethylenephenyl	
2662	"	3-cyanophenyl	
2663	"	3-cyanomethylphenyl	
2664	"	3-hydroxy-methylenephenyl	
2665	"	3-carboxylphenyl	
2666	"	3-mercaptophenyl	
2667	"	3-methoxyphenyl	
2668	"	3,4-methylene-dioxophenyl	
2669	"	3-tetrazolephenyl	
2670	"	3-aminosulfonylphenyl	
2671	"	3-methylamino-sulfonylphenyl	
2672	"	3-ethylamino-sulfonylphenyl	
2673	"	3-tertbutylamino-sulfonylphenyl	
2674	"	3-methylsulfonylphenyl	
2675	"	4-methoxyphenyl	
2676	"	4-phenylphenyl	
2677	"	4-(2-hydroxymethylene-phenyl)-phenyl	
2678	"	4-(2-tert-butylamino-sufonylphenyl)-phenyl	
2679	"	4-(2-methylamino-sufonylphenyl)-phenyl	
2680	"	4-(2-ethylamino-sufonylphenyl)-phenyl	
2681	"	4-(2-aminosufonyl-phenyl)-phenyl	
2682	"	4-(2-chlorophenyl)-phenyl	
2683	"	4-(2-fluorophenyl)-phenyl	
2684	"	4-(2,4-dichlorophenyl)-phenyl	
2685	"	4-(2,6-dichlorophenyl)-phenyl	

2686	"	4-(3,5-dichlorophenyl)-phenyl	
2687	"	4-(2,3-dichlorophenyl)-phenyl	
2688	"	4-(2-methylphenyl)-phenyl	
2689	"	4-(2-tetrazole-phenyl)-phenyl	
2690	"	4-(2-methoxy-phenyl)-phenyl	
2691	"	4-(2-tmethyl-phenyl)-phenyl	
2692	"	4-(2-formyl-phenyl)-phenyl	
2693	"	4-(2-amino-phenyl)-phenyl	
2694	"	4-(2-methylamino-phenyl)-phenyl	
2695	"	4-(2-ethylamino-phenyl)-phenyl	
2696	"	4-(2-propylamino-phenyl)-phenyl	
2697	"	4-(2-methylsulfonylamino-phenyl)-phenyl	
2698	"	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
2699	"	4-(3-methylphenyl)-phenyl	
2700	"	4-(3-isopropylphenyl)-phenyl	
2701	"	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
2702	"	4-(3-methylsulfonyl-amino-phenyl)-phenyl	
2703	"	4-(3-amino-phenyl)-phenyl	
2704	"	4-(3-nitro-phenyl)-phenyl	
2705	"	2-pyridyl	
2706	"	3-pyridyl	
2707	"	4-pyridyl	
2708	"	3-amino-4-pyridyl	
2709	"	3-hydroxy-4-pyridyl	
2710	"	3-imidazole	
2711	"	2-nitro-3-imidazole	
2712	"	5-thiazole	
2713	"	5-oxazole	
2714	"	4-pyazole	
2715	"	phenylethyl	
2716	"	2-aminophenylethyl	
2717	"	2-methylsulfonylamino-phenylethyl	
2718	"	2-trifluoromethylsulfonylamino-phenylethyl	
2719	"	2-hydroxymethylene-phenylethyl	
2720	"	2-aminomethylene-phenylethyl	
2721	"	2-tetrazolephenylethyl	
2722	"	2-tertbutylamino-sulfonylphenylethyl	
2723	"	2-aminosulfonyl-phenylethyl	
2724	"	2-methoxyphenylethyl	
2725	"	3-aminophenylethyl	
2726	"	3-methylsulfonylamino-phenylethyl	

2727	"	3-trifluoromethyl-sulfonylamino-phenylethyl	
2728	"	3-hydroxy-methylenephenylethyl	
2729	"	3-aminomethylene-phenylethyl	
2730	"	3-tetrazolephenylethyl	
2731	"	3-tertbutylamino-sulfonylphenylethyl	
2732	"	3-aminosulfonyl-phenylethyl	
2733	"	3-methoxyphenylethyl	
2734	"	4-phenylphenylmethyl	
2735	"	4-(2-hydroxy-methylenephenyl)-phenylmethyl	
2736	"	4-(2-tert-butylaminosufonyl-phenyl)-phenylmethyl	
2737	"	4-(2-methylamino-sufonylphenyl)-phenylmethyl	
2738	"	4-(2-ethylamino-sufonylphenyl)-phenylmethyl	
2739	"	4-(2-aminosufonyl-phenyl)-phenylmethyl	
2740	"	4-(2-chlorophenyl)-phenylmethyl	
2741	"	4-(2-fluorophenyl)-phenylmethyl	
2742	"	4-(2,4-dichlorophenyl)-phenylmethyl	
2743	"	4-(2,6-dichlorophenyl)-phenylmethyl	
2744	"	4-(3,5-dichlorophenyl)-phenylmethyl	
2745	"	4-(2,3-dichlorophenyl)-phenylmethyl	
2746	"	4-(2-methylphenyl)-phenylmethyl	
2747	"	4-(2-tetrazole-phenyl)-phenylmethyl	
2748	"	4-(2-methoxy-phenyl)-phenylmethyl	
2749	"	4-(2-tmethyl-phenyl)-phenylmethyl	
2750	"	4-(2-formyl-phenyl)-phenylmethyl	
2751	"	4-(2-amino-phenyl)-phenylmethyl	
2752	"	4-(2-methylamino-phenyl)-phenylmethyl	
2753	"	4-(2-ethylamino-phenyl)-phenylmethyl	
2754	"	4-(2-propylamino-phenyl)-phenylmethyl	
2755	"	4-(2-methylsulfonylamino-phenyl)-phenylmethyl	
2756	"	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenylmethyl	
2757	"	4-(3-methylphenyl)-phenylmethyl	
2758	"	4-(3-isopropylphenyl)-phenylmethyl	

2759	"	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenylmethyl	
2760	"	4-(3-methylsulfonyl-amino-phenyl)-phenylmethyl	
2761	"	4-(3-amino-phenyl)-phenylmethyl	
2762	"	4-(3-nitro-phenyl)-phenylmethyl	
2763			
2764	3-phenylpropyl	H	
2765	"	methyl	
2766	"	ethyl	
2767	"	n-propyl	
2768	"	n-butyl	
2769	"	n-pentyl	
2770	"	n-hexanyl	
2771	"	n-heptanyl	
2772	"	isopropyl	
2773	"	tert-butyl	
2774	"	cyclopropyl	
2775	"	cyclobutanyl	
2776	"	cyclpentanyl	
2777	"	cyclohexanyl	
2778	"	cycloheptanyl	
2779	"	phenyl	
2780	"	phenylmethyl	
2781	"	3-hydroxyphenyl	
2782	"	3-hydroxy-4-methoxyphenyl	
2783	"	3-fluorophenyl	
2784	"	3-chlorophenyl	
2785	"	3-nitrophenyl	
2786	"	3-aminophenyl	
2787	"	3-methyl-sulfonamidephenyl	
2788	"	3-trifluoro-methylsulfonamidephenyl	
2789	"	3-Ac-NHphenyl	
2790	"	3-Boc-NHphenyl	
2791	"	3-Cbz-NHphenyl	
2792	"	3-aminomethylenephenyl	
2793	"	3-aminoethylenephenyl	
2794	"	3-cyanophenyl	
2795	"	3-cyanomethylphenyl	
2796	"	3-hydroxy-methylenephenyl	
2797	"	3-carboxylphenyl	
2798	"	3-mercaptophenyl	
2799	"	3-methoxyphenyl	
2800	"	3,4-methylene-dioxophenyl	
2801	"	3-tetrazolephenyl	
2802	"	3-aminosulfonylphenyl	
2803	"	3-methylamino-sulfonylphenyl	
2804	"	3-ethylamino-sulfonylphenyl	
2805	"	3-tertbutylamino-sulfonylphenyl	
2806	"	3-methylsulfonylphenyl	
2807	"	4-methoxyphenyl	
2808	"	4-phenylphenyl	
2809	"	4-(2-hydroxy-methylenephenyl)-phenyl	
2810	"	4-(2-tert-butylamino-sufonylphenyl)-phenyl	

2811	"	4-(2-methylamino-sufonylphenyl)-phenyl	
2812	"	4-(2-ethylamino-sufonylphenyl)-phenyl	
2813	"	4-(2-aminosufonyl-phenyl)-phenyl	
2814	"	4-(2-chlorophenyl)-phenyl	
2815	"	4-(2-fluorophenyl)-phenyl	
2816	"	4-(2,4-dichlorophenyl)-phenyl	
2817	"	4-(2,6-dichlorophenyl)-phenyl	
2818	"	4-(3,5-dichlorophenyl)-phenyl	
2819	"	4-(2,3-dichlorophenyl)-phenyl	
2820	"	4-(2-methylphenyl)-phenyl	
2821	"	4-(2-tetrazole-phenyl)-phenyl	
2822	"	4-(2-methoxy-phenyl)-phenyl	
2823	"	4-(2-tmethyl-phenyl)-phenyl	
2824	"	4-(2-formyl-phenyl)-phenyl	
2825	"	4-(2-amino-phenyl)-phenyl	
2826	"	4-(2-methylamino-phenyl)-phenyl	
2827	"	4-(2-ethylamino-phenyl)-phenyl	
2828	"	4-(2-propylamino-phenyl)-phenyl	
2829	"	4-(2-methylsulfonyl-amino-phenyl)-phenyl	
2830	"	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
2831	"	4-(3-methylphenyl)-phenyl	
2832	"	4-(3-isopropylphenyl)-phenyl	
2833	"	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenyl	
2834	"	4-(3-methylsulfonyl-amino-phenyl)-phenyl	
2835	"	4-(3-amino-phenyl)-phenyl	
2836	"	4-(3-nitro-phenyl)-phenyl	
2837	"	2-pyridyl	
2838	"	3-pyridyl	
2839	"	4-pyridyl	
2840	"	3-amino-4-pyridyl	
2841	"	3-hydroxy-4-pyridyl	
2842	"	3-imidazole	
2843	"	2-nitro-3-imidazole	
2844	"	5-thiazole	
2845	"	5-oxazole	
2846	"	4-pyazole	
2847	"	phenylethyl	
2848	"	2-aminophenylethyl	
2849	"	2-methylsulfonylamino-phenylethyl	
2850	"	2-trifluoromethylsulfonylamino-phenylethyl	

2851	"	2-hydroxymethylene-phenylethyl	
2852	"	2-aminomethylene-phenylethyl	
2853	"	2-tetrazolephenylethyl	
2854	"	2-tert-butylamino-sulfonylphenylethyl	
2855	"	2-aminosulfonyl-phenylethyl	
2856	"	2-methoxyphenylethyl	
2857	"	3-aminophenylethyl	
2858	"	3-methylsulfonylamino-phenylethyl	
2859	"	3-trifluoromethylsulfonylamino-phenylethyl	
2860	"	3-hydroxymethylene-phenylethyl	
2861	"	3-aminomethylene-phenylethyl	
2862	"	3-tetrazolephenylethyl	
2863	"	3-tertbutylamino-sulfonylphenylethyl	
2864	"	3-aminosulfonyl-phenylethyl	
2865	"	3-methoxyphenylethyl	
2866	"	4-phenylphenylmethyl	
2867	"	4-(2-hydroxymethylene-phenyl)-phenylmethyl	
2868	"	4-(2-tert-butylaminosufonyl-phenyl)-phenylmethyl	
2869	"	4-(2-methylaminosufonyl-phenyl)-phenylmethyl	
2870	"	4-(2-ethylaminosufonyl-phenyl)-phenylmethyl	
2871	"	4-(2-aminosufonylphenyl)-phenylmethyl	
2872	"	4-(2-chlorophenyl)-phenylmethyl	
2873	"	4-(2-fluorophenyl)-phenylmethyl	
2874	"	4-(2,4-dichlorophenyl)-phenylmethyl	
2875	"	4-(2,6-dichlorophenyl)-phenylmethyl	
2876	"	4-(3,5-dichlorophenyl)-phenylmethyl	
2877	"	4-(2,3-dichlorophenyl)-phenylmethyl	
2878	"	4-(2-methylphenyl)-phenylmethyl	
2879	"	4-(2-tetrazole-phenyl)-phenylmethyl	
2880	"	4-(2-methoxy-phenyl)-phenylmethyl	
2881	"	4-(2-tmethyl-phenyl)-phenylmethyl	
2882	"	4-(2-formyl-phenyl)-phenylmethyl	
2883	"	4-(2-amino-phenyl)-phenylmethyl	
2884	"	4-(2-methylamino-phenyl)-phenylmethyl	

2885	"	4-(2-ethylamino-phenyl)-phenylmethyl	
2886	"	4-(2-propylamino-phenyl)-phenylmethyl	
2887	"	4-(2-methylsulfonylamino-phenyl)-phenylmethyl	
2888	"	4-(2-trifluoromethylsulfonyl-amino-phenyl)-phenylmethyl	
2889	"	4-(3-methylphenyl)-phenylmethyl	
2890	"	4-(3-isopropylphenyl)-phenylmethyl	
2891	"	4-(3-trifluoromethylsulfonyl-amino-phenyl)-phenylmethyl	
2892	"	4-(3-methylsulfonylamino-phenyl)-phenylmethyl	
2893	"	4-(3-amino-phenyl)-phenylmethyl	
2894	"	4-(3-nitro-phenyl)-phenylmethyl	

What is claimed:

1. A compound of the formula I:



Formula I

or a pharmaceutically acceptable salt form or a steroisomer thereof, wherein:

R^1 is selected from:
$-CO_2H$, $-C(O)NHOH$, $-C(O)NHOR^7$, $-SH$, $-CH_2CO_2R^7$, $-COR^7$, $-N(OH)COR^7$, $-SN_2H_2R^7$, $-SONHR^7$, $-CH_2CO_2H$, $-PO(OH)_2$, $-PO(OH)NHR^7$, $-CH_2SH$, $-C(O)NHOR^7$, $-CO_2R^7$, and common prodrug derivatives;

R^2 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional

heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^3 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4

heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^4 is selected from:
hydrogen, (C_1-C_5)alkyl, (C_1-C_5)alkyl-aryl,

R^5 and R^6 are independently selected from:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$,

$C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^7 is selected from: C_1-C_{10} alkyl, alkylaryl, and common prodrug derivatives

A is selected from:
SO_2, SO, CHOH;

E is $(CR^8R^9)_m$-W-$(CR^8R^9)_n$,
wherein W can be absent or selected from:
CH_2, CO, O, $S(O)_m$ and NR^{10},
m is 0-2,
n is 0-2;

with the proviso that when W is O, S or NR^{10} then m must not be 0;

R^8 and R^9 is independently selected from:
H,
C1-C8 alkyl substituted with 0-5 R^b,
C1-C8 alkenyl,
C1-C8 alkylaryl substituted with 0-5 R^b,
C_{3-13} carbocyclic residue substituted with 0-5 R^b,
5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;
amino,
C1-C8 alkyl-NR^{10}
hydroxyl,

R^8 and R^9 can also form a ring interrupted by NR^{10}, O, S(O)m.

R^{10} is selected from:
hydrogen,
C1-C8 alkyl
C1-C8 alkylaryl

J^1, J^2, J^3, J^4 are independently selected from:
CH, or N.
with no more than two N in the cycle.

2. A compound of claim 1 wherein:

R^1 is selected from:
$-CO_2H$, $-C(O)NHOH$, $-C(O)NHOR^7$, $-SH$, $-CH_2CO_2R^7$, $-COR^7$, $-N(OH)COR^7$, $-SN_2H_2R^7$, $-SONHR^7$, $-CH_2CO_2H$, $-PO(OH)_2$, $-PO(OH)NHR^7$, $-CH_2SH$, $-C(O)NHOR^7$, $-CO_2R^7$, and common prodrug derivatives;

R^2 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^3 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2,

$NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^4 is selected from:
hydrogen,

R^5 and R^6 are independently selected from:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and $C(O)$;

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^7 is selected from: C_1-C_{10} alkyl, alkylaryl, and common prodrug derivatives

A is selected from:
SO_2, SO, CHOH;

E is $(CR^8R^9)_m$-W-$(CR^8R^9)_n$,
wherein W can be absent or selected from:
CH_2, CO, O, $S(O)_m$ and NR^{10},
m is 0-2,
n is 0-2;

with the proviso that when W is O, S or NR^{10} then m must not be 0;

R^8 and R^9 is independently selected from:
H,
C1-C8 alkyl substituted with 0-5 R^b,
C1-C8 alkenyl,
C1-C8 alkylaryl substituted with 0-5 R^b,
C_{3-13} carbocyclic residue substituted with 0-5 R^b,
5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;
amino,
C1-C8 alkyl-NR^{10}
hydroxyl,

R^8 and R^9 can also form a ring interrupted by NR^{10}, O, $S(O)_m$.

R^{10} is selected from:
hydrogen,
C1-C8 alkyl
C1-C8 alkylaryl

J^1, J^2, J^3, J^4 are independently selected from:

CH, or N.

with no more than two N in the cycle.

3. A compound of claim 1 wherein:

R^1 is selected from:
$-CO_2H$, $-C(O)NHOH$, $-C(O)NHOR^7$, $-SH$, $-CH_2CO_2R^7$, and common prodrug derivatives;

R^2 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and $C(O)$;

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^3 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^4 is selected from:
hydrogen,

R^5 and R^6 are independently selected from:

$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4

heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^7 is selected from: C_1-C_{10} alkyl, alkylaryl, and common prodrug derivatives

A is selected from:
SO_2, SO, CHOH;

E is $(CR^8R^9)_m$-W-$(CR^8R^9)_n$,
wherein W can be absent or selected from:
CH_2, CO, O, $S(O)_m$ and NR^{10},

m is 0-2,
n is 0-2;

with the proviso that when W is O, S or NR^{10} then m must not be 0;

R^8 and R^9 is independently selected from:
H,
C1-C8 alkyl substituted with 0-5 R^b,
C1-C8 alkenyl,
C1-C8 alkylaryl substituted with 0-5 R^b,
C_{3-13} carbocyclic residue substituted with 0-5 R^b,
5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;
amino,
C1-C8 alkyl-NR^{10}
hydroxyl,

R^8 and R^9 can also form a ring interrupted by NR^{10}, O, S(O)m.

R^{10} is selected from:
hydrogen,
C1-C8 alkyl
C1-C8 alkylaryl

J^1, J^2, J^3, J^4 are independently selected from:
CH, or N.
with no more than two N in the cycle.

4. A compound of the formula II:



Formula II

or a pharmaceutically acceptable salt form or a steroisomer thereof, wherein:

R^1 is selected from:
$-CO_2H$, $-C(O)NHOH$, $-C(O)NHOR^7$, $-SH$, $-CH_2CO_2R^7$, and common prodrug derivatives;

R^2 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4

heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^3 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and $C(O)$;

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4

heteroatoms selected from the group consisting of N, O, and S;

R^5 is selected from:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^7 is selected from: C_1-C_{10} alkyl, alkylaryl, and common prodrug derivatives

E is $(CR^8R^9)_m$-W-$(CR^8R^9)_n$,

wherein W can be absent or selected from:

CH_2, CO, O, $S(O)_m$ and NR^{10},

m is 0-2,
n is 0-2;

with the proviso that when W is O, S or NR^{10} then m must not be 0;

R^8 and R^9 is independently selected from:
H,
C1-C8 alkyl substituted with 0-5 R^b,
C1-C8 alkenyl,
C1-C8 alkylaryl substituted with 0-5 R^b,
C_{3-13} carbocyclic residue substituted with 0-5 R^b,
5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;
amino,
C1-C8 alkyl-NR^{10}
hydroxyl,

R^8 and R^9 can also form a ring interrupted by NR^{10}, O, S(O)m.

R^{10} is selected from:
hydrogen,
C1-C8 alkyl
C1-C8 alkylaryl

J^1, J^2, J^3, J^4 are independently selected from:
CH,or N.
with no more than two N in the cycle.

5. A compound of claim 4 wherein:

R^1 is selected from:
-C(O)NHOH,
and common prodrug derivatives;

R^2 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^3 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^5 is selected from:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^7 is selected from: C_1-C_{10} alkyl, alkylaryl, and common prodrug derivatives

E is $(CR^8R^9)_m$-W-$(CR^8R^9)_n$,

wherein W can be absent or selected from:

CH_2, CO, O, $S(O)_m$ and NR^{10},

m is 0-2,

n is 0-2;

with the proviso that when W is O, S or NR^{10} then m must not be 0;

R^8 and R^9 is independently selected from:

H,

C1-C8 alkyl substituted with 0-5 R^b,

C1-C8 alkenyl,

C1-C8 alkylaryl substituted with 0-5 R^b,

C_{3-13} carbocyclic residue substituted with 0-5 R^b,
5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;
amino,
C1-C8 alkyl-NR^{10}
hydroxyl,

R^8 and R^9 can also form a ring interrupted by NR^{10}, O, S(O)m.

R^{10} is selected from:
hydrogen,
C1-C8 alkyl
C1-C8 alkylaryl

J^1, J^2, J^3, J^4 are independently selected from:
CH,or N.
with no more than two N in the cycle.

6. A compound of formula III wherein:



Formula III

or a pharmaceutically acceptable salt form or a steroisomer thereof, wherein:

R^1 is selected from:

$-C(O)NHOH$

and common prodrug derivatives;

R^2 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and $C(O)$;

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^3 is selected from the formula:

$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4

heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^5 is selected from:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^8 and R^9 is independently selected from:

H,

C1-C8 alkyl substituted with 0-5 R^b,

C1-C8 alkenyl,

C1-C8 alkylaryl substituted with 0-5 R^b,

C_{3-13} carbocyclic residue substituted with 0-5 R^b,

5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

amino,

C1-C8 alkyl-NR^{10}

hydroxyl,

R^8 and R^9 can also form a ring interrupted by NR^{10}, O, S(O)m.

R^{10} is selected from:
hydrogen,
C1-C8 alkyl
C1-C8 alkylaryl

J^1, J^2, J^3, J^4 are independently selected from:
CH,or N.
with no more than two N in the cycle.

7. A compound of the formula IV:



IV

or a pharmaceutically acceptable salt form or a steroisomer therof, wherein:

R^2 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^3 is selected from the formula:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^5 is selected from:

$$U\text{-}X\text{-}Y\text{-}Z\text{-}U^a\text{-}X^a\text{-}Y^a\text{-}Z^a$$

wherein:

U is absent or is selected from: O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^b and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;

U^a is absent or is selected from: H, O, NR^a, C(O), C(O)O, OC(O), $C(O)NR^a$, $NR^aC(O)$, OC(O)O, $OC(O)NR^a$, $NR^aC(O)O$, $NR^aC(O)NR^a$, $S(O)_p$, $S(O)_pNR^a$, $NR^aS(O)_p$, and $NR^aSO_2NR^a$;

X^a is absent or selected from H, C_{1-10} alkylene, C_{2-10} alkenylene, C_{2-10} alkynylene;

Y^a is absent or selected from H, O, NR^a, $S(O)_p$, and C(O);

Z^a is absent or selected from H, a C_{3-13} carbocyclic residue substituted with 0-5 R^c and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^c;

R^a, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

$R^{a'}$, at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl or benzyl;

alternatively, R^a and $R^{a'}$ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^b, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, and CF_2CF_3;

R^c, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a, Cl, F, Br, I, =O, CN, NO_2, $NR^aR^{a'}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a'}$, $NR^aS(O)_2R^{a'}$, $S(O)_2NR^aR^{a'}$, $S(O)_pR^a$, CF_3, CF_2CF_3, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^8 and R^9 is independently selected from:
H,
C1-C8 alkyl substituted with 0-5 R^b,
C1-C8 alkenyl,
C1-C8 alkylaryl substituted with 0-5 R^b,
C_{3-13} carbocyclic residue substituted with 0-5 R^b,
5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-5 R^b;
amino,
C1-C8 alkyl-NR^{10}
hydroxyl,

R^8 and R^9 can also form a ring interrupted by NR^{10}, O, S(O)m.

R^{10} is selected from:
hydrogen,
C1-C8 alkyl
C1-C8 alkylaryl

8. A compound of claim 1, selected from the group consisting of:

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-butanediamide;

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-3(S)-(5-hydroxycarbonyl)-pentanamide;

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-3(S)-methyl-butanediamide;

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-3(S)-propyl-butanediamide;

N1-(2(R)-hydroxy-1(S)-indanyl)-N4-hydroxy-2(R)-hexyl-3(S)-propyl-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-hydroxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-methoxy-phenyl)methyl]butanediamide;

N1-[1(S)-indanyl]-N4-hydroxy-2(R)-[4-(hydroxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-phenyl-propyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(benzyloxy)-phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-(benzyloxy)-phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(fluoro-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3,4-(methylenedioxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(methoxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-trifluoromethyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-tert-butylaminosulfonyl-phenyl)phenyl]methyl]-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-methoxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[(3-hydroxy-4-methoxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-(3-thiophene)isoxazoline]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-chloro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-benzofuran)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-methyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3,4-(methylenedioxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-tetrazole-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-methyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(amino-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(benzyloxy-carbonyl)amino]phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-hydroxymethlene)phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,4,5-trimethoxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2,4-di-methoxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,5-di-chloro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-trifluoromethyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-isopropyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2,4-dichloro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-chloro-4-fluoro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(p-toluenesulfonyl-amino)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-phenylmethyl-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,4-methylenedioxyphenyl)phenyl]methyl]-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-methoxyphenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-fluorophenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(fluoro-phenyl)methyl]-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-nitrophenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-(methylsulfonyl-amino)-phenyl)phenyl]methyl]-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(3-trimethylsilyl-propyl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2,2-dimethyl-propionamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(ethyloxy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(iso-butyloxy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(propionamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-methyl-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2,2-dimethylpropyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(methylsulfonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-amino-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(methylsulfonylamino)-phenyl)methyl]-butanediamide;

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-butanediamide;

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-3(S)-(5-hydroxycarbonyl)-pentanamide;

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-3(S)-methyl-butanediamide;

N1-(2(R)-hydroxy-1(S)-indanyl)- N4-hydroxy-2(R)-isobutyl-3(S)-propyl-butanediamide;

N1-(2(R)-hydroxy-1(S)-indanyl)-N4-hydroxy-2(R)-hexyl-3(S)-propyl-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-hydroxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-methoxy-phenyl)methyl]butanediamide;

N1-[1(S)-indanyl]-N4-hydroxy-2(R)-[4-(hydroxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-phenyl-propyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(benzyloxy)-phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-(benzyloxy)-phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(hydroxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(fluoro-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3,4-(methylenedioxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(methoxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-trifluoromethyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-tert-butylaminosulfonyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-methoxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[(3-hydroxy-4-methoxy-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-(3-thiophene)isoxazoline]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-chloro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-benzofuran)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-methyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3,4-(methylenedioxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-tetrazole-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[3-methyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4-(amino-phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(benzyloxy-carbonyl)amino]phenyl)methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-hydroxymethlene)phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,4,5-trimethoxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2,4-di-methoxy-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,5-di-chloro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2-trifluoromethyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-isopropyl-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(2,4-dichloro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-chloro-4-fluoro-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(p-toluenesulfonyl-amino)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-phenylmethyl-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3,4-methylenedioxyphenyl)phenyl]methyl]-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-methoxyphenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-fluorophenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(fluoro-phenyl)methyl]-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(tert-butylxoy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-nitrophenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(3-(methylsulfonyl-amino)-phenyl)phenyl]methyl]butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(3-trimethylsilyl-propyl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2,2-dimethyl-propionamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(ethyloxy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(iso-butyloxy-carbonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(propionamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-methyl-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2,2-dimethylpropyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(methylsulfonyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-amino-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(cyclobutane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-hydroxymethyl-isobutanamide)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-hydroxyl-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-phenyl-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(bezene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-cyano-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-phenyl-cyclopentane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-methyl-cyclohexane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-indole carboxamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-furan carboxamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-quinoline carboxamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(3,4,5-trimethoxy benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-methyl-3-amino-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-methyl-6-amino-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(3-pyridine carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-(2,4-dichloro-phenyl)-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-(4-chloro-phenyl)-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(3-methylsulfonyl)-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-methylsulfonyl-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(3-cyano-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(6-quinoline carboxamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-ethyl,3-methyl-pyrazole 5-carboxamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3-(4-morpholino-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-chloro-4-methylsulfonyl-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(4-(imidazol-1-yl)benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-thiophene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-tert-butyl,3-methyl-pyrazole 5- carboxamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(4-aminomethyl benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-hydroxyl-isobutanamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(cyclopentane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-cyclopentyl acetamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(cyclohexane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(4-(4-N-Boc-piperazinyl-1-yl)benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(4-(piperazinyl-1-yl)benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-Fluoro-6-chloro-benzene carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-amino-cyclohexane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-methylthio-acetamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-methoxy-acetamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-allyl-cyclopentane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-n-propyl-cyclopentane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-allyl-cyclopropane carboxamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(8-quinoline-sulfonamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(4-nitro-benzene sulfonamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1,4-di-methyl-2-chloro-pyrazole-3- sulfonamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1,5-dimethyl-isooxazole 3- sulfonamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-methyl-imidazole 3-sulfonamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(benzene sulfonamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1,4-dimethyl pyrazole 3-sulfonamido)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-methylsulfonyl benzene sulfonamido-1-yl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(cyclohexylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(iso-propylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[4(2-trifluoromethylphenyl)-phenylmethyl]-3(S)-(2,2-dimethylpropyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(cyclopentylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(cyclopropylmethyl)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(benzylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-furanmethylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-4-methylphenyl)methyl]-3(S)-(3-cyanophenylmethylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2,2-dimethylpropyl-amino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-pentylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(bis-cyclopropylmethyamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-thiophenemethylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(2-methyl-propylamino)-butanediamide;

N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[3-(hydroxy-phenyl)methyl]-3(S)-(1-methyl-cyclopropane carboxamido-1-yl)-butanediamide;

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 2.

11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 3.

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 4.

13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a

therapeutically effective amount of a compound of Claim 5.

14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 6.

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 7.

16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 8.

17. A method of treating an inflammatory disease in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

18. A method of treating an inflammatory disease in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 2.

19. A method of treating an inflammatory disease in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 3.

20. A method of treating an inflammatory disease in a mammal comprising administering to the mammal in

need of such treatment a therapeutically effective amount of a compound of Claim 4.

21. A method of treating an inflammatory disease in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 5.

22. A method of treating an inflammatory disease in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 6.

23. A method of treating an inflammatory disease in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 7.

24. A method of treating an inflammatory disease in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 8.

25. A method of treating a condition or disease mediated by MMPs and/or TNF and/or aggrecanase in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

26. A method of treating a condition or disease mediated by MMPs and/or TNF and/or aggrecanase in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 2.

27. A method of treating a condition or disease mediated by MMPs and/or TNF and/or aggrecanase in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 3.

28. A method of treating a condition or disease mediated by MMPs and/or TNF and/or aggrecanase in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 4.

29. A method of treating a condition or disease mediated by MMPs and/or TNF and/or aggrecanase in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 5.

30. A method of treating a condition or disease mediated by MMPs and/or TNF and/or aggrecanase in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 6.

31. A method of treating a condition or disease mediated by MMPs and/or TNF and/or aggrecanase in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 7.

32. A method of treating a condition or disease mediated by MMPs and/or TNF and/or aggrecanase in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 8.

33. A method of treating a condition or disease wherein the disease or condition is referred to as rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, solid tumor growth and tumor invasion by secondary metastases, neovascular glaucoma, multiple sclerosis, or psoriasis in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

34. A method of treating a condition or disease wherein the disease or condition is referred to as rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, solid tumor growth and tumor invasion by secondary metastases, neovascular glaucoma, multiple sclerosis, or psoriasis in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 2.

35. A method of treating a condition or disease wherein the disease or condition is referred to as rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, solid tumor growth and tumor invasion by secondary metastases, neovascular glaucoma, multiple sclerosis, or psoriasis in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 3.

36. A method of treating a condition or disease wherein the disease or condition is referred to as rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, solid tumor growth and tumor invasion by secondary metastases, neovascular glaucoma, multiple sclerosis, or psoriasis in a mammal

comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 4.

37. A method of treating a condition or disease wherein the disease or condition is referred to as rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, solid tumor growth and tumor invasion by secondary metastases, neovascular glaucoma, multiple sclerosis, or psoriasis in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 5.

38. A method of treating a condition or disease wherein the disease or condition is referred to as rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, solid tumor growth and tumor invasion by secondary metastases, neovascular glaucoma, multiple sclerosis, or psoriasis in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 6.

39. A method of treating a condition or disease wherein the disease or condition is referred to as rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, solid tumor growth and tumor invasion by secondary metastases, neovascular glaucoma, multiple sclerosis, or psoriasis in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 7.

40. A method of treating a condition or disease wherein the disease or condition is referred to as

rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, solid tumor growth and tumor invasion by secondary metastases, neovascular glaucoma, multiple sclerosis, or psoriasis in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 8.

41. A method of treating a condition or disease wherein the disease or condition is referred to as fever, cardiovascular effects, hemorrhage, coagulation, cachexia, anorexia, alcoholism, acute phase response, acute infection, shock, graft versus host reaction, autoimmune disease or HIV infection in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

42. A method of treating a condition or disease wherein the disease or condition is referred to as fever, cardiovascular effects, hemorrhage, coagulation, cachexia, anorexia, alcoholism, acute phase response, acute infection, shock, graft versus host reaction, autoimmune disease or HIV infection in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 2.

43. A method of treating a condition or disease wherein the disease or condition is referred to as fever, cardiovascular effects, hemorrhage, coagulation, cachexia, anorexia, alcoholism, acute phase response, acute infection, shock, graft versus host reaction, autoimmune disease or HIV infection in a mammal comprising administering to the mammal in need of such

treatment a therapeutically effective amount of a compound of Claim 3.

44. A method of treating a condition or disease wherein the disease or condition is referred to as fever, cardiovascular effects, hemorrhage, coagulation, cachexia, anorexia, alcoholism, acute phase response, acute infection, shock, graft versus host reaction, autoimmune disease or HIV infection in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 4.

45. A method of treating a condition or disease wherein the disease or condition is referred to as fever, cardiovascular effects, hemorrhage, coagulation, cachexia, anorexia, alcoholism, acute phase response, acute infection, shock, graft versus host reaction, autoimmune disease or HIV infection in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 5.

46. A method of treating a condition or disease wherein the disease or condition is referred to as fever, cardiovascular effects, hemorrhage, coagulation, cachexia, anorexia, alcoholism, acute phase response, acute infection, shock, graft versus host reaction, autoimmune disease or HIV infection in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 6.

47. A method of treating a condition or disease wherein the disease or condition is referred to as fever, cardiovascular effects, hemorrhage, coagulation,

cachexia, anorexia, alcoholism, acute phase response, acute infection, shock, graft versus host reaction, autoimmune disease or HIV infection in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 7.

48. A method of treating a condition or disease wherein the disease or condition is referred to as fever, cardiovascular effects, hemorrhage, coagulation, cachexia, anorexia, alcoholism, acute phase response, acute infection, shock, graft versus host reaction, autoimmune disease or HIV infection in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 8.